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Using the natural resistance of motor neuron subpopulations to identify therapeutic targets 
in amyotrophic lateral sclerosis 
Krista Spiller 
Though mutant proteins are broadly expressed in neurodegenerative diseases, only some 
neuronal subsets are vulnerable.  In patients with amyotrophic lateral sclerosis (ALS), most 
motor neurons degenerate but those innervating extraocular muscles, pelvic sphincters and slow 
limb muscles exhibit selective resistance.  Previous work in our lab used laser capture 
microdissection followed by microarray analysis of vulnerable lumbar level (L5) motor neurons 
and the resistant motor neuron populations that innervate the extraocular muscles (III) and the 
pelvic sphincter muscles (DL) to identify hundreds of molecular markers of each subset. By 
looking at the genes that had >10 fold differential expression and that were selectively and 
strongly expressed in motor neurons into adulthood, we identified matrix metalloproteinase-9 
(MMP-9) as a potential susceptibility gene.  We first examined the expression of MMP-9 in 
wild-type mice and found that it is expressed only after postnatal day 5 in fast motor neurons, 
which are selectively vulnerable in ALS.  Further, MMP-9 was the only secreted member of the 
MMP family constitutively expressed in this population.  In mutant SOD1 mice, MMP-9 
expression was strongly positively correlated with cell loss at end-stage of the disease and with 
early induction of endoplasmic reticulum stress, as measured by p-EIF2α.   
To test whether MMP-9 is a driver of disease, we crossed Mmp9 null mice with mSOD1 
mice and found that both partial reduction and complete ablation of MMP-9 levels delayed 
muscle denervation, prolonged survival, and improved motor function, measured both 
behaviorally and electrophysiologically.  Importantly, even acute knock-down in motor neurons 
 with AAV6 gene therapy or central inhibition of MMP-9 after symptom-onset were able to 
protect muscle innervation of the fast hindlimb muscle, TA.  Further, MMP-9 expressed by 
motor neurons is required for full ER stress activation, suggesting it may be a very early 
intermediate in the disease pathway triggered by mutant SOD1.  However, virally introducing 
MMP-9 into resistant pools does not confer susceptibility, implying that there is an additional 
factor (or factors) also present in fast motor pools that is necessary to induce axonal die-back.  
These studies suggest that MMP-9 is a promising candidate therapeutic target for ALS.  
Importantly, these data support the study of neuronal diversity as a potential way to define novel 
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For all neurodegenerative disorders, identifying mutant proteins in the familial forms of 
the disease has allowed researchers to make both cell culture and vertebrate models that have 
helped elucidate underlying molecular mechanisms of cellular dysfunction and eventual death.  
However, in all cases, the expression of these mutant forms of proteins leaves important 
unanswered questions with regard to the age-dependence and regional selectivity that 
characterize neurodegenerative diseases.   Specifically, 1) what makes only some neuronal 
subsets vulnerable when mutant proteins are broadly expressed? And, 2) why do 
neurodegenerative diseases occur in middle age and old age despite the fact that mutant proteins 
are expressed over a patient’s whole lifetime?  In this thesis, I will attempt to probe these 
questions through a study of regional selectivity in amyotrophic lateral sclerosis.  
 
Part I. Selective neuronal loss is a hallmark of neurodegenerative disease 
 
Selective vulnerability at the level of cell type, population, and subclass 
The neurodegenerative diseases Parkinson’s disease (PD), Alzheimer’s disease (AD), and 
motor neuron diseases like amyotrophic lateral sclerosis (ALS) are estimated to affect some 20 
million people worldwide (Mayeux, 2003).  Though the clinical presentations of these three 
devastating disorders are very different, there are striking similarities between them.  All three of 
these disorders feature onset that normally occurs during middle age or in the later years of life, 
each can occur as an inherited disorder but is more often sporadic, and all three are relentlessly 
progressive.   Further, there is strong evidence that these disorders feature common underlying 
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cellular changes like protein misfolding and accumulation, mitochondrial dysfunction, oxidative 
stress, excitotoxicity, transcriptional dysregulation, neuroinflammation, and axonal transport 
defects (Double et al., 2010; Mattson and Magnus, 2006; Saxena and Caroni, 2011).   A 
combination of some or all of these events impairs normal neuronal function and results in 
clinical signs that are often evident even before frank neuronal loss.  However, as the diseases 
progress, dramatic differences between the clinical phenotypes of PD, AD, and ALS result from 
the remarkable degree of specificity in the identity of the neurons that degenerate in each and the 
resulting selective loss of the corresponding neuronal function.  Put another way, at late disease 
stages, the symptoms are influenced more by the location of the cell death than the mechanism of 
cell death.   
The first level of specificity of cell death is at the level of the neuronal class that is 
principally affected in these disorders (Figure 1.1A).  For example, PD is the most common 
neurodegenerative movement disorder and is pathologically defined by dysfunction in basal 
ganglia circuits and the eventual selective cell death of dopamine neurons of the substantia nigra.  
AD is the most common form of dementia and the memory deficits associated with its onset 
result from a selective loss of cells in the entorhinal cortex, and CA1 and subiculum of the 
hippocampus.  Finally, ALS is characterized by progressive paralysis that results from the cell 
death of upper and lower motor neurons.     
However, for all of these disorders, there exists a second, finer-grained layer of 
selectivity: subpopulations within a single neuronal class.  Using PD as an example, though 
dopamine neurons of the ventral midbrain are the class principally affected, subpopulations vary 
in their susceptibility to degeneration.  Specifically, melanized dopamine neurons of the ventral 
tier of the substantia nigra (vtSN) are the most vulnerable, neurons of the dorsal tier of the 
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substantia nigra (dtSN) are more resistant and dopamine neurons of the ventral tegmental area 
(VTA) are the most resistant to degeneration (Elstner et al., 2011).  This difference is apparent 
even though these cells form a continuous sheet of dopamine neurons that occupy the ventral 
midbrain and merge seamlessly with one another (Collier et al., 2011). 
 
Patterns of selective vulnerability in ALS  
ALS provides another clear example of regional selectivity at every level: though motor 
neurons are the class principally affected, individual motor pools at different levels of the 
neuraxis have very different disease vulnerabilities.  Further, even within a given motor pool, 
there is a spectrum of disease susceptibility of different functional motor neuron subtypes.  Like 
the other neurodegenerative diseases mentioned, ALS is age-dependent with clinical onset most 
commonly occurring between 40 and 60 years of age.  Patients typically present with motor 
deficits in one particular region which result from the dieback of axons of motor neurons from 
individual muscle fibers and subsequent motor neuron death (Munsat et al., 1988).  Early in the 
course of the disease, muscle denervation and motor neuron loss is compensated for by collateral 
reinnervation by the remaining motor neurons and this preserves strength (Bromberg et al., 
1993).  However, as the disease progresses, compensation fails and complete paralysis results 
when fewer than 5% of motor units remain (Swash and Schwartz, 1992).    
The rate of loss of motor units is greatest at the site of onset of disease and the 
denervation of neuromuscular junctions has been shown to follow an exponential decline 
(Baumann et al., 2012).  This is consistent with an early study which found that the motor neuron 
population in ALS patients is reduced by 50% every 6 months in the first year and more slowly 
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thereafter (Dantes and McComas, 1991).  About one quarter of ALS patients exhibit primary 
bulbar symptoms, and there is a tendency for patients with bulbar onset to be older (mean 59 
versus 55 years for limb onset) (Turner et al., 2012).  Of non-bulbar patients, approximately 
equal numbers exhibited first symptoms in their arms (47.7%) or legs (46.5%), with 5.8% in both 
arms and legs, and, of these, the overwhelming majority presented in the most distal portions 
(73%) (Haverkamp et al., 1995).  In fact, less than 3% of ALS patients present with motor 
deficits beginning in the respiratory or axial musculature (Shoesmith et al., 2007).  Therefore, the 
motor neuron subsets that innervate respiratory muscles, which are part of the so-called 
“hypaxial motor column”, are much more spared by the disease than the motor pools which 
project to the limbs, those that comprise the “lateral motor columns” of the spinal cord (Kanning 
et al., 2010). 
Importantly, even within a given motor column, nearby motor pools that innervate 
different muscles can have very different half-lives (Baumann et al., 2012), suggesting that 
individual motor pools have differing intrinsic susceptibility to disease.  For example, in most 
ALS patients, the thenar hand is involved earlier and more severely than the hypothenar hand 
(Eisen and Krieger, 1993), a pattern of atrophy that is termed “split hand” (Wilbourn, 2000).  
Specifically, among the intrinsic hand muscles, wasting predominantly affects the median 
innervated muscles (abductor pollicis brevis and opponens pollicis) and the ulnar innervated 
muscles (first dorsal interosseous, adductor pollicis and flexor pollicis brevis), with relative 
sparing of the hypothenar muscles (the abductor digiti minimi)(Baumann et al., 2012).  In fact, 
this is such a common divergence in weakness that over the past decade, the split hand has 
become increasingly recognized as a useful clinical sign of ALS (Figure 1.1C) (Eisen and 
Kuwabara, 2012).  This example highlights that specific motor pools are differentially affected in 
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ALS, but a growing body of evidence reveals that even within a vulnerable motor pool, motor 






Figure 1.1 Specific regions and neuronal subclasses affected early in neurodegenerative 
diseases 
A. There is a remarkable level of specificity in the identity of the first neurons that degenerate in 
each neurodegenerative disease (shown in red) and the corresponding neuronal function is what 
defines the clinical phenotype in these diseases. The hippocampus and some cortical areas are 
primarily affected in AD, the substantia nigra in PD, and the spinal cord and in ALS. 
B. Dopamine neurons of the ventral midbrain vary in their susceptibility to degeneration, with 
neurons of the ventral tier of substantia nigra (vtSN, shown in red) being the most vulnerable, the 
dorsal tier of substantia nigra (dtSN, shown in yellow) being less vulnerable, and the adjacent 
cells of the ventral tegmental area (VTA, shown in green) being the least vulnerable. Figure is 
reproduced from (Collier et al., 2011). 
C. Representative photo (left) and schematic (right) of an ALS patient’s hand showing prominent 
atrophy of the thenar eminence (red) but sparing of the hypothenar eminence (green). Photo is 
reproduced from Student BMJ archive 
http://archive.student.bmj.com/issues/07/12/education/460.php [9/16/13]  
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Evidence for a role of motor neuron subtype in selective vulnerability  
Each motor pool and the muscle it innervates is made up of a defined set of functionally 
distinct motor units, defined in 1925 as the “motoneurone axon and its adjunct muscle fibres” 
(Sherrington, 1925).  In the 1970s, Burke and colleagues developed a classification scheme for 
motor units based on the physiological properties of the motor units (contractile time and 
sensitivity to fatigue) and the histochemical profiles of the associated muscle fibers (using a 
method of glycogen depletion for muscle unit identification) (Burke et al., 1971; Burke et al., 
1973).  They classified all motor units of the cat gastrocnemius as fitting into one of three major 
types, including two “fast” groups with relatively short twitch contraction times (types FF and 
FR, which were differentiable from one another on the basis of sensitivity to fatigue) and one 
“slow” group with relatively long contraction times (type S, which were extremely resistant to 
fatigue and were further distinguished from FF and FR units on the basis of the shape of unfused 
tetani in response to a standardized stimulus protocol) (Figure 1.2).    Since the classification 
scheme was developed in those seminal papers, the three main functional types have been further 
differentiated by their recruitment order, their size and morphology, and their electrical 
properties (Kanning et al., 2010).   
First, in a given motor pool, the earliest recruited motor units are type S; these exert the 
smallest forces and fatigue the least.  Conversely, the last-recruited motor units are type FF, 
which exert greater forces but only for brief periods of activity (Duchateau and Enoka, 2011).  
The differences in size of the motor neuron subtypes and consequent electrical properties likely 
underlie this recruitment order (Kanning et al., 2010).  Specifically, FF motor neurons are the 
largest subtype, followed by FR, and the S motor neurons are the smallest.  But, S motor neurons 
are not just smaller than FF motor neurons; rather, they also show a clear difference in axonal 
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and dendritic branching complexity (Cullheim et al., 1987).  The result of the size and 
differences in synaptic input is that smaller S motor neurons have higher input resistance and 
therefore require less synaptic activation to initiate action potentials.  Accordingly, the large FF 
motor neurons are activated last. This rule is known as the “size principle” (Kanning et al., 2010; 
Mendell, 2005).  Further, S type motor neurons were shown to have, on average, a significantly 
slower time course of post-spike after-hyperpolarization, a smaller rheobase, and more slowly 
conducting axons than those innervating fast-twitch muscle units (Bakels and Kernell, 1993).   In 
reality, despite the appeal of these clear distinctions, it has been observed that the properties of 
the functional subtypes of motor units in both experimental animals and humans do not exhibit 
discrete distributions, but rather extend along a continuum from one extreme to 
another (Duchateau and Enoka, 2011).   
There is also evidence that the functional subtypes of motor neurons are differentially 
susceptible to disease.  One report from a human ALS patient who died as a result of surgical 
complications suggested there is early axonal dieback and selective susceptibility of FF axons 
(Fischer et al., 2004).  However, most analyses are restricted to the postmortem examination of 
end-stage disease and cannot identify the earliest morphological changes in the motor unit.  As a 
result, mouse models of ALS should be particularly useful in determining the order of motor unit 
death, provided they can be shown to faithfully mirror the disease process in humans.   
Though most cases of ALS are sporadic, approximately 10% are classified as familial, or 
having a known genetic origin.  Importantly, the pathology and pattern of selective motor neuron 
vulnerability is similar in familial and sporadic ALS (Shaw et al., 1997).  Of the familial forms, 
the most studied and most common (roughly 20% of these cases) involve toxic gain-of-function 
mutations in the gene that codes for superoxide dismutase (SOD1).  No common biophysical or 
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biochemical denominator has been found for all mutations in the small SOD1 gene (Andersen et 
al., 2003), but it is most commonly suggested that protein misfolding must be a common initial 
trigger (Boillée et al., 2006a).  As I describe in more detail below, transgenic mice expressing 
mutant forms of human SOD1 (mSOD1) recapitulate the selective motor neuron degeneration 
and death seen in human sporadic and familial ALS (Chiu et al., 1995; Wong et al., 2002).  This 
mouse model has allowed research to be done on the differential vulnerability of FF, FR, and S 







Figure 1.2 Principle differences between alpha motor neuron subtypes 
A. Alpha motor neurons innervate extrafusal muscle fibers to form three subtypes of motor unit: 
Slow-twitch (S) units control Type I fibers (yellow), fast-twitch fatigue-resistant (FR) units 
control Type IIa fibers (blue), and fast-twitch fatigable (FF) units control Type IIb/x fibers 
(green).  
B. Different types of alpha motor neurons can innervate different fibers of a single muscle.  The 
size and morphological complexity of alpha motor neurons diminish progressively from FF 




Early subtype-specific differences in disease susceptibility in mSOD1 mouse motor neurons 
In the last 13 years, there have been several careful studies to elucidate the differential 
vulnerability of FF, FR, and S motor neuron subtypes.  First, Frey et al. demonstrated that the 
functionality and maintenance of neuromuscular synapses are affected very early in motor 
neuron diseases, before any gross motor deficit is detected (Frey et al., 2000).  The authors 
looked at muscle fiber subtypes in mouse triceps surae muscles (MGC, LGC, and soleus) and 
found that generally type IIb fibers (innervated by FF motor neurons) were located most 
laterally, and type I fibers (innervated by S motor neurons) were most medial.  They also report 
that there was very little animal-to-animal variation in proportions of fiber types in these muscle 
compartments.  Further, in the mSOD1 mouse, which typically begins showing gross motor 
dysfunction around 3 months of age, they reported extensive local muscle denervation already at 
postnatal day 50 (P50) in FF motor units.  By P80, denervation and atrophy could also be 
observed in the medial gastrocnemius.  However, in the slow soleus muscle, significant 
denervation was restricted to the very last phase of the disease (P120).  Not only do the synapses 
on type I fibers resist denervation, they also sprout to reinnervate nearby vacated synapses (Frey 
et al., 2000). 
A later study replicated this finding by observing neuromuscular junction denervation at 
P47, but also extended their analysis to include numbers of spinal motor neurons and axons in 
the nerve roots (Fischer et al., 2004).  They found severe loss of motor axons from the ventral 
root between days 47 and 80, and loss of α-motor neuron cell bodies from the lumbar spinal cord 
after day 80.  The authors thus suggested that the pattern implies that motor neuron disease in the 
mSOD1 mouse is a “dying back” motor neuropathy, where distal axonal degeneration occurs 
early during the disease.  
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Pun et al. went on to precisely characterize the remarkably synchronous timing of this 
dieback in FF, FR, and S motor units (Pun et al., 2006).  Again in the mSOD1 model, they 
showed that there are two well-defined episodes of axon loss in the hindlimb muscles such as the 
tibialis anterior, lateral gastrocnemius, and soleus (Figure 1.3A).  From P48-P52, muscles or 
parts of muscles innervated by FF motor neurons (such as the superficial portion of the tibialis 
anterior or the most lateral subcompartment of gastrocnemius) become completely and 
reproducibly denervated.  In the portions of muscle innervated by a mix of FF and FR motor 
neurons (for example, in the deep, bone-facing third of the tibialis anterior), NMJs were partially 
denervated between P48 and P55, but were also partly reinnervated at P60 before a second 
denervation episode between P80 and P90 caused a permanent loss of NMJs and axons (Figure 
1.3B).  The slow soleus muscle showed no denervation or nerve loss before P85.  The authors 
concluded that FF motor neurons disconnect their nerves from muscle first around P50, and then 
FR motor neurons innervating the same muscle sprout and reinnervate the unoccupied type IIb 
fibers.  These new NMJs are unstable, and there is a second pruning phase around P80.   Finally, 
type S motor neurons compensate efficiently through sprouting and those connections are 
maintained until the terminal disease stage.  Electrophysiological and fiber typing studies have 
generally supported this general sequence of degeneration, though with subtle differences.  
Specifically, analysis of the TA muscle revealed a more gradual, incomplete loss of FF motor 
units accompanied by a parallel increase in FR motor units (Hegedus et al., 2007; Hegedus et al., 
2008).  However, the force of individual motor units was reduced, suggesting that the FR motor 
units were unlikely to have sprouted to reinnervate the vacant NMJs.  Instead, the authors 
propose that a switch in motor unit phenotype from FF to FR precedes the apparent loss of FF 
motor axons (Hegedus et al., 2008).  
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These results have made it possible to investigate the process of disease-related axon loss 
with precision and identify earlier alterations in neuromuscular junctions and axons that are 
predictive of subsequent axon loss (Saxena and Caroni, 2007).  For example, starting about 8–10 
days prior to axon degeneration, vulnerable FF axons exhibit local accumulations of synaptic 
vesicles and a loss of synaptic vesicles from neuromuscular junctions, suggesting the presence of 
a defect in anterograde transport in these vulnerable axons (Pun et al., 2006).   
Another change that precedes this subtype selective vesicular stalling and axonal dieback, 
is specific upregulation of the unfolded protein response (UPR) (Saxena et al., 2009).  Using 
laser-capture microdissection of retrogradely-labeled resistant (soleus) or vulnerable (LGC) 
motor neurons of mSOD1mice, Saxena et al. they show that at early stages all mutant motor 
neurons transiently upregulate ubiquitin levels, likely reflecting ubiquitous expression of mutant 
SOD1 in the transgenic mice.   However, only in the vulnerable (putative FF) motor neurons is 
there a concurrent upregulation of genes involved in stress-related pathways, including protein 
ubiquitination, hypoxia and NRF2-mediated stress.  This stress-related response increased up to 
P26 but was abruptly lost at P32 and beyond. Further, the loss of early stress-related responses 
was accompanied by an upregulation of unfolded protein response (UPR)-related genes and a 
downregulation of ubiquitin proteasome system (UPS)-related genes in vulnerable motor 
neurons, a strong cellular stress response that peaked at P38.  This pattern was further confirmed 
by immunocytochemistry for ATF4, PERK, and P-eIF2α. A similar wave of upregulation of 
UPR genes occurs in FR motor units later, and also appears to directly precede denervation.  At 
P80, additional cell types besides just motor neurons also had upregulated UPR markers.  
Interestingly, treatment of mice with salubrinal, a blocker of dephosphorylation of eukaryotic 
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initiation factor 2α prevented upregulation of ER stress markers in FF motor neurons, delayed 
denervation of NMJs, and extended the lifespan of mSOD1 mice.    
 A very recent study extended these findings to include an analysis of MN excitability 
(Saxena et al., 2013).  First, the authors used an antibody to detect disease-associated epitopes of 
SOD1 (misfSOD1) and found selective immunoreactivity in the FF subpopulation of α-MNs 
from P7.  The misfSOD1 signal increased with age, eventually appearing in FR MNs before 
clinical disease onset (~P75 in their SOD1
G93A
 “fast” mice).  This protein misfolding colocalized 
in cells with an accumulation of ER stress signals (BiP and p-EIF2α) and was blocked with 
salubrinal treatment.  In contrast, SOD1 misfolding and ER stress were potentiated with 
pharmacological treatment with compounds that reduced excitability (CNQX, Ketanserin + Way, 
and AP-5).  Further, chronic CNQX treatment accelerated muscle denervation and motor 
dysfunction in these animals.  These results demonstrated that reduced excitability was MN 
subtype-specific and resulted in aggregates and other disease-related pathology in mSOD1 mice.  
 Moreover, the authors also showed that enhanced excitability can protect vulnerable MNs 
(Saxena et al., 2013).  AMPA treatment significantly reduced protein misfolding and ER stress 
and also delayed FR + S denervation (but not FF) and extended survival 25-30 days.  Further, 
using a floxed pharmacologically selective module coupled to receptors for depolarization or 
hyperpolarization delivered unilaterally to lumbar α-MNs, the authors showed that this enhanced 
excitability is neuroprotective in a cell-autonomous manner.  Finally, Saxena et al. implicated the 
mTOR signaling pathway, as SOD1
G93A
 mice with treated with rapamycin had an exacerbated 
ALS phenotype whereas those treated with oxotremorine to stimulate mTOR and salubrinal to 
inhibit ER stress had significantly delayed MN degeneration and a lifespan extension of 50 days 
(2013).  Therefore, these key findings suggest FF motor neurons are particularly vulnerable 
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because of their low excitability and moderate levels of glutamate receptor activation can engage 
adaptive cellular stress response pathways to promote MN survival.   
Though these studies have greatly advanced our understanding of motor neuron subtype-
specific susceptibility, the molecular basis of this selective FF-vulnerability remains an open 
question.  Further, future studies on mechanisms underlying selective vulnerability would be 
greatly aided by having reliable molecular markers to identify these motor neurons subtypes 







Figure 1.3 Timing of axonal dieback by motor unit subtype in mSOD1 mice 
A. Muscles of the leg. Gastrocnemius, soleus, and tibialis anterior of the mutant SOD1 mouse 
were investigated to characterize the timing of axonal dieback in FF, FR, and S motor units.  
Picture is reproduced from 
http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/17238.jpg [9/17/13]. 
B. Timeline of the denervation of a typically FF-innervated muscle, reported by (Pun et al., 
2006).  The authors report a first pruning episode between P48 and P52 (dashed red line), 
followed by a period of reinnervation of the unoccupied type IIb fibers by the FR motor neurons 
innervating the same muscle at P60 (green dashed line).  These new NMJs are unstable, and 
there is a second pruning phase around P80 (red dashed line).    
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A clear example of disease resistance: oculomotor and Onuf’s nuclei 
Aside from the fast versus slow distinction with regard to differential vulnerability of 
motor neurons to ALS, several motor pools have been identified as being disease-resistant.  In 
fact, two motor pools in particular are extremely well-preserved, even to late stages of the 
disease in patients: motor neurons innervating the extraocular muscles and those innervating the 
pelvic sphincter muscles (Kanning et al., 2010).  The resistance of these motor pools 
(oculomotor, trochlear, and abducens nuclei in the midbrain and Onuf’s nucleus in the sacral 
spinal cord), corresponds to clinical studies that show a maintenance of motor function in ocular 
movement and voluntary control of eliminative functions (Mitsumoto et al., 2006).  In fact, it has 
been well documented that the cell bodies of these motor neurons are still intact at the time of 
ALS patient autopsy (Figure 1.4) (Iwata and Hirano, 1978; Kiernan and Hudson, 1993; Mannen 
et al., 1977; Okamoto et al., 1993; Schrøder and Reske-Nielsen, 1984; Sobue et al., 1981).  
Based on commonalities between these pools, there is a variety of potential mechanisms 
that could underlie their resistance to ALS.  For example, like S motor neurons, oculomotor and 
Onuf’s motor units have small soma size.  This could be relevant, as it has been speculated that 
disease vulnerability in motor neurons could result from the high energy demands and high 
metabolic rates that large cells with very long axonal processes have (Shaw and Eggett, 2000).   
That said, another way these resistant pools are different from other motor neurons is that they 
are almost always active, even during sleep (Enck and Vodusek, 2006; Navarro-López et al., 
2004; Robinson, 1981), suggesting that metabolic demands alone are not enough to confer 
disease vulnerability.  It could be the case that the oculomotor nucleus and Onuf’s nucleus are 
well adapted to dealing with the high energy requirements as it has been shown that these motor 
pools have greater calcium buffering capacity and express parvalbumin and calbindin (Alexianu 
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et al., 1994; Brockington et al., 2013; Shaw and Eggett, 2000).  In fact, it has been reported that 
parvalbumin expression may contribute to a certain degree to ALS resistance, as the genetic 
overexpression of parvalbumin in neurons of mutant SOD1 mice resulted in attenuation of motor 
neuron loss by 33% and a modest survival increase of 11% (Beers et al., 2001).  However, the 
expression data are somewhat unclear, as robust expression of parvalbumin has also been 
reported in vulnerable spinal motor neurons (Laslo et al., 2000; Sasaki et al., 2006).  
 Therefore, these groups have a number of potentially disease-resistant properties in 
common.  Further, these extraocular muscle and pelvic muscle innervating motor pools have an 
advantage over fast and slow motor neuron subtypes in studying disease resistance because they 
are relatively easy to distinguish by location and morphology.  Some molecular differences 
between oculomotor and other motor neurons have already been reported (Alexianu et al., 1994; 
Aronica et al., 2001; Hedlund et al., 2010; Laslo et al., 2000; Sasaki et al., 2006).  For example, 
Hedlund et al. compared global gene expression profiles from laser-captured motor neurons of 
the oculomotor nucleus to those from the vulnerable hypoglossal nucleus and cervical motor 
neurons from adult rats and found that the oculomotor motor neurons had the most dissimilar 
transcriptomes (2010).  Among the hundreds of genes differentially enriched in the oculomotor 
neurons, insulin-like growth factor II (Igf2) and guanine deaminase (Gda) were selected and 
shown to be protective in primary spinal cord cultures against glutamate-induced neurotoxicity.  
Though this study is very encouraging, the molecular basis of disease resistance in vivo still 







Figure 1.4 Preservation of extraocular motor nuclei and Onuf’s nucleus in ALS  
A. Images of midbrains at the level of the oculomotor nuclei from a control patient (left) and an 
ALS patient (right) stained with cresyl violet. Note preservation of large diameter purple-staining 
cells in the oculomotor nucleus of ALS patient.   
 
B. Images of the ventral horns of lumbar spinal cord from a control patient (left) and an ALS 
patient (right) stained with cresyl violet. Note near complete absence of these cells in ALS 
ventral horn. Images in A and B are courtesy of Dr. Arthur Hays, Dept. of Pathology, Columbia 
University. 
 
C. Images of the ventral horns of S2 spinal cord from a control patient (left) and an ALS patient 
(right) stained with Kluver-Barrera myelin stain.  Onuf’s nucleus is located along the 
ventrolateral edge of the ventral horn is circled with a red dashed line.  In S2 ventral horn of ALS 
patient, most LMC motor neurons have degenerated while Onuf’s nucleus appears virtually 
intact.  Images are reproduced from (Mannen, 2000).  
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Part II. Shared gene expression in resistant motor nuclei compared to a vulnerable 
population 
Given the clear distinction between the resistance of different populations of motor 
neurons, previous work in the Henderson lab focused on the extraocular and pelvic motor 
neurons of healthy mice in order to identify the molecular basis of their intrinsic disease 
resistance.  Specifically, Artem Kaplan performed a comparative microarray to analyze gene 
expression in three groups of motor neurons: the resistant oculomotor and Onuf’s (DL in 
rodents) nuclei, and the disease vulnerable lateral motor column neurons of the L5 lumbar 
segment.  
All three pools had some similarities as they all expressed a set of “generic motor neuron 
genes” (Figure 1.5A, yellow).   However, the different motor populations also expressed a subset 
of genes linked to its specific function and rostrocaudal position.  Further, an additional subset of 
genes were expressed in both resistant populations but were absent from vulnerable L5 motor 
neurons, and these were considered potential ALS resistance genes (Figure 1.5A, green).  
Conversely, those genes that were highly expressed in vulnerable L5 motor neurons but were 
absent from oculomotor and DL motor pools were considered putative ALS susceptibility genes 
(Figure 1.5A, red).  
When the analysis was limited to genes whose expression levels showed >10-fold 
differences, only four genes were expressed at high levels in both resistant nuclei but at low 
levels in vulnerable L5, whereas 14 genes were more strongly expressed in vulnerable motor 
neurons than in the two resistant populations (Figure 1.5B).  For half of these 18 genes, in situ 
hybridization was used to validate the microarray data.  For example, Sema3E (semaphorin 3E) 
was confirmed to be strongly expressed in oculomotor and DL nuclei but absent from L5, 
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whereas Mmp9 (matrix metalloproteinase 9) and Hsd17b2 (estradiol 17-β-dehydrogenase 2) were 
strongly expressed in L5 motor neurons but absent from DL and oculomotor nuclei (Figure 
1.5C).  
Though limiting the analysis to >10 fold changes reduced the number of target genes 
(Figure 1.5B), further criteria were needed to select targets for further investigation.  Because 
ALS is an adult-onset disease of motor neurons, the first criterion for selection was that a target 
gene be expressed selectively in motor neurons through adulthood.  Of the group of potential 
disease susceptibility genes, only Hsd17b2 and Mmp9 maintained high levels at P57.   
To choose between them, their ranking by three-way triangulation was compared, with 
the idea that a gene whose ranking was low in both individual pairwise comparisons but high 
using the three-way triangulation had the greatest chance of being linked to ALS rather than to 
specific properties of either pool.  Table 1.1 shows the gene rankings by fold change, with the 
last column giving a number called the “added value of triangulation” (calculated by first ranking 
all of the genes from greatest fold change to least fold change, then taking the sum of the ranks in 
each 2-way comparison and subtracting from that the rank in the 3-way comparison).  For 
example, MMP-9 was only 77
th
 in the III/L5 list and 24
th
 in the DL/L5 but was #10 in the 3-way 
comparison.  Since Hsd17b2 was #3 on the comparison between DL and L5, Mmp9 was selected 
for further study.  This decision was further supported by a broad existing literature on the 








Figure 1.5 Microarray profiling of motor neurons from oculomotor (III), DL, and L5 
motor neurons reveals robust genetic differences among these populations and points to a 
common set of genes relevant to ALS resistance  
 
A.  Experimental design. Comparison of genetic differences between mouse lumbar MN (L5), 
oculomotor nucleus (III, purple), and Onuf’s nucleus (DL, blue) provides markers of these 
populations among which genes related to ALS resistance may be found.  ALS resistance genes 
are more likely to be found among genes commonly enriched (green) in both III and DL, while 
susceptibility genes (red) are more likely to be found among genes commonly depleted in III and 
DL.  
 
B. Comparison of the numbers of differentially expressed genes with 10-, 7-, and 5-fold cutoffs. 
Note that regardless of the cutoff value, genes that are commonly–regulated between III and DL 
as compared to the L5 motor neurons represent a much smaller set than comparisons among 
individual nuclei. 
 
C.  Sample validation of the microarray data. (top) ISH for Sema3e on cryosections of P7 
brainstem and lumbar spinal cord.  At L6, DL nucleus motor neurons are identified by injection 
of CT-B555 (red) into the IC muscle at P5.  (middle and bottom) ISH for Mmp9 and Hsd17b2 on 
cryosections of wild-type brainstems and spinal cords at P7. Mmp9 and Hsd17b2 are expressed 
at different levels in subsets and L5 motor neurons, but oculomotor and DL nucleus motor 






Table 1.1 Table of gene rankings by fold change 
 
  
















Aldh1a2 -19.4 -274.7 1 2 9 11 10 
Nts -120.1 -19.2 2 33 1 34 32 
Trhr -18 -72.7 3 30 10 40 37 
Hsd17b2 -35.5 -32.9 4 22 3 25 21 
Il1f9 -17.7 -18.7 5 34 11 45 40 
Arhgap9 -13.9 -22 6 29 35 64 58 
1500015O10
Rik -11.8 -23.8 7 27 22 49 42 
Cited1 -20 -15.2 8 40 8 48 40 
Dlk1 -15.6 -14.6 9 44 15 59 50 
Mmp9 -16 -11.1 10 77 24 101 91 
Mgam -13.2 -13.7 11 50 19 69 58 
Vipr2 -11.4 -14.5 12 45 25 70 58 
Egln3 -13.2 -11.9 13 42 18 60 47 
Npr3 -11.1 -12.5 14 55 29 84 70 
Uts2 -16.2 -6.7 15 107 13 120 105 
Agtr2 -7.1 -14 16 48 64 112 96 
Fbxw8 -8.4 -11.1 17 65 47 112 95 
Kcnj14 -7.7 -10.6 18 68 56 124 106 
4932431H17
Rik -11.9 -5.6 19 126 21 147 128 
Rora -9.8 -5.3 20 141 33 174 154 
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Table 1.1 Table of gene rankings by fold change 
The table shows the gene rankings of the top 20 potential susceptibility genes.  Columns 2 and 3 
show the fold changes for individual comparisons between DL and L5 and III and L5.  Column 4 
shows the rank of the genes with the greatest summed differences (calculated by summing the 
fold differences in the two pairwise comparisons).   In column 7, we show the “added value of 
triangulation”, which is the sum of the ranks in each 2-way comparison minus that the rank in the 
3-way comparison.  Genes of particular interest are those not ranked very high in either pairwise 
comparison, but which come near the top of the list in the three-way comparison.  By this 





Part III. Structure and function of MMP- 9 
MMP-9 is perhaps the most studied member of a large family of zinc-dependent proteolytic 
enzymes.  In humans, 24 different MMPs have been identified (Lee and Murphy, 2004).  These 
MMPs are generally divided into subgroups, based on their architectural features and, 
importantly, their preferred substrate or substrates.  MMPs are grouped into gelatinases (MMP-2 
and MMP-9), collagenases (MMP-1, -8, -13, and -18), stromelysins (MMP-3, -10, and -11), 
matrilysins (MMP-7 and MMP-26), membrane-type (MT)-MMPs that include 4 type I 
transmembrane proteins (MMP-14, -15, -16, and -24) and  two glycosylphosphatidylinositol-
anchored proteins (MMP-17 and -25), and 7 others that do not easily fit into a single category 
(Nagase et al., 2006).  The main function of MMPs has been classically considered to be the 
degradation and removal of ECM molecules.  However, recent reports have taken a more 
nuanced view of this role, emphasizing that the breakdown of ECM molecules or cell surface 
molecules alters cell–matrix and cell–cell interactions and the release of growth factors that are 
bound to the ECM makes them available for cell receptors (Cauwe et al., 2007; Nagase et al., 
2006).  Further, a number of non-ECM molecules are also potential substrates of MMPs and 
their importance in cell growth, the regulation of apoptosis, and cell migration are becoming 
increasingly appreciated (McCawley and Matrisian, 2001).  Finally, though most MMPs are 
secreted and act extracellularly, some substrates that MMPs are known to process are localized 
intracellularly (Butler and Overall, 2009).   
Structure of MMP-9 
The activity of all MMPs is intimately linked to their structure, and MMP-9 serves as an 
excellent example of how the structure of these proteins affects their activity and substrate 
specificity.  MMP-9 is secreted in a latent, zymogen form that requires posttranslational 
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modification to become activated.  Specifically, MMP-9 consists of a propeptide domain, an 
active site, a zinc binding domain, a fibronectin domain, a linker (hinge) region, and a 
hemopexin domain (Figure 1.6).   
The propeptide domain is made up of 80 amino acids at the N-terminus and consists of three 
α-helices and connecting loops.  The loop between helix 1 and 2 is a protease-sensitive area, 
sometimes called a “bait region”, and a peptide region after helix 3 lies in the substrate-binding 
cleft of the catalytic domain (Vandooren et al., 2013b).  This region contains the “cysteine 
switch”, which constitutes a fourth ligand of the active-site zinc, effectively blocking the active 
site and maintaining an inactive state (Visse and Nagase, 2003).  MMP-9 is activated when a 
conformational change in the pro-domain pulls out the cysteine residue and enables water to 
interact with the zinc ion in the active site (Van Wart and Birkedal-Hansen, 1990).  This change 
reduces the size of active MMP-9 to 82 kDa (from 92 kDa in the proform).  The conformational 
changes that result in the disruption of the interaction between the cysteine switch and zinc will 
be discussed later in more detail. 
 The 3-D structure of the catalytic domain consists of a 5-stranded β-pleated sheet, three 
α-helices, and connective loops and contains one catalytic zinc, one structural zinc, and three 
calcium ions (Visse and Nagase, 2003).  The substrate-binding cleft is formed by strand IV, helix 
B, and the extended loop region after helix B, and it contains a catalytically essential Glu402 and 
a Zn
2+
 ion (Vandooren et al., 2013b).   Between the active site and the metal binding site there 
are a cluster of three fibronectin repeats, and these are thought to be important for the binding 
and catalysis of large substrates such as elastins and denatured collagens or gelatins (Shipley et 
al., 1996; Vandooren et al., 2013b). 
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The fibronectin portion of the protein is connected to the C-terminal hemopexin domain via a 
flexible hinge region originally named the collagen type V-like domain, but now more accurately 
called the O-glycosylated domain.  This hinge region consists of more than 50 amino acids, the 
longest linking region of all MMPs (Van den Steen et al., 2006) and this unusual length and the 
greater flexibility it provides to the molecule is the biggest structural difference between MMP-9 
and the closely related MMP-2 (Rosenblum et al., 2007).  Importantly, the O-glycosylated 
domain allows for independent movements of the terminal hemopexin and catalytic domains of 
the MMP-9 molecule (Vandooren et al., 2013b).  It was also reported that a recombinant MMP-9 
mutant with the O-glycosylated domain deleted showed decreased affinity to TIMP-1, low-
density lipoprotein receptor related-protein-1 (LRP-1), and megalin, suggesting that this linking 
domain is essential for regulating the bioavailability of active MMP-9 (Rosenblum et al., 2007; 
Van den Steen et al., 2006).  
The importance and uniqueness of the hemopexin domain of MMP-9 is also becoming 
increasingly appreciated.  Whereas the prodomain and catalytic domains are very conserved 
between MMPs, the hemopexin domains are more differentiated (Andreini et al., 2004).  
Specifically, MMP-9 is the only secreted MMP that forms a homodimer through its hemopexin 
domain mainly by hydrophobic interactions (Cha et al., 2002) and that has a cysteine residue in 
this domain (Dufour et al., 2008; Van den Steen et al., 2006).  In fact, because the hemopexin  
domain of MMP-9 shares such low amino acid identity with other secreted MMPs (only 25% to 
33%), it has been proposed that more selective and specific inhibitors of MMP-9 could be 
developed by targeting this domain (Dufour et al., 2011).  Moreover, its 3-D shape has been 
described as barrel-like, with a 4-bladed β-propeller structure with a single disulfide bond 
between the first and the fourth blades (Nagase et al., 2006). 
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Four major functions have thus far been ascribed to the hemopexin domain of MMP-9, 
including: interaction with substrates, binding to inhibitors, binding to cell surface receptors and 
induction of auto-activation (Vandooren et al., 2013b).  The hemopexin domain has been 
reported to have a high affinity for substrates like collagen type I and IV, elastin, and fibrinogen.  
Interestingly, the hemopexin domain of the inactive proMMP-9 has been shown to have higher 
affinity for binding these ECM components than the hemopexin domain of active MMP-9,  
without the propeptide (Burg-Roderfeld et al., 2007).  However, though interactions with the 
hemopexin domain appears to regulate the enzyme’s bioavailability, the actual cleavage of a 
number of substrates (including IL-8) by MMP-9 is equally efficient for an MMP-9 mutant 
without the hemopexin domain (Van den Steen et al., 2006). 
Further, because dysregulation of the net activity level of MMP-9 is pathological in multiple 
situations in both the periphery and in the central nervous system, as reviewed in more detail 
below, another important role of the hemopexin domain is inhibition, which occurs directly and 
indirectly through interactions with endogenous inhibitors.  First, MMP-9 activity has been 
shown to be specifically reduced by interaction with its own hemopexin domain, expressed in E. 
coli (Roeb et al., 2002).  The authors speculate that the reason for this antagonism is because of 
the hemopexin domain’s affinity for gelatin; that is, the catalytically inactive hemopexin domain 
binds to the substrate and competes with active MMP-9.  Second, besides this type of 
antagonism, the hemopexin domain of MMP-9 also asserts an inhibitory effect via its interaction 
with endogenous tissue inhibitors of metalloproteinases (TIMPs).  There are four TIMPs (TIMP-
1,-2,-3, and -4) which act as broad spectrum inhibitors of MMPs, though with differences in their 
specificity.  Generally, the overall shape of the TIMP molecule is like a wedge, which fits into 
the active-site cleft of an MMP (Nagase et al., 2006).  Though all TIMPs can inhibit MMP-9, 
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MMP-9’s hemopexin domain has specific interactions with TIMP-1 and TIMP-3 that increase 
the efficiency of inhibition.  In fact, when the hemopexin domain of MMP-9 is deleted, TIMP-1 
inhibits 17.5-fold less efficiently than it does the intact proteinase (Goldberg et al., 1992).  Also, 
like TIMP-1, TIMP-3 can bind to proMMP9, but not to a mutant that lacks the hemopexin 
domain, indicating that these C-terminal domain interactions are sufficient and necessary to yield 
a stable proenzyme-inhibitor complex (Butler et al., 1999).  
Another way in which MMP-9’s hemopexin domain is involved in the tight regulation of its 
activity levels is through its interaction with receptors at the cell surface.  For example, the 
hemopexin domain interacts with LRP-1, and this interaction leads to endocytosis and 
intracellular degradation of MMP-9 (Hahn-Dantona et al., 2001; Van den Steen et al., 2006). 
Interestingly, the binding sites for LRP-1 and TIMP-1 in the hemopexin domain do not overlap, 
as the MMP-9/TIMP-1 complex still binds to LRP-1.  This could suggest that these two routes of 
MMP-9 activity inhibition can occur simultaneously (Piccard et al., 2007).  As an example of the 
potential importance of the interaction of LRP-1 and the hemopexin domain of MMP-9, LRP 
levels and activity are known to be substantially decreased in tumors (de Vries et al., 1996), 
which decreases catabolism of MMP-9 and could be one of the leading reasons why there are 
higher levels of MMP-9 at the tumor site (Hahn-Dantona et al., 2001).  Aside from this 
interaction leading to endocytosis, the hemopexin domain of MMP-9 also interacts with docking 
molecules such at the Ku protein and CD44 to localize MMP-9 to cell surfaces, thereby 
facilitating their activation and proteolytic activities (Monferran et al., 2004; Stamenkovic, 
2000).  
Another potentially important role for the hemopexin domain of MMP-9 may be zymogen 
activation.  Though auto-activation has been much more studied in other MMPs, particularly 
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MMP-2 and MMP-14 (Morrison and Overall, 2006), it has now also been reported for MMP-9.  
Specifically, it was shown that the interaction of hemin or β-hematin with the proMMP-9 
hemopexin domain primes MMP-9 activation via an autocatalytic process (Geurts et al., 2008). 
Finally, the hemopexin domain of MMP-9 also exerts non-catalytic effects through its 
binding with integrins.  The binding of the MMP-9 hemopexin domain to α4β1-integrin (in 
conjunction with CD44v) contributes to B-cell leukemia lymphocytes pathogenesis in a way that 
does not require catalytic activity, but is simply mediated by the binding (Redondo-Muñoz et al., 
2008; Redondo-Muñoz et al., 2010; Ugarte-Berzal et al., 2012). Further, when the interaction 
between the integrin epidermal growth factor (I-EGF)-like domains of β5 integrins andMMP-9’s 
hemopexin domain is blocked by a synthetic peptide, in vitro cell migration and in vivo tumor 
cell growth are prevented, without any direct effect on MMP-9’s proteolytic activity (Björklund 
et al., 2004). 
  Therefore, the relationship between the hemopexin domain and MMP-9’s net activity levels 
is a complicated one as the hemopexin domain has been shown to 1) inhibit activity, 2) activate 







Figure 1.6 Schematic of the primary and 3D structure of MMP-9 
 
A.. Domain structure of MMP-9 which consists of a signal peptide (white), a propeptide (green), 
a catalytic domain that contains the active site (red), a zinc ion (grey), and three tandem repeats 
of fibronectin type II inserts (blue), a proline-rich and heavily O-glycosylated linker (dashed 
line), and a hemopexin-like domain (grey). 
B. Ternary structure of MMP-9, where the domains are shown in the same colors as in A.  Figure 
modified from  Dziembowska and Wlodarczyk (2012).  
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Regulation of the enzymatic activity of MMP-9 
Given its large number of substrates and the potential destruction that unregulated 
proteolysis could cause in the body, MMP-9’s activity is tightly regulated at multiple levels 
(Figure 1.7).   A first level of regulation is transcriptionally, and there are a variety of signaling 
pathways that stimulate or reduce the transcription of the Mmp9 gene.  Next, MMP-9 is regulated 
at the level of the secretion of its proform (“proMMP9”).  Importantly, once proMMP9 is 
secreted, it still must be activated.  Finally, once activated, this activity is regulated by 
endogenous MMP inhibitors. 
Like most MMPs, MMP-9 is not constitutively expressed in the majority of cells, but 
gene transcription is induced in response to stressors or other signals.  In fact, there is a wide 
literature on its transcriptional control by cytokines, growth factors, hormones and other cell 
interactions (Opdenakker et al., 2001).  The gene for MMP-9 is located on human chromosome 
20 and its transcription is regulated by 670 base pairs of upstream sequence which includes 
binding sites for activator protein 1 (AP-1), nuclear factor kappa B (NF-κB), the Ets factor PEA-
3, and specificity protein 1 (Sp-1) (Sato and Seiki, 1993).  While Sp-1 and PEA-3 act as co-
activators, the AP-1 and NF-κB binding sites appear to be essential for Mmp-9 gene expression. 
Correspondingly, the most often reported cause of suppression of MMP-9 transcription is 
interference with the binding of NF-κB and AP-1 to the promoter region (Vandooren et al., 
2013b).  For example, SIRT1 is a repressor of Mmp9 transcription and the inhibition of SIRT1 
results in increased epigenetic expression of AP-1 and NF-κB by histone-4 acetylation 
(Nakamaru et al., 2009).   It is also worth noting that resveratrol, a SIRT1-activating molecule, as 
well as lentiviral expression of SIRT1 in the hippocampus, slowed in vitro neuronal death as well 
as in vivo neurodegeneration and cognitive decline, though a connection with MMP-9 repression 
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was not investigated (Kim et al., 2007).  Finally, another example of a compound that has been 
shown to repress Mmp9 transcription is Simvastatin, through a mechanism by which 
RhoA/ROCK inhibition leads to a reduction in Mmp9 mRNA levels (Turner et al., 2005).   
Simvastatin has an additional effect on MMP-9 activity, in that it and another HMG-CoA 
reductase inhibitor, fluvastatin, also reduce secretion of proMMP9 from macrophages, an effect 
that can be overcome by exogenous addition of mevalonate, a precursor of isoprenoids (Bellosta 
et al., 1998). 
Compartmentalization and secretion of MMP-9 has the most substantial effect on the 
timing of its activation.  MMP-9 produced by neutrophils is stored in zymogen granules, ready to 
be secreted very quickly (< 15 min) upon an inflammatory stimulus, without the need for 
transcription and translation (Van den Steen et al., 2002).  This secretion has been shown to be 
mediated by Rab27a, a GTPase involved in specific vesicle trafficking (Brzezinska et al., 2008).   
In contrast, it was very recently demonstrated that in M1-type macrophages, MMP-9 can be 
found intracellularly in small Golgi-derived cytoplasmic vesicles along with calreticulin (CRT) 
and protein disulfide isomerase (PDI), and the secretion of these vesicles is not Rab27a 
dependent (Hanania et al., 2012).  Also, because these macrophages rely on de novo synthesis 
prior to the secretion of MMP-9, release takes several hours (Opdenakker et al., 2001).  Though 
secretion is important, it is also worth mentioning  that a broad range of intracellular proteins 
located in vesicles, mitochondria, the nucleus and cytoplasm can be processed by MMP-
9 (Cauwe and Opdenakker, 2010), though there is some debate on whether that actually occurs 
intracellularly or if those proteins are also secreted and processed in the extracellular milieu.   
As mentioned above, MMP-9 has an aminoterminal propeptide domain which contains 
the “cysteine switch” that is responsible for the latency of proMMP-9.   Any means that can pull 
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the cysteine away from the Zn
2+
 ion will result in activation and catalytic activity (Vandooren et 
al., 2013b).  The earliest demonstrated in vivo activator was MMP-3 (Ogata et al., 1992), though 
even before that it had been documented that compounds, such as AMPA or trypsin could 
activate proMMP-9 in vitro (Masure et al., 1990; Moll et al., 1990).  Since then, other activators 
have been identified including plasmin (Gong et al., 2008), kallikrein-related peptidase 7 
(Ramani et al., 2011), MMP-26 (Yamamoto et al., 2004; Zhao et al., 2003), and human 
neutrophil elastase (HNE) (Jackson et al., 2010). 
Perhaps of particular interest in a thesis about neuronal degeneration, proMMP9 can also 
be activated by nitric oxide (NO) by a process called S-nitrosylation.  Gu et al. first showed that 
NO can directly activate proMMP9 and induce neuronal apoptosis in cerebrocortical cultures 
(Gu et al., 2002).  Then, to confirm their results in vivo, they used mass spectrometry to 
characterize the events during focal ischemia and reperfusion.  In this way, they showed that 
proMMP9 is activated by S-nitrosylation of a cysteine residue followed by a further irreversible 
modification of the residue into a sulfinic (–SO2H) or sulfonic (–SO3H) acid. 
Once activated, MMP-9 is subject to a final level of activity regulation: inhibition, 
usually by TIMPs.  Though all TIMPs can inhibit active MMP-9, TIMPs-1 and -3 have the best 
inhibitory efficacy.  Further, most cell types that express MMP-9 also express TIMP-1 
(Vandooren et al., 2013b).  Chemical inhibitors have also been developed and have been used in 






Figure 1.7 Schematic of the multiple layers of regulation of the activity of MMP-9 
First, transcription is regulated by 670 base pairs of upstream sequence which includes binding 
sites for activator protein 1 (AP-1), nuclear factor kappa B (NF-κB), the Ets factor PEA-3, and 
specificity protein 1 (Sp-1). Next, MMP-9 is regulated at the level of the secretion of its proform. 
Once proMMP9 is secreted, it must be activated by removal of the prodomain (green).  Finally, 
once activated, this activity is regulated by endogenous MMP inhibitors (TIMPs, purple), which 




MMP-9 in physiological and pathological roles in the periphery 
While the structure of MMP-9 and its activation and regulation were fairly well worked 
out in the 1990s and early 2000s, new reports of functional effects of MMP-9 continue to appear.  
First, the majority of studies concern the role that MMP-9 plays in the remodeling and 
degradation of the extracellular matrix (ECM).  As such, MMP-9 participates in many of the 
physiological events that require ECM breakdown and modification, such as cell migration, 
proliferation, morphogenesis, and apoptosis (Page-McCaw et al., 2007; Vandooren et al., 2013b; 
Vu and Werb, 2000).    
Wound healing provides a good example of many of these processes.  Following injury to 
skin, the normal path to healing involves initial hemostasis, edema formation, inflammation, and 
scab formation.  Though MMP-9 is not constitutively expressed in epithelial cells, its expression 
is induced following injury.  Additional MMP-9 is expressed and provided by infiltrating 
inflammatory macrophages (Vandooren et al., 2013b).  These initial responses are followed by 
cell proliferation and migration, production and remodeling of the ECM, angiogenesis, and 
reepithelialization.  This later wave of wound healing depends on MMP-9 (and other MMPs), as 
MMPs act not only to degrade and remodel selected ECM components, but also can liberate 
growth factors and bioactive fragments through targeted cleavage.  The cleavage of both ECM 
and non-ECM molecules in order to release additional factors can ultimately influence later cellular 
behavior beyond simple mechanical changes in cellular architecture (Heissig et al., 2003; Mott 
and Werb, 2004).  In fact, angiogenesis can be either stimulated or inhibited based on MMP-9’s 
early actions (Schultz and Wysocki, 2009).   
Consistent with an overall positive role for MMPs in wound healing, it has been shown 
that wounds treated with MMP inhibitors heal at a delayed rate (Agren et al., 2001; 
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Mirastschijski et al., 2004).  Further, wounds in MMP-9 null mice displayed compromised 
reepithelialization and reduced clearance of fibrin clots as well as exhibited abnormal matrix 
deposition, as evidenced by the irregular alignment of immature collagen fibers (Kyriakides et 
al., 2009).  However, the balance is important: high concentrations of MMP-9 and high MMP-9–
to–TIMP-1 ratios in wound fluid predict poor wound healing in diabetic foot ulcers (Liu et al., 
2009). 
   Wound healing and related angiogenesis are just one example of MMP-9’s critical role in 
maintenance and normal physiology.  MMP-9 is also important for important processes like 
reproduction (Dubois et al., 2000) and bone development and remodeling (Ortega et al., 2004). 
Further, MMPs also influence normal cellular functions when they target non-matrix proteins, 
including other proteinases, proteinase inhibitors, clotting factors, chemotactic molecules, latent 
growth factors, growth factor-binding proteins, cell surface receptors and cell-cell adhesion 
molecules (Tonti et al., 2009).  However, when MMP-9 is dysregulated in the periphery, its 
actions can have a myriad of pathological consequences in diverse problems ranging from 
cardiovascular disease to cancer. 
For example, MMPs have been implicated in muscle disease.  In models of disuse-
induced muscle atrophy in which either a leg is mechanically immobilized in a cast or by 
suspension, or by transecting the Achilles tendon, both MMP-9 and MMP-2 have been shown to 
be upregulated in rat gastrocnemius (Reznick et al., 2003), rat soleus (Berthon et al., 2007), as 
well as in wild-type mouse gastrocnemius (Liu et al., 2010c).   However, though both gelatinases 
are upregulated to similar levels, only Mmp2 knockout mice show significantly reduced muscle 
atrophy when compared to wild-type littermates (Liu et al., 2010c).  Another example of the role 
of MMP-9 comes from studies of tumor necrosis factor-related weak inducer of apoptosis 
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(TWEAK), which was shown to be involved in muscle atrophy (Dogra et al., 2007).   Using 
genome wide microarray analysis of RNA samples from control and TWEAK-treated myotubes, 
Li et al. showed that the expression and production of MMP-9 are drastically increased in 
TWEAK-treated cultures and that NIK-, IKKβ-, and protein kinase 38 (p38) MAPK-dependent 
activation of NF-κB underlie this increased expression (Li et al., 2009).  They further observed 
higher expression of MMP-9 in the skeletal muscle tissues of TWEAK transgenic mice and 
demonstrated that TWEAK-induced myopathy is significantly attenuated in Mmp9 knock-out 
mice. 
 Still, the most studied role of MMP-9 in pathological processes is its involvement in the 
growth and spread of cancer.  In fact, MMP-9 was first identified as a result of cloning its cDNA 
from a tumor cell line (Huhtala et al., 1990).  Two specific observations led researchers to 
examine the link: first, MMP-9 is overexpressed in a variety of malignant tumors, and, second, 
its expression and activity are often associated with tumor aggressiveness and a poor prognosis 
(Bauvois, 2012).  Elevated levels of MMP-2 and MMP-9 are found in breast, brain, ovarian, 
pancreas, colorectal, bladder, prostate and lung cancers and melanoma and dysregulated MMP 
expression is observed in hematological malignancies such as different types of leukemia and 
Hodgkin's and non-Hodgkin's lymphoma (Bauvois, 2012; Vandooren et al., 2013b).  In fact, 
MMP-9 has been implicated in shaping the microenvironment in ways that critically affect all 
four major hallmarks of cancer: migration, invasion, metastasis and angiogenesis (Gialeli et al., 
2011).  Many aspects of these processes are obviously dependent on matrix remodeling, but 




First, as previously mentioned, Redondo-Muñoz and colleagues showed that the binding 
of proMMP-9's hemopexin domain to the docking receptors α4β1 integrin and CD44 induces an 
intracellular signaling pathway that allows for the survival of CLL cells isolated from the 
lymphoid organ of human patients (Redondo-Muñoz et al., 2010).  The authors go to show that 
this survival is dependent on Lyn kinase activation, STAT3 phosphorylation and upregulation of 
Mcl-1.  High levels of proMMP-9 and Mcl-1 have also been found in CLL cells isolated from 
patients’ blood (Chen et al., 2010).  In addition to this signaling pathway, MMP-9 multimers 
were shown to interact with CD44, leading to the activation of EGFR and consequently the 
MAPK (ERK1/2) pathway, thereby mediating cancer cell migration (Dufour et al., 2008).  By 
the use of a small compound  that fit within the loops of the barrel structures of the hemopexin 
domain, the formation of MMP-9 multimers could be hindered and cancer cell migration was 
abolished (Dufour et al., 2011).  These results, and others in preclinical models, suggested that 
reducing MMP-9 levels either with classical inhibitors or by the use of newer compounds could 
have a therapeutic benefit in cancer patients.  This will be discussed in more detail later. 
 
 MMP-9 in physiological roles in the central nervous system 
MMP-9 has also been implicated in physiological and pathological roles in the central 
nervous system (CNS).  For example, in the postnatal developing rat cerebellum, MMP-9 is 
expressed in migrating granule cell precursors, growing Purkinje cells, dendrites, and Bergmann 
glial cells (Ayoub et al., 2005; Vaillant et al., 1999) and is spatiotemporally associated with 
granule cell migration, axonal outgrowth,  and induction of apoptosis (Vaillant et al., 2003).  In 
the adult rodent CNS, total brain samples generally have low transcript levels for most MMPs, 
47 
 
but there are certain regions where high levels of constitutive MMP-9 expression are detected 
(Huntley, 2012).   
One such region of high constitutive MMP-9 expression is the hippocampus, where 
MMP-9 has been shown to localize in neurons.  In the hippocampus, MMP-9 plays an important 
role in learning and memory.  When two neurons fire together, their structure and function are 
altered to create an enhancement of signal transduction.  This process is called long-term 
potentiation (LTP).  Hippocampal slice cultures from Mmp9 knockout mice show impaired LTP, 
which can be restored by the application of recombinant MMP-9 (Nagy et al., 2006).  
Correspondingly, Mmp9
-/- 
mice show behavioral impairments in hippocampus-dependent 
associative learning (that is, pairing a footshock with a tone and quantifying the amount of time 
spent freezing 24 hours later), but do not have impairments in non-hippocampal learning (cued 
conditioning and activity suppression) (Nagy et al., 2006).  In another study, transient induction 
of hippocampal MMP-9 was observed when animals were trained in the Morris water maze.  
Also, inhibition of MMP-9 activity with antisense oligonucleotides altered LTP and prevented 
the animals’ learning in this paradigm (Meighan et al., 2006).   
Further, it has been shown that during LTP dendritic spines undergo significant 
remodeling in association with the long-lasting plasticity (Yuste and Bonhoeffer, 2001).  In 
2008, Wang et al. reported that proteolysis by MMP-9 is both necessary and sufficient to drive 
lasting spine enlargement and synaptic potentiation and this plasticity requires β1-integrin-
dependent actin remodeling and protein synthesis (Wang et al., 2008).  Specifically, they show 
that local application of proteolytically active MMP-9 to unstimulated dendritic spines of CA1 
pyramidal neurons induces an LTP-like increase in synaptic signal strength and concurrent spine 
enlargement, both of which reach a maximum in the 15–20 min period after the spines are first 
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exposed to the enzyme.  This is a specific function of MMP-9’s activity, as plasticity is not 
observed when spines are exposed to proMMP9 or to active MMP-2 (Huntley, 2012; Wang et 
al., 2008).  
Also with regard to learning, it was very recently shown that MMP-9 activity in the 
central amygdala is required for appetitive, but not aversive, instrumental learning (Knapska et 
al., 2013).  In that study, three kinds of appetitively motivated conditioning were impaired by 
either genetic deletion of Mmp9
 
or by blocking extracellular MMP-9 activity by nanoparticle-
based release of recombinant TIMP-1 in the central amygdala.  Interestingly, another recent 
study showed that conditional taste aversion causes a significant down-regulation in MMP-9 
expression in the amygdala of rats (Panguluri et al., 2012).  Further, it has been suggested that a 
decrease in MMP-9 levels in the hippocampus of abstinent cocaine addicts may underlie the 
neural deficit that makes the addict vulnerable to relapse (Mash et al., 2007). 
Aside from synaptic plasticity and reward signaling, another important role for MMP-9 in 
the nervous system is the regulation and maintenance of Schwann cells.  MMP-9 functions as a 
modulator of Schwann cell signaling and induces remodeling after nerve injury (Vandooren et 
al., 2013b).  There is robust MMP-9 induction within 24 hours in both degenerating (distal) and 
regenerating (proximal) nerve segments of axotomized sciatic nerves (Chattopadhyay and 
Shubayev, 2009).   Further, there is also increased Schwann cell mitosis in axotomized Mmp9
−/−
 
nerves, suggesting that MMP-9 is responsible for decreased mitosis.  This inhibition of mitosis 
by MMP-9 was demonstrated to occur via ErbB-mediated activation of the extracellular receptor 
kinase (ERK) MAPK pathway in cultured Schwann cells.  Finally, treatment with a broad-
spectrum MMP inhibitor promotes Schwann cell proliferation (Chattopadhyay and Shubayev, 
2009; Liu et al., 2010a). 
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Also with regard to myelination, it was shown that although initial demyelinating injury 
is equivalent between Mmp9 null and wild-type mice, Mmp9
-/-
 mice exhibit a significant deficit 
in remyelination (Larsen et al., 2003).  The authors postulate that the mechanism underlying this 
could be the failure of MMP-9 null mice to remove injury-induced deposits of NG2 
proteoglycan.  Therefore, MMP-9 may have a beneficial role in remyelination.  
MMP-9 in pathological roles in the nervous system 
MMP-9 also has been linked to a number of pathological events in the nervous system 
including chronic neuropathic pain, stroke, blood-brain barrier (BBB) dissolution, and, of special 
interest here, neurodegeneration (Vandooren et al., 2013b).  First, two major studies implicate 
MMP-9 in spinal cord-relevant pathology.  Kawasaki and colleagues show a rapid and transient 
upregulation of MMP-9 in injured dorsal root ganglion (DRG) primary sensory neurons after 
sciatic nerve ligation (Kawasaki et al., 2008).  They also show that MMP-9 produced in injured 
DRG neurons serves as one of the triggers for spinal microglial activation and neuropathic pain 
development and that MMP-9-induced pathophysiology involves IL-1β cleavage and microglial 
p38 activation.  Finally, they were able to use TIMP-1 to suppress neuropathic pain.  
A related study looked at the connection between opioid withdrawal and MMP-9 and 
found that spinal administration of exogenous MMP-9 induces morphine withdrawal-like 
behavioral signs and mechanical allodynia, activates NR1 and NR2 receptors, and down-
regulates integrin-β1 (Liu et al., 2010b).  Because a function-neutralizing antibody against 
integrin-β1 suppressed the MMP-9-induced phosphorylation of NR1 and NR2B and morphine 
withdrawal-induced MMP-9 activity is reduced by an nNOS inhibitor, the authors hypothesized 
that spinal MMP-9 may contribute to the development of morphine dependence primarily 
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through neuronal activation and interaction with NR1 and NR2B receptors via integrin-β1 and 
NO pathways. 
Another example of MMP-9’s role in pathologies of the nervous system is that MMP-9 
has been shown to be prominently involved in oxidative stress-related disruption of the blood-
brain barrier (BBB) during cerebral ischemia (Gasche et al., 2001; Pustovrh et al., 2005).  Mmp9
-
/- 
mice are protected from cerebral ischemia (Asahi et al., 2000) and the degradation of the 
critical components of the BBB and white matter after transient focal ischemia were significantly 
slowed in these mice compared with wild-type littermates (Asahi et al., 2001).  Further, MMP-9 
has also been implicated in BBB disruption in an experimental model of Huntington’s disease 
(Duran-Vilaregut et al., 2011).  3-NPA is a natural toxin which, when administered systemically 
to experimental animals, reproduces the selective neurodegeneration of striatal neurons 
associated with Huntington’s disease (HD).  In 3-NPA-treated rats, MMP-9 was present in most 
of the degraded blood vessels of the injured striatum, while it was totally absent from vessels in 
non-injured tissue (Duran-Vilaregut et al., 2011).  This is not the only link with HD; in fact, 
MMP-9 has been found to be upregulated in post-mortem brains of patients (Silvestroni et al., 
2009) and it was also found that MMP-9 may assist in the cleavage of the huntingtin protein 
(Miller et al., 2010). 
Other links to neurodegenerative disease have been reported (Rosenberg, 2009).  
Connections have been made to AD, though it remains unclear if MMP-9 is harmful or helpful in 
this situation.  First, MMP-9 was shown to be upregulated in brain tissue of patients with AD 
(Backstrom et al., 1996), as well as in plasma (Lorenzl et al., 2003), but not in cerebrospinal 
fluid (Adair et al., 2004).  These increases are thought to result from increased inflammation, and 
reducing inflammation has been tested unsuccessfully as a therapeutic strategy in the treatment 
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of AD (Rosenberg, 2009).  Further, it has been demonstrated that MMP-9 plays a significant role 
in brain β-amyloid (Aβ) degradation and clearance.  Yin et al. showed by immunohistochemistry 
and analysis of laser-captured mRNA that levels of MMP-9 are upregulated in activated 
astrocytes surrounding amyloid plaques in aged APP/PS1 transgenic mice and that MMP-9 can 
catabolize Aβ (Yin et al., 2006).  They further showed that significant increases in the steady-
state levels of Aβ are found in Mmp9-/- brains and that pharmacological inhibition of MMPs by a 
general MMP inhibitor increased brain interstitial fluid Aβ levels and half-life of elimination in 
APPsw mice.  Not only can MMP-9 degrade soluble Aβ, it can also digest tightly aggregated Aβ 
fibrils (Yan et al., 2006).  Finally, tau is a substrate of MMP-9 and the tau cleavage pattern of 
MMP-9 facilitates aggregation (Nübling et al., 2012).  
There is also a documented link between ALS and MMP-9.  First, it has been very 
recently reported that the C(−1562)T polymorphism in the MMP-9 gene, which leads to higher 
promoter activity, is significantly associated with a risk for sporadic ALS (and PD) in a Chinese 
population (He et al., 2013), though these results differed from an earlier study in a small Polish 
population that found no association between that polymorphism and risk of sporadic ALS 
(Zawiślak et al., 2009).  Also, the total amount of both the pro and active forms of MMP-9 is 
higher in the serum of ALS patients than in controls (Beuche et al., 2000; Demestre et al., 2005).  
Further, high CSF MMP-9 levels were associated with a rapid progression of disease in human 
ALS patients (Fang et al., 2009).  The same group found that there was also an increase in MMP-
9 in homogenized skin and spinal cords of SOD1 mice only after 90 days of age, but not at early 
disease stages (Fang et al., 2010).  Another, independent group also showed that the timing of 
MMP-9 induction overlapped in the spinal cord and blood of a different (low copy number) 
tgSOD1 mouse model, and given that 1) astrocytes have been implicated in ALS disease 
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progression (Di Giorgio et al., 2007; Nagai et al., 2007; Yamanaka et al., 2008) and 2) reactive 
astrocytes are known to secrete MMPs (Muir et al., 2002), the authors speculated that circulating 
MMP-9 may be derived centrally and reflect an elevated inflammatory process in the spinal cord 
(Soon et al., 2010),  
To further explore the relationship between MMP-9 and the pathogenesis of ALS, two 
separate groups crossbred MMP-9 knock-out mice with mutant SOD1 mice, but got very 
different results (Dewil et al., 2005; Kiaei et al., 2007).  First, Dewil, Robberecht and colleagues 
showed by zymography that astrocytes and microglia cultured from SOD1
G93A
 P0 pups release 




 cells in late stage G93A 
spinal cords, they speculate that these are the sources of the late-stage MMP-9 induction that had 
been previously reported.  The researchers then crossed Mmp9
-/-
 mutant mice with a 129 
background onto a C57B1/6 background for 6 generations.  These mice were then crossed with 
G93A mice from Jackson lab (B6SJL) for an additional 2 generations.  Surprisingly, they report 
that their Mmp9
-/-
;G93A mice had significantly shorter lifespans  than Mmp9
+/+
;G93A littermate 
controls (131.9 ± 2.9 days vs. 138.7 ± 3.1 days).  However, they saw no influence of MMP-9 
deletion on rotarod performance, despite the significant exacerbation of disease in terms of 
survival (Dewil et al., 2005).   
In contrast, Kiaei et al. found a survival benefit of approximately 30% when they crossed 
Mmp9
-/-
 on a CD-1 background from Zena Werb’s lab (Vu et al., 1998) with G93A mice (B6SJL, 
from Jackson Laboratories) for 6 generations.  They also report a significant preservation of 
motor neurons in the Mmp9
-/-
;G93A spinal cords at P115 (Kiaei et al., 2007).  This is the earliest 
time-point that the authors investigated, but from these results they conclude that MMP-9 is 
likely contributing to the pathogenesis of ALS by 1) facilitating the cleavage of TNF-α and 
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related proinflammatory cytokines, or by 2) anchorage-dependent detachment of cells from the 
extracellular matrix.  The difference between these results from the Beal group and those 
previously reported by the Robberecht group remain unresolved. 
Though the majority of these studies have implicated glia as being the main source of 
MMP-9 in ALS, an early study showed that monoclonal antibodies to MMP-9 weakly labeled 
pyramidal neurons in the motor cortex and about 60% of motor neurons in the ventral horn of the 
lumbar spinal cord of both control and ALS specimens (Lim et al., 1996).  Not only did this 
paper establish that MMP-9 is predominantly localized in the neurons, the pattern of 
immunoreactivity shown (cytoplasmic, extending into the dendrites and axons throughout the 
neuropil, but non-nuclear) as well as the proportion of positively stained  motor neurons is 
remarkably similar to our own findings in WT and SOD1 mice (Chapter 2).  Therefore, though 
MMP-9 has been implicated in ALS for nearly two decades, many open questions remain about 
whether MMP-9 is actually involved in the ALS disease pathogenesis, its site of origin and 
action, and the timing of its possible involvement.  
The use of MMP-9 inhibitors: past, present, and future 
Clearly, MMP-9 plays an important but complicated role in the organism.  Its tightly 
regulated activity, large range of substrates, role in proteolytic processing to regulate the 
functions of bioactive molecules, and non-enzymatic activity make attempts to regulate specific 
pathologic roles of MMP-9 very challenging.  The development and use of MMP inhibitors in 
cancer over a decade ago provides a good example of the difficulty.   
As discussed earlier, MMPs were considered the prime suspects in the spread of cancer, 
as they could readily destroy the matrix barriers surrounding a tumor and thus permit invasion 
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into surrounding tissues and metastasis to distant organs.  Moreover, MMPs are upregulated in 
virtually all human and animal tumors.  Once the causal relationship between MMP 
overexpression and tumor progression was solidly established, many companies began 
developing MMP inhibitors as cancer therapeutics (Coussens et al., 2002).  The first wave of 
MMP inhibitors were developed at a time when only 3 MMPs had been discovered (MMP-1 
“collagenase”, MMP-2 “gelatinase” and MMP-3 “proteoglycanase”) and their complete set of 
actions were poorly understood.  The compounds were further hampered by poor bioavailability 
(Overall and López-Otín, 2002).  A next wave of inhibitors were rapidly developed that were 
orally available, but these too were problematic as early phase I clinical dose escalation studies 
revealed that prolonged treatment with these inhibitors caused musculoskeletal pain and 
inflammation.  Although the conditions were reversible and patients were able to continue 
treatment after a brief drug holiday, the unexpected side effects limited the inhibitor dosages that 
could be administered in subsequent trials (Coussens et al., 2002).   
Problems with dosage were only one of the issues with MMP inhibitors in Phase II/III 
trials; there were also issues with suboptimally designed endpoints as well as unexpected 
outcomes at this stage.  The preclinical evidence suggested that MMP inhibitors would stop the 
growth of tumors, but not kill cells.  Therefore, rather than looking for a reduction in tumor size, 
Phase II/III trials were designed to assess whether inhibitors like marimastat could decrease the 
rate of tumor markers appearance or disappearance in patients’ serum  (Coussens et al., 2002; 
Miller et al., 2002).  This was criticized as an endpoint because changes in biomarker levels in 
serum do not necessarily reflect tumor regression.  Ultimately, marimastat failed to prolong 
survival when used after first-line chemotherapy for metastatic breast cancer, though the patients 
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did experience musculoskeletal toxicity causing the researchers to conclude that the 
metalloproteinases were actually being inhibited (Sparano et al., 2004). 
Troublingly, two studies showed diminished survival with an MMP Inhibitor (BAY 12-
9566) evaluated in pancreatic cancer and small-cell lung cancer (Moore et al., 2003; Nozaki et 
al., 2003).  In fact, only one study has demonstrated a possible benefit for use of MMP inhibitors 
in cancer, showing significant improvement in progression-free survival and overall survival in a 
subgroup of 132 patients with unresectable or metastatic gastric or gastroesophageal 
adenocarcinoma.  However, the study failed to meet the primary end point of improving survival 
in the entire group of 369 patients (Bramhall et al., 2001).   
More recent studies may give clues to the failures of these trials.  For example, 
surprisingly, general MMP inhibitors can induce the expression of MMP-9 in human 
fibrosarcoma cells, thereby potentially promoting rather than inhibiting tumor progression 
(Maquoi et al., 2002).   As an additional example, following batimastat treatment, human breast 
carcinoma cells metastasized to the liver in nude mice and caused liver specific overexpression 
of MMP-2 and MMP9-9 even in tumor-free animals (Krüger et al., 2001).  Therefore, the 
induction of organ-specific side effects may have hindered the development and clinical use of 
synthetic MMP inhibitors.  Further, these results suggest that individual MMPs may have very 
different roles in cancer; that is, elevated protease levels may favor tissue-destructive processes 
such as those taking place in cancer, whereas specific protease deficiencies may lead to the 
development of many other pathological conditions (López-Otín and Matrisian, 2007).  Beyond 
this, some have advocated a general rethinking of MMPs in cancer progression as a host 
response rather than an induction by tumors (Coussens et al., 2002).  Generally, the field seems 
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to be moving away from broad spectrum inhibition and towards blocking individual MMPs 
under pathological conditions (López-Otín and Matrisian, 2007). 
 To do this for MMP-9, a few other inhibitory strategies are being pursued.  For 
example, because of their ability to selectively bind closely related antigens, antibodies provide 
an excellent scaffold for creating function blocking inhibitors for individual MMPs.  REGA-
3G12 was among the first inhibitory antibodies reported that selectively targets the MMP-9 
active site (Martens et al., 2007).  However, the most recent breakthrough in MMP-specific 
monoclonal antibody technology was the development of  “metallobodies” (Vandooren et al., 
2013b).  These are generated by immunizing mice with a small, synthetic, organic metal-ligand 
molecule—tris-imidazole zinc complex (Zn-tripod)—which was specifically designed to mimic 
structural and chemical motifs of  the relatively exposed catalytic zinc-protein machinery in the 
active form of MMPs lacking their prodomain.  After repetitive immunization with the Zn-
tripod, further immunizations of mice with recombinant MMP-9 was used to select for highly 
selective monoclonal antibodies.  Excitingly, these dual-specific antibodies were shown to be 
effective in an animal model of inflammatory bowel disease (Sela-Passwell et al., 2012).  
 Another strategy that is being used is a genetic one.   As mentioned earlier, many 
experiments have demonstrated that the selective, early inhibition of MMP-9 significantly 
reduces the degree of brain infarction, clearly demonstrating the importance of this enzyme in 
contributing to focal ischemic brain injury (Yong et al., 2001).  Direct delivery of siRNA against 
MMP-9 into the lateral ventricle of a rat brain in a middle cerebral artery occlusion model was 
shown to be as effective as inhibition, since disruption of BBB, brain edema, and the brain 
infarction volume after cerebral ischemia were significantly reduced by MMP-9 siRNA 
treatment (Hu et al., 2009).  As another example, using siRNA oligonucleotides to knock down 
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the MMP-9 gene in the B16 cell line significantly inhibited tumor cell migration and invasion in 
vitro and caused tumor regression in vivo (Tang et al., 2013).  Therefore, MMP-9 silencing also 
has therapeutic potential as a specific inhibitory strategy. 
 
Conclusions and open questions 
Given that 1) MMP-9 was identified in a previous screen as being a potential disease 
susceptibility factor of lumbar motor neurons in ALS and 2) it is a well-studied enzyme that has 
been previously linked to the function and dysfunction of the central nervous system, I wanted to 
ask: what can the biology of MMP-9 tell us about selective neurodegeneration?  Specifically, 
where and when is MMP-9 expressed in wild-type as well as in mutant SOD1 mice?  Further, is 
MMP-9 labeling a vulnerable subpopulation and, if so, can it serve as a biomarker for that 
susceptibility?  Also, of great importance, does MMP-9 actively play a role in the disease 
process and if it does, by what mode of action?  And finally, can we generalize the research 




Chapter 2: MMP-9 is selectively expressed in vulnerable motor neurons 
 
Introduction 
As discussed in the preceding chapter, there are at least two aspects of differential motor 
neuron vulnerability in ALS: a pool-specific resistance typified by oculomotor and Onuf’s 
nuclei, and a subtype-specific vulnerability of FF as compared to S motor units.  Using 
microarray profiling of isolated wild-type motor neurons to identify genes whose expression was 
characteristic of both oculomotor and Onuf’s nuclei but not of vulnerable lumbar spinal neurons, 
or vice versa, a putative vulnerability gene, MMP-9, was identified. 
MMP-9 has a restricted pattern of expression that changes from development to maturity. 
In the periphery, MMP-9 is frequently expressed at sites of active tissue remodeling and 
neovascularization. It is highly expressed during embryonic development by trophoblast cells at 
the implantation site and by osteoclasts.  Later, it is expressed mainly by inflammatory cells and 
in pathological processes such as inflammatory arthritis, tumor invasion, and skin blistering 
diseases (Vu and Werb, 2000).  In the central nervous system, MMP-9 generally has very low 
basal levels of expression.  However, in the normal adult brain, MMP-9 mRNA has been 
detected in the hippocampus, cerebellum and cortex.  In these areas, MMP-9 is predominantly 
expressed in neurons and, at the protein level, it has been found mainly in cell bodies and 
dendrites (Dzwonek et al., 2004).  Further, a more limited level of MMP-9 expression has also 
been observed in glia, in particular in astrocytes and microglia, both in vivo and in vitro (Dewil 




 It is now also well documented that excessive or inappropriate expression of MMP-9 can 
contribute to pathologic processes, and alterations in the expression and activity of MMPs are 
correlated with the development of several brain diseases (Yong et al., 2001). Increased levels of 
MMPs have been found in degenerative disorders such as multiple sclerosis, AD, PD and ALS 
diseases (Rosenberg, 2009).  For most of these diseases, though it seems apparent that MMP-9 is 
neuronal in origin, it is not clear whether it is expressed by the neurons prone to death or those 
attempting to recover from the damage (Dzwonek et al., 2004).  For ALS in particular, it is also 
not clear whether the reported increases in MMP-9 at late disease stages come from glia or from 
vulnerable motor neurons, though these studies strongly suggest that circulating microglia may 
be the source (Fang et al., 2010; Kiaei et al., 2007).  However, the results of the Henderson lab 
oculomotor/Onuf’s nuclei microarray suggest that MMP-9 is expressed by vulnerable motor 
neurons themselves as early as P7 (Figure 1.5).  Therefore, there are unanswered questions about 
the timing and localization of MMP-9 expression with regard to ALS. 
Furthermore, though the microarray result suggests that MMP-9 is a potential marker for 
vulnerable motor neurons because it is highly expressed in L5 motor neurons but absent from 
resistant oculomotor and Onuf’s nuclei, how this relates to the second layer of selective 
vulnerability (that is, of motor neuron subtypes) is an open question.  Though oculomotor and 
Onuf’s motor neurons have some characteristics in common with type S motor neurons (for 
example, small soma size, low innervation ratios, and higher levels of active duty), whether their 
shared molecular expression profiles extend to this resistant motor neuron subtype is not yet 
known.  Therefore, in this chapter, we investigate the time course and specificity of MMP-9 
expression in the WT mice and then relate these results to mutant SOD1 mice.  In particular, we 
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show that MMP-9 is expressed in fast motor neurons from P5 onward.  Further, we show that 




MMP-9 is selectively expressed by vulnerable motor neurons 
The results of the microarray showed that the levels of Mmp9 mRNA were 16-fold lower 
in oculomotor than L5 motor neurons, and 11-fold lower in DL at P7.  Though this was 
confirmed by in situ hybridization (ISH) at P7 (Figure 1.5), given that ALS is an adult-onset 
disease, we wanted to confirm that Mmp9 was still expressed in vulnerable motor neurons into 
adulthood.  We performed ISH on P57 wild-type mouse cryosections and confirmed that the 
pattern of expression remains into adulthood; that is, Mmp9 is highly expressed in vulnerable 
cranial motor pools like the trigeminal nucleus (Figure 2.1B) and the vulnerable spinal motor 
neurons at L5 (Figure 2.1C) and RDL in L6 (Figure 2.1D), but is absent from the resistant 
oculomotor pool (Figure 2.1A) and the DL nucleus at L6 (Figure 2.1D).  At the protein level, 
using an MMP-9 antibody that gave no signal in Mmp9 knockout mice, MMP-9 was not detected 
in any of the three cranial nuclei (III, IV and VI) (Figure 2.1E, and not shown) that innervate 
extraocular muscles, nor in the ventrolateral region of the DL nucleus in the L6 spinal cord 
(Figure 2.1E).  In contrast, motor neurons expressing high levels of MMP-9 were abundant in 
trigeminal and facial nuclei as well as in L5-L6 spinal motor neurons (Figures 2.1F-G, and not 
shown). Therefore, MMP-9 is absent from ALS-resistant populations in midbrain and spinal cord 
but present in many other motor neurons. Further, in the spinal cord, strong MMP-9 motor 
61 
 
neuron expression is first detected only postnatally at P5 (Figure 2.2B), but subsequently remains 
expressed at high levels until the latest time point studied, P165 (Figures 2.2C to 2.2E). 
Because MMP-9 is one of a family of MMPs, we wanted to check for the presence of 
other family members in motor neurons, especially the closely related gelatinase MMP-2.  First, 
no other secreted MMPs were present as indicated by the original microarray (Fig 2.3A), and, 
among the probes for 20 transcripts encoding MMPs represented on the array, only Mmp9 was 
differentially expressed among disease-resistant and vulnerable populations.  Furthermore, 
besides Mmp9, only four other MMPs appeared to have high expression values in motor neurons: 
Mmp15, Mmp16, Mmp17, and Mmp24.  These are all members of the same sub-family of non-
secreted, membrane-type MT-MMPs (Yong, 2005).  Also, as a second check beyond the 
microarray data, MMP-2 was confirmed to not be expressed in the adult mouse lumbar spinal 
cord at the level of L5 (where MMP-9 is strongly expressed in approximately 60% of motor 
neurons), nor in the DL nucleus (where MMP-9 levels are very low) (Fig 2.3 C, G).  Somewhat 
surprisingly, levels of TIMP2, which regulates MMP-2, are very high (Fig 2.3D, H), whereas 
TIMP3, which can inhibit both MMP-2 and MMP-9, is only moderately expressed (Figure 2.3 E, 
I).  
 Given the high expression of MMP-9 in motor neurons, we wanted to know if it also was 
expressed in other motor relevant cell types in postnatal mice.  First, IHC of a whole coronal 
section of the lumbar region of spinal cord shows that MMP-9 protein is expressed strongly by 
motor neurons in the ventral horn, but by few other neurons in the spinal cord and only very 
weak dorsal horn staining is observed (Figure 2.4A).  This image is from a presymptomatic 
(P25) SOD1
G93A 
animal, which we have found to have the same expression pattern as wild-type 
littermates prior to disease onset (compare ventral horns shown in Figure 2.4B and C). Mutant 
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SOD1 does not therefore itself trigger misexpression of the enzyme.  Further, we confirmed the 
absence of MMP-9 in proprioceptive dorsal root ganglia from WT and SOD1
G93A
 mice, 
identified by labeling with neurofilament (Figures 2.4D and E).  Mmp9 RNA is also absent from 
muscle sections of these mice (Figures 2.4F and G).  Finally, given that MMP-9 is a secreted 
enzyme, we checked the axons of a SOD1
G93A
 mouse at P40 for MMP-9 and found that it was 
expressed there (Figure 2.4H), though we did not see MMP-9 at the NMJ.  Therefore, MMP-9 is 
specifically expressed in postnatal, disease-susceptible motor neurons. 
MMP-9 is selectively expressed by fast motor neurons 
Even within motor neuron populations that expressed MMP-9, strongly labeled cells were 
intermingled with MMP-9-negative neurons (Figures 2.4B, 2.5).  Additionally, the MMP-9 
staining pattern in L5 motor neurons was not completely uniform; some motor neurons clearly 
exhibited high intensities of MMP-9 staining (termed “MMP9hi”), while others exhibited only 
moderate levels of staining (termed “MMP9lo”).  Still others were completely devoid of MMP-9 
staining, and were thus termed MMP-9
neg 
(Figure 2.5A, B). To further explore this heterogeneity, 






 motor neurons at L5 
and in the DL and RDL nuclei at L6.  To confirm our observation that the MMP-9 staining 
pattern fell into the 3 categories that we assigned, we first used Image J software (Windows 
version; National Institutes of Health) to quantify the intensity of MMP-9 staining in every L5 
motor neuron from one animal.  We determined that the spread of absolute intensity values fitted 
best to a 3
rd 
order polynomial function.  This suggested that these values can be separated into 
three distinct bins with thresholds at the two points of the function inflection corresponding, 






distinctions we obtained by visual 
inspection (Figure 2.5D).  We then performed manual counts using the same set of images. 
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Reassuringly, we found that the total counts of motor neurons with MMP-9 intensities within 
each bin were very similar whether measured by the software image analysis or by manual 
counts (Figure 2.5E).  We therefore went on to count manually the relative abundance of each 
MMP-9 staining category in 3-4 WT animals. 
Of all ChAT positive motor neurons at L5, 42.6 ± 1.6% were MMP-9
hi
, 22.1 ± 1.1% were 
MMP-9
lo
 and the remaining 35.1 ± 1.2% did not express MMP-9 (mean ± s.e.m, n=4).  In L6, the 
overall distribution of MMP-9 intensities in the RDL nucleus were similar to those at L5 
(MMP9
hi
: 24.6 ± 4.8%; MMP-9
lo
: 30.0 ± 1.2%; and MMP-9
neg
: 45.4 ± 5.3%).  In contrast, the 
resistant DL nucleus showed significantly less MMP-9 expression than L5 or RDL motor 
neurons: 70.0 ± 3.6% of DL motor neurons were MMP-9
neg
 while only 19.5 ± 2.6% were MMP-
9
hi
, and 10.5 ± 1.8% MMP-9
lo
 (mean± s.e.m, n=3) (Figure 2.5C).  Given the very low variability 
between animals, we hypothesized that MMP-9 labels defined subpopulations of lumbar motor 
neurons.  We therefore sought to determine whether the ALS-vulnerable population labeled by 
MMP-9 might correspond to a previously identified functional subtype.  
Given that MMP-9 was present in susceptible pools, and that FF/FR motor neurons have 
been shown to be more disease-vulnerable than S motor neurons (Pun et al., 2006), we asked 
whether the MMP-9-expressing neurons might be fast alpha-motor neurons.  To test whether 
MMP-9 is expressed by a particular class of motor neurons (alpha or gamma), we performed 









 gamma motor neurons (Friese et al., 2009; 
Shneider et al., 2009).  First, we found that 17.5±1.5% of all ChAT
+
 motor neurons at L5 were 
NeuN
–
 (mean± s.e.m, n=3) and, in agreement with earlier reports, these putative gamma MNs 
tended to be the smallest ChAT
+







neuron lacked MMP-9 immunoreactivity (Figure 2.6B-C).  This suggests that gamma motor 
neurons, like the disease-resistant extraocular and pelvic motor pools, do not express MMP-9.  
Of the remaining alpha motor neurons at this level, not all were MMP-9 positive, 
meaning that MMP-9 is not a general alpha motor neuron marker.  To identify if MMP-9 
expression marked a given alpha motor neuron subtype, we undertook 3 additional analyses.  
First, a characteristic of FF/FR motor neurons is that they are larger than S motor neurons 
(Cullheim et al., 1987; Kanning et al., 2010). We limited our analysis to putative α-motor 
neurons co-stained for NeuN in a random sampling of L5 of WT P40 (n=3 animals, 
approximately 75 cells from each, Figure 2.6D).  All 3 populations of motor neurons (hi, lo, and 
neg) had normally distributed cell soma sizes (Figure 2.6 E).  The MMP-9
hi
 population was the 
largest (the mean ± SEM was 1193 ± 31 µm
2









 population).  Though FF, FR, and S motor neuron subtypes exist along a 
spectrum, it was tempting to propose from these data that MMP-9
hi





 are S. We therefore conducted two additional sets of experiments to further 
correlate MMP-9 intensity and motor neuron subtype.     
We identified motor neurons of the slow soleus (Sol) and fast tibialis anterior (TA) pools 







 combined) and MMP-9
neg
 abundance closely 
matched the percentage of fast and slow fiber types, respectively, in Sol (53% MMP-9
+
; 54% 
FF+FR) and TA (90% MMP-9
+
; 93% FF+FR) muscles (Hegedus et al., 2007). It was also 
reported that the most lateral subcompartment of the lateral gastrocnemius (GC-L1) is innervated 
exclusively by FF motor neurons (Pun et al., 2006).  We hypothesized that if we injected CTB-





neurons.  Though we confirmed that the majority of the labeled pool was MMP-9
+





 motor neurons as well (Figure 2.7G).  One potential explanation for this comes 
from the fact that, in contrast with the situation with the TA and Sol muscles for which we were 
able to confirm that tracer remained in the targeted muscle, all 3 animals that received GC-L1 
injections appeared to have some level of tracer leakage to adjacent muscle subcompartments.   
As a final indicator of fast vs. slow, we analyzed how MMP-9-labeled cells compared to 
those labeled with putative markers of fast type  motor neurons (Enjin et al., 2010) and type S 
motor neurons (Chakkalakal et al., 2010) (Figure 2.8).  Because we found that the commercially 
available antibody to CHODL resulted in non-specific staining, we took advantage of Chodl
+/-
    
mice with the LacZ gene expressed in Chodl-positive cells.  When we stained for β-galactosidase 
and MMP-9 in cryosections of lumbar spinal cord, we found that a subset of motor neurons 
(76%) were positive for β-galactosidase, and thus putatively CHODL, and that almost all MMP-
9 positive motor neurons were also CHODL positive (Figure 2.8A-B).  In fact, of all MMP-9
+
 
motor neurons, 96% also expressed the CHODL-lacZ reporter, and only 29% of lacZ
+
 cells 
lacked MMP-9.   This could potentially indicate that MMP-9 labels a subset of fast motor 
neurons, but it is equally possible that the Chodl reporter is also expressed in some other motor 
neurons.  Since the Chodl
+/-
 mice have not yet been well characterized, we also looked in WT 
cord to see how the MMP-9
+




 cells by 
ISH.  We analyzed directly adjacent cryosections of L3 spinal cord (each 12 µm thick) for 
expression of Chodl, Mmp9, and Sv2a, and found that Chodl and Mmp9 appeared to be expressed 
in similar populations, but Sv2a did not (Figure2.8C-E). We were not successful in performing 
double labeling for MMP-9 IR and Chodl ISH on the same section but in the future this, or 
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double in situ hybridization, should further confirm our findings.  Overall our data show that 
MMP-9 is selectively expressed in fast α-motor neurons.  
 
MMP-9 as the first prospective marker for vulnerable motor neurons in mouse models of 
ALS 
Most of the experiments described thus far had been performed in WT animals and 
suggested that MMP-9 is a prospective marker for vulnerable motor neurons in ALS.  To test this 
in an animal model of ALS, we decided to look at end-stage SOD1
G93A
 mice (end-stage is 
defined as when the animal can no longer right itself within 30 seconds after being turned on its 
back, approximately P157 in our colony).  For a series of motor neuron subpopulations we 
compared the percentage of motor neurons lost at end-stage in SOD1
G93A
 mice (Ferrucci et al., 
2010) to the fraction that expressed MMP-9 in wild-type mice (Figure 2.9A).  Absolute values in 
the two datasets showed a remarkably strong positive correlation (y = 1.07x + 3.99, R
2
 >0.96), 
suggesting that motor neurons that express MMP-9 are those subsequently lost in ALS.  Further, 
when we compared the fraction of neurons in a given motor pool that express MMP-9, identified 
by retrograde labeling (Figure 2.7), and the innervation of the corresponding muscle at end-stage 
in SOD1
G93A 
mice, it appears the relationship also extends to axonal dieback (Fig. 2.9B). 
Therefore, in motor pools that have high baseline MMP-9 expression levels such as L5, 
there is a massive loss of motor neuron in ALS (Figure 2.10 B-C, E).  In fact, at this level, only 
~50% of motor neurons remain, and all of these were MMP-9-negative (Figures 2.10B, D, and 
E).  This suggested that MMP-9-expressing motor neurons are selectively lost during the ALS 
disease process.  However, at P75, prior to any significant motor neuron loss, the average 
number of MMP-9
neg
 motor neurons significantly increased from 6.5 ± 0.4 to 9.8 ± 0.1 per 
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ventral horn (p<0.001, Student’s t test).  This small but significant increase suggests that MMP-9 
down-regulates prior to cell death.  However, the absolute number of surviving motor neurons in 
L5 spinal cord at end-stage was not significantly different from the number of MMP-9-negative 
cells initially present (Figure 2.10E; p=0.62, t-test).  This, taken together with the strong 
correlation between MMP-9 expression and overall vulnerability (Figure 2.9), points to MMP-9 
as the first prospective marker for vulnerable motor neurons in mouse models of ALS.  
Interestingly, at end-stage MMP-9 could be detected in microglia (Figure 2.10F), and this could 
be why other groups have reported an increase in MMP-9 levels in late-stage mice and patients 
(Fang et al., 2009; Kiaei et al., 2007), despite the fact that there are no longer MMP-9 positive 
MNs. 
 As a final way to correlate MMP-9 positivity and disease susceptibility in SOD1
G93A
 
mice, we decided to look at one of the earliest molecular changes that take place in vulnerable 
motor neurons: ER stress.  We asked how the early wave of UPR detected by phosphorylation of 
eukaryotic initiation factor-2α (P-EIF2α) was localized relative to the MMP-9+ population of 
motor neurons.  As expected (Saxena et al., 2009), we observed a strong increase in P-EIF2α 
staining between P30 and P40, from 1.2 ±.29 MNs per ventral horn to 12.4 ± 1.1 (mean ± s.e.m, 
n=5, Fig. 2.11D-F). When we quantified the overlap with MMP-9 immunoreactivity (Figure 
2.11G), the number of double-labeled cells was significantly greater than expected by chance; 
n=5, χ2=3.96, d.f.=1, p<0.05). Therefore ER stress is likely selectively induced in MMP-9+ 
motor neurons, in agreement with their FF/FR identity. 
The MMP-9 expression pattern in human patients remains an open question  
The preceding data strongly suggest that MMP-9 can serve as a biomarker for vulnerable 
motor neurons in mice.  In order to assess the relevance to human patients, we wanted to check 
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the constitutive expression levels of MMP-9 in human spinal cords.  Because all available tissue 
from ALS patients comes from postmortem examination, our results in mice predict that at that 
time point there would have been massive cell death and the MMP-9 motor neurons would 
already be lost (Figure 2.10).  Therefore, we decided to analyze MMP-9 expression in a non-
ALS, control patient.  The NY Brain Bank provided tissue samples from 2 sources: the midbrain 
and lumbar and sacral spinal cord from a 78 year-old male patient who had been diagnosed with 
AD and the lumbar spinal cord of a 60 year-old male patient who died of non-neurological 
complications.  Unfortunately, the tissues from the first patient gave no immunofluorescence 
signal in any condition with any antibody tested.  We hypothesize that the fixation of these 
tissues (fresh frozen) was suboptimal for immunohistochemistry. 
 The second spinal cord sample had been formalin fixed and paraffin embedded, and was 
therefore considered a more reliable sample for a second round of immunostaining.  H&E 
staining identified large chromatolytic motor neurons (Figure 2.12A).  However, the cytoplasm 
of these motor neurons did not stain for MMP-9 with the same pattern as would be predicted 
based on the pattern in the mouse spinal cord (compare 2.4A and 2.12B).  Interestingly, when 
compared to the secondary antibody-only control on an adjacent paraffin section (Figure 2.12C), 
there does appear to be a generally higher amount of brown signal, possibly suggesting staining 
of the processes.  It was possible that the antibody was faulty, so we confirmed its specificity 
using a section of spleen from a different patient (generously provided by Dr. Kara Spiller, lab of 
Gordana Vunjak-Novakovic, Figure 2.12D).  Given that the antibody worked in the positive 
control, we can imagine a few scenarios that account for the lack of motor neuron staining.  First, 
it is possible that MMP-9 is not expressed by human motor neurons, despite an earlier report to 
the contrary (Lim et al., 1996).  It could also be that we did not see MMP-9 in this patient 
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because it is not expressed constitutively, but only on demand as in most other cell types (Nagase 
et al., 2006).  Another possibility, is that there is more variability in MMP-9 levels in humans, 
but with only an n=1 we cannot detect it.  Finally, MMP-9 expression may down-regulate with 
age.  Follow-up studies in more human tissues are needed. 
 
Discussion 
In this chapter, we show that MMP-9 is predominantly expressed by motor neurons and 
weakly by a small population of dorsal interneurons in the mouse spinal cord.  There are 3 types 
of motor neurons (alpha, beta, and gamma), which are classified based on which type of muscle 
fiber they innervate.  Based on size and co-labeling with NeuN, we have shown that MMP-9 is 
only expressed by alpha motor neurons, those that innervate extrafusal muscle fibers and directly 
initiate movement.  Alpha motor neurons constitute the largest population of motor neurons in 
the spinal cord and can be further subdivided based on the functional characteristics of their 
target muscles: fast-twitch fatigable (FF), fast-twitch fatigue-resistant (FR), and slow-twitch 
fatigue-resistant (S) (reviewed in Chapter 1).  These three MN subtypes differ with respect to 
soma size, morphology, and central connectivity, and importantly, in their vulnerability to 
disease (Kanning et al., 2010).  Because of this differential vulnerability, and to better understand 
basic motor neuron biology, it is useful to have molecular markers that could further distinguish 
these MN subtypes from each other. 
 Numerous groups have attempted to find such markers in recent years.  For example, 
Chakkalakal et al. provided evidence that the synaptic vesicle protein Sv2a is selectively 
expressed by slow MNs and specifically accumulates in motor axon terminals on slow muscle 
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fibers (Chakkalakal et al., 2010).  In the same year, Enjin et al. found that slow motor neurons 
were also labeled by Err2 (Enjin et al., 2010).  That paper also showed that chondrolectin 
(Chodl) had a complementary pattern of expression to Err2.  Moreover, ISH for Chodl labeled 
mostly large cells and patch-clamp recordings from Chodl-positive motor neurons showed that 
these cells have electrophysiological properties consistent with fast motor neurons.  Excitingly, 
based on the results presented in this chapter, we now feel it is appropriate to add MMP-9 to the 
set as a fast motor neuron marker.   
We demonstrated the specific presence of MMP-9 in this subpopulation using 3 different 
approaches: (1) co-labeling and/or labeling adjacent sections with a known fast and a known 
slow marker, (2) soma size comparisons, and (3) examining the MMP-9 staining levels in motor 
pools with known proportions of FF, FR, or S motor neurons (approximated by analyzing the 
fiber type composition of the target muscles).  Comparison of the MMP-9-positive motor neuron 
population with those expressing Chodl and Sv2a suggests that MMP-9 is a fast but not slow 
marker.  Moreover, the other 2 experiments imply that the intensity of MMP-9 immunopositivity 
could further subdivide the fast category.   
Given that the motor neuron subtypes are known to differ in size with FF being the 
largest, S being the smallest, and FR MNs being intermediate (Cullheim et al., 1987), it is 
tempting to hypothesize based on the distribution of soma areas of α-MNs (ChAT+/NeuN+) as a 
function of MMP-9 immunoreactivity that MMP-9
hi
 cells are the FF subtype, MMP-9
lo
 label the 
FR subtype, and the S subtype is MMP-9
neg
.  As another check, we ideally wanted to quantify 
MMP-9 levels in motor pools with relatively uniform subtype compositions, for example the 
GC-L1 been reported to be composed of nearly 100% FF motor neurons (Pun et al., 2006).  The 
prediction was that this motor pool would be comprised of only MMP-9
hi
 cells.  However, 
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although the majority of CTB positive cells were MMP-9 positive after injection into the lateral 




 cells labeled.  Unfortunately, this 
experiment was hampered by difficulty in the specificity of the injection, and we could detect 
fluorescence in neighboring muscle fibers outside of GC-L1.   
The injections in the SOL and TA, on the other hand, were determined to be much more 







neurons matched very closely with the fibers types reported in those pools by an independent 
group (Figure 2.7G and H).  Specifically, we found that on average highly vulnerable TA motor 




 and virtually no MMP-9
neg
 motor neurons, 
while more resistant Sol motor neurons contained only a small percentage of MMP-9
hi
 motor 




 motor neurons. Therefore, taken 
together our results raise the possibility that within generally vulnerable lumbar motor pools, 
MMP-9
hi
 motor neurons are those that undergo early degeneration, MMP-9
lo
 succumb later, and 
MMP-9
neg
 motor neurons, likely corresponding to a mixture of type S and gamma motor neurons, 
are those that survive until end-stage.  
Though both are reliable fast motor pool identifiers, MMP-9 has several advantages over 
the other candidate fast marker Chodl as a marker for selectively vulnerable cells.  First, Chodl is 
hard to detect by immunostaining whereas MMP-9 has at least 3 different commercially 
available antibodies that give strong, consistent signals and do no stain MMP-9 knock-out tissue.  
Further, specific motor neuron MMP-9 expression begins only around P5 (Figure 2.2), an age 
just before the first changes in mSOD1 mice can be detected suggesting that MMP-9 expression 
could be influencing motor neuron vulnerability (Kanning et al., 2010).  On the other hand, 
Chodl mRNA is expressed both in motor neurons and at the base of the developing limb at E10.5 
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and E11.5, the developmental stages when motor axons reach this region and make a number of 
decisions, suggesting a possible function of chondrolectin in guiding axons at this choice point 
(Enjin et al., 2010).  Further, it has been recently shown that Chodl is an in vivo genetic modifier 
of the SMA phenotype, as results from smn-depleted zebrafish suggest the possibility that 
upregulation of chondrolectin levels could protect motor neurons in SMA (Sleigh et al., 2013).  
For these reasons, we argue that MMP-9 is a better marker of vulnerable motor neurons.  
The microarray profiling that originally identified MMP-9 was done following the 
hypothesis that there could be a set of cell-intrinsic properties that render certain motor neurons 
more susceptible to damage than others.  We initially hypothesized that MMP-9 could be a 
putative susceptibility factor in motor neuron disease based on its absence from oculomotor and 
Onuf’s nuclei, and found it striking that its absence also extended to resistant S motor neurons.  
Among a group of neurons that are diverse by their ontogeny and function, it may be significant 
that all three resistant populations share characteristics other than lack of MMP-9 expression.  
The extraocular-innervating and the pelvic sphincter-innervating populations, like S motor 
neurons, have small cell bodies and axonal arbors and slower-conducting axons, and all fire at 
constant rates for extended periods of time (Kanning et al., 2010).  Despite these shared 
functional properties and shared lack of MMP-9, they do not necessarily fully share molecular 
profiles.  For example, CGRP has been shown to be expressed by larger diameter, more 
susceptible motor neurons, with 90% of CGRP-expressing motor neurons being lost in mutant 
SOD1 mice compared to the 50% degeneration of ChAT
+
 motor neurons (Piehl et al 1993; Vlug 
et al 2005).  However, both extraocular and pelvic motor pools express high levels of the Calca 
transcript encoding CGRP (Allen Brain Atlas).  This suggests that CGRP may be a marker for 
fast motor neurons, but shows that its absence does not reliably predict resistance.  Therefore, 
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MMP-9 may be unique in its absence from all small, extended-firing motor neurons and future 
studies to determine whether the presence or absence of MMP-9 affects functional properties 
such as motor neuron size and/or electrical properties will be of great interest.   
Having demonstrated that MMP-9 was selectively expressed in WT mice in motor 
neurons known to die in disease, we next extended the MMP-9 expression analysis to the best 
model of familial ALS available: mutant SOD1 mice.  We found a remarkable degree of positive 
correlation between the fraction of wild-type motor neurons expressing MMP-9 in a given spinal 
or brainstem region and the degree of susceptibility of that population to degeneration in the 
SOD1
G93A
 mice, suggesting that MMP-9 could be a prospective marker for future cell loss.  
Correspondingly, at end-stage in SOD1
G93A
 mice, the majority of the remaining cells (~50%) 
were negative for MMP-9.  Finally, it has been elegantly shown that in mutant SOD1 mice, large 
FF motor neurons generate an unfolded protein response before fatigue-resistant or slow motor 
neurons do and it has been hypothesized that this sequence of events may reflect a difference in 
the stress-coping capacity of these different types of neurons (Saxena et al., 2009; Saxena and 
Caroni, 2011).  Consistent with their identity as FF motor neurons, we show that upregulation of 
phosphorylated EIF2α occurs selectively in MMP-9-positive motor neurons at P40.  The 
relationship between ER stress and MMP-9 will be further addressed in Chapter 4.   
Taken together, these data distinguish MMP-9 as the most reliable biomarker for motor 
neuron susceptibility to ALS to date.  Given selective expression of MMP-9 in motor neurons in 
the spinal cord, and its exclusion from oculomotor and Onuf’s nuclei, and from the slow, ALS-
resistant subtype in spinal motor pools, MMP-9 provides a unifying hypothesis for class-, pool- 
and subtype-specific aspects of selective motor neuron resistance to ALS.  This striking 
expression pattern of MMP-9 suggests that this protein itself could be playing a role in the 
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degeneration of vulnerable motor neurons in mutant SOD1 mice.  This hypothesis will be 











Figure 2.1 MMP-9 is expressed in subsets of cranial and spinal motor neurons but is absent 
from oculomotor and DL nuclei. 
 
A-D. ISH for Mmp9 on cryosections of wild-type brainstem and spinal cord at P57 showing 
similar results to those at P7 (Figure 1.5C). Mmp9 is expressed at different levels in subsets of 
trigeminal motor nucleus (B) and L5 (C) motor neurons. Oculomotor (A) and DL nucleus motor 
neurons (D) do not express Mmp9. 
 
E- H. Immunostaining for MMP-9 (green) on P30 spinal cord of ChAT-Cre; Rosa-TdTomato 
(MN, red) reporter mice shows many motor neurons expressing high levels of MMP-9 in the 
vulnerable trigeminal nucleus (F), L5 spinal cord (G) and RDL in L6 (H).  In contrast, resistant 
oculomotor (E) and DL (H) nuclei show no or very little MMP-9 expression.  








Figure 2.2. Time course of MMP-9 expression in the non-transgenic mouse lumbar spinal 
cord 
 
A-D. ISH for Mmp9 on cryosections of wild-type lumbar spinal cords at various indicated ages 
reveals that MMP-9 is first detected postnatally at P5 (B), and subsequently remains expressed at 







Figure 2.3 Expression of other MMP family members and their endogenous inhibitors in 
motor neurons  
 
A. MMP-9 is the only secreted MMP expressed at high levels in motor neurons at P7. Raw 
expression values for indicated probes on microarrays for DL, III, and L5 samples were divided 
by the raw expression value of Mmp9 in L5 motor neurons. Transcripts were arranged into 
known subgroups based on protein domains and substrate specificity including: gelatinases 
(Mmp9 and Mmp2), collagenases (Mmp1a, Mmp1b, Mmp8, Mmp13), stromelysins (Mmp3, 
Mmp10, Mmp11), matrilysins (Mmp7) and membrane-type (MT–MMPs) (Mmp14, Mmp15, 
Mmp16, Mmp17, Mmp24), and other (Mmp12, Mmp19, Mmp20, Mmp23).  Only members of 
the MT-MMP subgroup showed similar or higher expression levels as compared to Mmp9 
whereas all other MMPs, including Mmp2, were nearly absent. Mmp15 and Mmp17 had >4-fold 
higher expression values compared to Mmp9 but were not specific to L5 motor neurons. 
Collaboration with A. Kaplan. 
 
B, F.  Adjacent cryosections were processed for Chat ISH to identify motor neurons at L5 (B) 
and DL and RDL nuclei at L6 (F). 
 
C,G. Mmp2 is absent from cryosections of adult L5 and L6 spinal cord, as detected by ISH. 
 
D,H. ISH forTimp2 on cryosections of adult, wild-type L5  (D) and L6 (H) shows that Timp2 is 
strongly expressed by all neurons 
 
E, I. ISH for Timp3 on cryosections of adult, wild-type L5 (E) and L6 (I) shows that Timp3 has 
generally low expression levels but appears to be expressed more strongly by subsets of RDL 







Figure 2.4 MMP-9 is specific for motor neurons within the neuromuscular system  
A. Representative coronal section from a P25 SOD1
G93A
 mouse lumbar spinal cord 
immunostained for MMP-9.  Intense MMP-9 staining is visible in motor neurons in the ventral 
horn, as well as some very weakly stained cells in the dorsal horn (arrows). This pattern is the 
same as in WT mouse lumbar spinal cord (B). Scale bar 100 μm.  
B-C. L5 spinal cord of SOD1
G93A
 (C) and age-matched wildtype control (B) at P40 
immunostained for MMP-9 (green) and VAChT (red) shows that the presence of mutant SOD1 
does not affect MMP-9 expression.  
D-E. MMP-9 is absent from DRGs; no MMP-9 staining (red) was detected in dorsal root ganglia 




F-G. In situ hybridization for Mmp9 on cryosections of P50 WT (F) and P60 G93A (G) TA 
shows that no signal is detected in that muscle.  
H. MMP-9 (green) is present in some axons of a P40 SOD1
G93A
 lumbar level ventral root, 








Figure 2.5 MMP-9 is expressed at variable levels in disease-vulnerable pools of lumbar 
motor neurons. 
 
A, B. Representative images showing levels of MMP-9 expression (red) categorized as being 
high (arrow), low (arrowhead), or negative (asterisk) at L5 in a wildtype P75 mouse. B, Motor 
neuron cell bodies are visualized using ChAT immunostaining (green). Scale bar, 20 μm. 
 
C. Quantification of MMP-9 staining intensities in L5, DL and RDL motor neurons (mean ± 
s.e.m, n=3-4). Resistant DL nucleus motor neurons expressed significantly lower levels of 
MMP-9 than did vulnerable L5 or RDL.  A two-way analysis of variance showed that differences 
between motor neuron subsets were significant [F(4, 29) = 34.1,p<0.001]. Post hoc comparisons 
using the Bonferroni analysis revealed that the DL nucleus contained a significantly higher 
proportion of MMP-9
neg
 motor neurons than L5 (t= 9.06, p<0.01) or RDL (t= 6.00, p<0.01).  
 
D. Scatter plot of MMP-9 signal corrected for background in a fixed area within each of 273 
motor neurons in the L5 spinal cord of one animal. A 3
rd
 order polynomial best fit trend line 
(red), determined by maximizing the R
2
 value (>0.98), was added and the second derivative was 
taken to find two inflection points of the function. The ordinate values of the two inflection 
points were set to be the bin thresholds. All motor neurons with MMP-9 intensity lower than the 
first inflection point were considered MMP-9
neg
, those between the two inflection points were 
considered MMP-9
lo




E. Close correspondence between automated and manual counts. Fraction of each category in L5 







Figure 2.6 The largest alpha motor neurons express MMP-9 
A,B. Representative images of triple labeling of L5 spinal cord cryosection with MMP-9 (red), 




 gamma motor neurons 
are denoted by arrows. Note the absence of MMP-9 staining in these motor neurons (B, arrows).  





 alpha motor neurons, 53.3 ± 1.2% were MMP-9
hi
, 25.6 ± 0.5% were MMP-9
lo
, 
while 21.1 ± 0.9% were MMP-9
neg




 gamma motor neurons 
were found to express MMP-9. Values are means ± s.e.m of counts performed in three animals.  
D. Example of soma size quantification from an image of L5 spinal cord cryosection labeled 
with MMP-9 (red), ChAT (blue), and NeuN (green).  
E. Distribution of soma areas of α-MNs (ChAT+/NeuN+) as a function of MMP-9 
immunoreactivity in lumbar spinal cord from 3 WT animals at P40. MMP-9 staining intensity 
was determined as in Figure 2.5.  Motor neurons expressing MMP-9 at the highest level (black 
bars) are the largest, consistent with a fast identity.  MMP-9-negative MNs were the smallest 







Figure 2.7 The slow soleus motor pool contains fewer MMP-9
+
 motor neurons as compared 
to the fast tibialis anterior and lateral gastrocnemius motor pools 
 
A-F. MMP-9 immunostaining (red) on alpha motor neurons labeled with NeuN (blue) of the TA 
and Sol motor pools of adult WT mice identified by retrograde labeling with CTB488 (green). 
Many motor neurons of the fast TA pool are intensely MMP-9-positive, whereas Sol motor 
neurons tend to be negative or express low levels of MMP-9.    
 
G. Quantification of MMP-9 staining in the GC, TA and Sol motor pools (mean ± s.e.m., n=3) 
shows a larger fraction of MMP-9-negative motor neurons in the slow Sol pool as compared to 
the faster TA and lateral subcompartment of GC.   
 
H. Percentages of type I (slow, light grey) and type IIa (FR, dark grey) and II b (FF, black) fibers 
in GC-L1, TA and Sol muscles replotted from Pun et al., 2006 and Hegedus et al., 2007 as an 
indicator of subtype composition of the corresponding motor pools. Values for fast fibers are 
very close to those for MMP-9 for TA and Sol, but not GC-L1, likely reflecting leakage of 
retrograde tracer into adjacent muscle subcompartments.  
 










Figure 2.8  MMP-9 labels a similar subpopulation of motor neurons as the previously 
identified fast molecular marker CHODL   
A, B.  Immunostaining for VAChT (green), MMP-9 (red), and LacZ (blue) on adult spinal cord 
of CHODL:lacZ mouse.  A subset of VAChT
+
 MNs are LacZ-positive, and a subset of those (all 
but 29%) are also MMP-9-positive. 
 
C-E. Adjacent cryosections of lumbar WT P40 spinal cord were processed by ISH for Chodl (C) 
to identify fast motor neurons and Sv2a (E) to identify slow motor neurons.  The pattern of 







Figure 2.9 MMP-9 expression in wild-type motor neurons correlates tightly with levels of 
degeneration in mutant SOD1
G93A 
mice at end-stage. 
 
A. Tight correlation between MMP-9 expression in WT and ALS vulnerability. For a given 
motor neuron population, percentages of motor neurons expressing MMP-9 (both high and low 
levels) were plotted on the y-axis, and percentages lost in SOD1
G93A
 mice at end-stage as 
counted by us or presented by Ferucci et al. plotted on the x-axis (2010). Data were fitted with a 
linear regression (y = 1.07x + 3.99, R
2
 >0.96). Values are mean ± s.e.m. (n=3). Collaboration 
with A. Kaplan. 
 
B. Quantification of MMP-9-negative motor neurons (black bars) retrogradely labeled from 
different muscles (Sol, EOM, GC-L1, and TA; indicated on x-axis) as compared to % of intact 
NMJs at end-stage in SOD1
G93A 
mice (white bars), as measured by VAchT/Btx co-localization, 









Figure 2.10 MMP-9 is a prospective marker for motor neurons lost at end-stage in ALS 
model mice.  
By end-stage, although there is a 50% loss of total motor neurons at L5 in SOD1
G93A
 mice, there 
is no decrease in the MMP-9
neg
 population, in agreement with the model that they are ALS-
resistant.   
A-B. Immunostaining for VAChT (red) to label MNs and MMP-9 (green) in age-matched WT 
and mSOD1 mice shows that there has been a massive loss of MMP-9-positive MNs in the 
mSOD1 mice by P160.   
C-D. ISH confirms both the loss of ChAT-positive MNs (C) and the absence of MMP-9 RNA in 
cell bodies.  
E. Quantification of total number of MNs (orange) and those that are MMP-9-negative (white 
bars). Values are mean ± s.e.m from three animals.  
F. All MMP-9 expressed in spinal cord at end-stage co-localizes with microglial marker IBA-1 








Figure 2.11 MMP-9-expressing motor neurons preferentially activate ER stress. 
A–F. Immunostaining for MMP-9 (green) and ER stress marker phospho-EIF2α (P-EIF2α, red) 
in P40 spinal cord of non-transgenic (WT) and SOD1
G93A
 mice.  P-EIF2α is restricted to mSOD1 
mice (compare E with B) and co-localizes with MMP-9 (F).  Scale bars, 20 μm.  
 
G. MMP-9-expressing motor neurons preferentially activate ER stress. There are significantly 
more SOD1
G93A
 motor neurons co-positive for P-EIF2α and MMP-9 (yellow) than would be 
predicted by chance (grey bar; defined as the probability of being MMP-9 positive*probability of 







Figure 2.12 MMP-9 has a different expression pattern in a human’s spinal cord than in the 
mouse   
A. H&E-stained section showing large chromatolytic motor neurons of human lumbar spinal 
cord from a 60 year old man who died of non-neurological disease. 
B. Immunostaining of an adjacent paraffin section revealed very low levels of MMP-9 in the cell 
bodies of these motor neurons, but possible staining of the processes (compare the brown 
neuropil of B with the control secondary only stain in C). 










In Chapter 2, I confirmed the results of the Henderson lab microarray and extended them 
considerably.  I showed that the expression of a single gene, Mmp9, distinguishes different 
subpopulations of wild-type motor neurons and its expression is related to their vulnerability in 
motor neuron disease.  Specifically, the most highly resistant extraocular motor pools expressed 
virtually no MMP-9, while pelvic muscle innervating motor pools in the DL nucleus expressed 
very low levels of MMP-9.  In contrast, the majority of motor neurons in vulnerable pools 
expressed MMP-9.  In the most vulnerable population of motor neurons we sampled, lumbar 
level alpha motor neurons, we found that MMP-9 specifically labeled the most disease prone 
subtype: fast MNs.  We also investigated MMP-9 expression in the most commonly used mouse 
model of the disease: SOD1
G93A
 mice.   
In humans, approximately 10% of all ALS cases have been identified as being familial in 
origin.  Of these, the most prevalent identified mutations are gain-of-function point mutations in 
superoxide dismutase 1 (SOD1) and hexanucleotide repeat expansions in chromosome 9 open 
reading frame 72 (C9ORF72) (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Rosen et al., 
1993).  Missense mutations in the SOD1 gene are responsible for between 14% (France) and 
23% (US and Scandinavia) of familial ALS, and the G93A mutation, in which a glycine is 
replaced by an alanine, is frequently observed (Andersen, 2006; Siddique and Lalani, 2002).   
SOD1
G93A
 mice have clinical manifestations and exhibit pathology similar to human ALS 
(Gurney, 1994).  We found a remarkable degree of positive correlation between the fraction of 
wild-type motor neurons expressing MMP-9 in a given region of the spinal cord or brainstem 
100 
 
and the degree of susceptibility of that population to degeneration by end-stage in the SOD1
G93A 
mice.  Moreover, the clinical presentations in both mutant SOD1 mice and in human patients 
show a high correlation between FF motor neurons and vulnerability and we show that MMP-9 
is selectively expressed in these fast motor neurons in mice.  However, questions still remain 
about whether the SOD1
G93A
 mouse fully recapitulates the selective vulnerability seen in patients 
(described in Chapter 1).  We will address this question in this chapter by analyzing the amount 
of denervation in individual muscles of terminal SOD1
G93A
 mice.  Further, identifying MMP-9 as 
a marker for vulnerable motor neurons in disease suggests that this protein could potentially have 
a functional role in the degeneration of the motor neurons that express it in mutant SOD1 mice.  





monitoring the disease progression in these animals, with the hypothesis that if MMP-9 makes 
motor neurons vulnerable to disease, then genetically depleting it will render these cells more 
disease-resistant.   
This type of cross-breeding strategy has been used many times before to evaluate the role 
of a given protein, and thus often of a putative disease mechanism, downstream of mutant 
SOD1-induced toxicity in ALS (Turner and Talbot, 2008).  The read-out for many of these 
studies is often a change in total lifespan for the genetically modified mutant SOD1 mice, or less 
often, changes in earlier disease processes such as behavioral motor deficits or selective cell 
death.  Because the timing of degeneration is very well characterized in the SOD1
G93A
 model, 
changes in either direction can be detected (that is, disease worsening or symptom alleviation).   
For instance, cross-breeding depletion strategies have been used to examine whether 
impaired neurotrophin support of motor neurons might underlie their degeneration.  As one 







mice exacerbates disease onset, leading these mice to develop ALS approximately 10 weeks 
earlier than their littermates that have normal CNTF levels, as measured by counting motor 
neurons of age-matched animals at lumbar levels (Giess et al., 2002).  On the other hand, 
crossing knock-out mice for potentially disease-relevant proteins with SOD1
G93A
 mice has also 
led to partial disease alleviation.  Human ephrin type-A receptor 4 (EPHA4), like MMP-9, is 
expressed by the largest alpha motor neurons.  A 50% reduction in Epha4 expression in 
SOD1
G93A
 mice led to improved motor performance, reduced motor neuron degeneration, and 
prolonged survival by 8.5% (Van Hoecke et al., 2012). 
Genetic intervention studies in mutant SOD1 mice have also attempted to dissect out 
critical inflammatory mediators, including MMP-9, with mixed results (Turner and Talbot, 
2008).  First, several studies using conditional reduction of mutant SOD1 in glia, bone marrow 
transplants or chimeric animals, have strongly suggested that microglia significantly influence 
non–cell-autonomous damage of motor neurons and contribute to ALS disease progression 
(Beers et al., 2006; Boillée et al., 2006a; Boillée et al., 2006b; Clement et al., 2003).  Microglia 
are the source of NADPH oxidase, the main enzyme producing reactive oxygen species during 
inflammation.  It has been shown to be upregulated in familial and sporadic ALS and in mutant 
SOD1 mice (Wu et al., 2006).  Inactivation of NADPH oxidase 2 by deletion of its subunit 
gp91
phox 
extended survival in these mice from 122 days to 135 days, and also lessened other 
indicators of neurodegeneration, such as motor neuron and large axon loss (Wu et al., 2006).  
These results were supported by a later study on a mixed genetic background (Marden et al., 
2007).  Interestingly, deletion of TNF-α, a potent proinflammatory cytokine that can be 





 mice, nor did it influence motor neuron loss or gliosis (Gowing et al., 
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2006).  Further, there are conflicting results with regard to whether or not IL-1β affects ALS 
pathogenesis, with one study showing no effect of deletion on the disease (Nguyen et al., 2001), 
and another on a different background using a different SOD1 mutation (G93A vs. G37R)  
showing that IL-1β deficiency slowed disease progression but did not affect disease onset 
(Meissner et al., 2010).  A similar discrepancy was reported for the MMP-9, with one group 
reporting its deletion exacerbated the disease and another later study saying its removal 
improved the disease course (Dewil et al., 2005; Kiaei et al., 2007). 
First, as alluded to earlier, when Mmp9
-/-
 mice on a mixed C57BL/6 129 background 
were crossbred to SOD1
G93A
 on a pure C57BL/6 background, the average lifespan deceased from 









(Dewil et al., 2005).  A later study, however, reported a significant survival benefit when they 
crossed Mmp9
-/-
 mice on a CD-1 background to SOD1
G93A
 mice on the B6SJL background 
(Kiaei et al., 2007).  In fact, they showed a very large increase in survival; in their colony, the 









 was 155± 12 days.  They also showed significant protection of motor neurons 









 at the same age, 
though this was the earliest time point that group examined.  Neither group looked at early 
changes such as muscle denervation or differential ER stress responses in these mice, since both 
groups came to study MMP-9 from the perspective of its late-stage inflammatory induction. 




Therefore, despite the existence of these reports, the role of MMP-9 in motor neuron 
degeneration in ALS has not yet been conclusively established. Given the striking correlation of 
MMP-9 expression in wild-type motor neurons with their susceptibility in SOD1
G93A
 mice 
reported in Chapter 2, we will assess whether or not the expression of MMP-9 by vulnerable 
motor neurons might contribute to their degeneration in ALS.  Importantly, we focus on other 
metrics in addition to lifespan in order to assess the influence of MMP-9, including muscle 
denervation over time, motor neuron numbers, behavior, and muscle physiology.  Promisingly, 
as Kiaei et al had done for lifespan, we report that deleting even just one allele of Mmp9 has 
beneficial effects on all of these metrics and discuss clinical implications. 
 
Results  
Denervation of individual extraocular muscles and lumbar sphincters is significantly 
delayed in ALS model mice 
After establishing that MMP-9 selectively labels the most disease susceptible populations 
of motor neurons, our next goal was to determine the functional contribution of MMP-9 to the 
disease process in ALS.  Before doing so, we needed to evaluate the degree of ALS resistance of 
individual motor pools in SOD1
G93A
 mice in our colony, and confirm that these animals 
phenocopied human patients with the sporadic form of ALS in this way.  We quantified 
denervation of multiple muscles at end-stage by immunostaining serial longitudinal cryosections 
throughout the full extent of each muscle for the cholinergic synaptic marker, vesicular 
acetylcholine transporter (VAChT) to label motor terminals, and fluorophore-conjugated alpha-
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bungarotoxin (BTX) to mark motor endplates and assessing their overlap.  We observed 200-900 
neuromuscular junctions per muscle.  
In agreement with previous reports (Pun et al., 2006), the fast hindlimb muscle TA 
showed nearly complete denervation by this time, with only 13.7 ± 1.2% (mean ± standard error 
of mean (s.e.m), n=3) of NMJs still intact by end-stage, whereas the slow Sol was significantly 
more resistant with preserved innervation of approximately 50.2 ± 4.5% of endplates, again 
confirming previous studies (Figures 3.1A, 3.1C and 3.1E).  In striking contrast, the extraocular 
muscles were remarkably preserved.  Valdez et al. also recently reported the extraocular muscles 
to be collectively resistant in ALS mice (2012), but we extended this analysis by examining the 
eight muscles individually.  Even at end-stage, the extraocular muscle superior rectus (SR) 
showed normal healthy synaptic morphology (Fig. 3.1B) with essentially no loss of innervation 
(98 ± 1 % innervated) and this resistance was shared by all eight extraocular muscles (Figure 
3.1E).  Likewise, innervation of the external urethral and anal sphincters (EUS and EAS) was 
well preserved with 85.4 ± 1.0% and 81.6 ± 4.3% of all motor endplates remaining innervated at 
end-stage (Figures 3.1D and 3.1E).  In contrast, the innervation of muscles associated with the 
external genitalia, the ischiocavernosus (IC) and bulbocavernosus (BC) muscles, had 
significantly reduced innervation 45.1 ± 15% and 42.1 ± 14.3%, respectively.  Though these 
numbers are much more variable than those reported for all other muscles, they generally 
correspond to an intermediate level of resistance, comparable to slow muscles (Figure 3.1E).  
Therefore, this remarkable degree of overlap between the selectivity of muscle denervation in the 
SOD1
G93A
 mouse and that in human patients with sporadic ALS strongly suggests the existence 




Genetic ablation of MMP-9 in ALS has strong protective effects 
 In order to ascertain whether MMP-9 is playing a functional role in the ALS 




 mice, both on a pure C57BL/6 background.   
MMP-9 knockout mice are healthy and have a normal lifespan (Vu et al., 1998).   Although they 
have been reported to show mild deficits in hippocampal-dependent learning  (Nagy et al., 2006) 
and delays in wound healing (Kyriakides et al., 2009), no motor dysfunction has been found in 
these mice.  Further, in our colony we found no muscle denervation or motor behavioral 
phenotype at any stage as compared to WT controls (not shown).  We therefore sought to 
analyze how the absence of MMP-9 might affect the SOD1
G93A
 phenotype. 
 First, we confirmed by Western blot that MMP-9 is completely absent from Mmp9
-/- 
mice 
and that MMP-9 levels in heterozygous Mmp9
+/-
 mice were ~50% of those in WT mice (Figure 
3.2A), and this was unchanged in combination with mutant SOD1 (Figure 3.2G and 3.2H).    
Further, there were no changes in SOD1
G93A
 copy number or expression in the absence of MMP-
9 (Figure 3.2B and 3.2J-K).  We next analyzed muscle denervation in SOD1
G93A
 mice lacking 
MMP-9 as compared to SOD1
G93A
 controls.  The % innervation (mean ± s.e.m.) of one fast 
muscle (TA) and one slow muscle (Sol) are shown in Table 3.1.  
 Axonal die-back occurred early in the TA muscle of SOD1
G93A
 mice, as expected: 41 ± 
2% (mean ± s.e.m.; n=4 animals, 1 muscle from each) of fibers were denervated by P50 and 71 ± 
6% by P100 (Figures 3.3A, 3.3B and 3.3G).  In contrast, Sol muscle showed no significant 
denervation at P50 and only 22 ± 5% loss at P100 (Figures 3.3C and 3.3H).  These values are 
similar to those reported by Caroni and colleagues (Pun et al., 2006), and reflect the greater 
fraction of FF motor neurons in the TA pool.  We therefore considered muscle denervation to be 
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a sensitive and early endpoint through which to measure disease onset and progression.  




 mice, no denervation was detected 
relative to WT controls (p=0.16) and even at P100 approximately 77% of motor endplates 
remained innnervated, representing a 2.5-fold improvement over mSOD1 controls (Figures 3.3D, 
3.3E and 3.3G).  This >2.5-month delay in loss of innervation of a fast muscle is the strongest 
effect so far reported in ALS model mice, other than by removing the disease gene itself 
(reviewed in Turner and Talbot, 2008).  Significant, though less dramatic given its greater 
resistance, protection was also observed in the slow Sol muscle (Figures 3.3F and 3.3H).   
Importantly, inactivation of just a single allele of Mmp9 also conferred significant benefit 




 mice exhibited ~70% of the protection provided by complete 
ablation up to P100, and equivalent protection at end-stage (Figure 3.3G).  In the slow Sol 
muscle there was also a beneficial effect of partial Mmp9 deletion at late disease stages (Figure 
3.3H).  Given that we showed that MMP-9 is selectively expressed by fast motor neurons 
(Chapter 2, Figures 2.6-2.8), we considered a possible explanation of our data that deleting 
MMP-9 in SOD1
G93A
 mice leads motor neurons to adopt a more S-like phenotype.   
In SOD1
G93A
 mice, denervation of the “skin-facing” compartment of the TA muscle 
(approximately 1/3 of whole muscle, 525 µm) precedes that of the “bone-facing” fibers by >20 
days, suggesting that the compartments have FF and FR character, respectively (two way 





 mice the two compartments became denervated at an identical rate 
(F=0.360, p=0.560; Figure 3.4B).  This suggested that in the absence of MMP-9 either FF motor 
neurons adopt FR-like properties, or both FF and FR tend toward the resistance of S motor 
neurons.  We therefore compared the rate of muscle denervation by the “fast” motor neurons of 
107 
 




 (Figure 3.3G, red points) with that observed for the mostly 
slow motor neurons of the neighboring Sol pool in SOD1
G93A
 mice with normal levels of MMP-9 
(Figure 3.3H, black points).  Superposition showed that there are similar levels of denervation 
over time except at P160, where the values are significantly different (t= -3.4, d.f.=4, p=0.026; 
Figure 3.4C).  Therefore, although muscle-specific differences may also contribute, we conclude 
that FF and FR motor neurons lacking MMP-9 both adopt an axonal die-back phenotype 
comparable to that of S motor neurons.  However, removal of MMP-9 does not completely 
convert FF motor neurons to the S subtype since we detected no change in cell body size of fast 
motor neurons between TA innervating MNs from age and weight-matched Mmp9
-/-
 and WT 
animals (p=0.21), nor from all Chat
+










To confirm that the preserved synapses were functional, we measured the compound 
muscle action potentials (CMAP; Towne et al., 2011) and also used a non-invasive measure of 
muscle atrophy, electrical impedance myography (Li et al., 2013).  First, for CMAP, recording 
electrodes were inserted into the TA muscle, while another pair was used to stimulate the sciatic 
nerve until a maximal response was reached (Figure 3.5A).  Using a computer code written by 
Turgay Akay that measures peak to peak CMAP amplitude but excludes the stimulus artifact 
(which is not produced by the nerve itself and varied from preparation to preparation, 
independent of the genotype of the animal), we found that from P100-P130, the CMAP in 
SOD1
G93A
 mice was reduced to 10% of that in WT controls.  However, deletion of one or two 
copies of Mmp9 rescued up to 50% of normal values (Figure 3.5B).  
 In order to find a non-invasive way to detect whether the electrical activity in these 
muscles could be preserved, potentially at earlier time-points, in collaboration with Dr. Seward 
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Rutkove (Beth Israel Deaconess Medical Center) we next undertook a very preliminary study to 
evaluate EIM from GC muscles of 10 SOD1
G93A
 male mice (with or without altered Mmp9 
levels) at multiple time-points, ranging from P43 to P146 (Figure 3.5C).  It has been previously 
reported that of the parameters that EIM measures (resistance, reactance, and phase), the phase-
slope provides the strongest correlation between rate of disease progression and death (Wang et 
al., 2011b).  Therefore, this is the measure we used in our animals to determine the rate of 
disease progression.  Though generally EIM phase decreased over time for all groups, it did not 





  was 17 % lower in the oldest animal of that genotype (P143) than the 
youngest (P43), however there was barely a difference between the phase at P80 and P100 (2 % 









  GC phase at P80 (by 15.7 %).  However, by P145 the phase value was 




 mouse (12.2 and 12.5, respectively), and this 
represents a 10.7 % decline from the earliest point and the latest time-point measured for this 
genotype.   
Increasing the numbers of animals is critical to assess the outcome as the data are 
currently underpowered, but another explanation for variability could be that the GC muscle was 
evaluated, and that muscle is composed of a mixture of fiber types.  Perhaps a better muscle for 
EIM analysis would be the TA, whose skin facing compartment has been reported to be 
comprised of only  FF fibers (Pun et al., 2006).   To further assess EIM as a method for 
preclinical evaluations, I also measured peak CMAP from the TA and L-GC from the same 
animals at the P80 and P100 time-points and correlated the 2 measures (Figure 3.5D).  The P100 
TA CMAP values from these animals were in line with numbers we had obtained previously 
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(Figure 3.5B), confirming that the animals themselves were not the source of variability in the 
data set.  Because the EIM measurements were done on the GC muscle, I also did CMAP 
recordings from that muscle and found a positive (though weaker) correlation between the 2 
measures (Figure 3.5D).  Therefore, the results of the CMAP study (and to a lesser extent the 
EIM measures), show that the neuromuscular junctions preserved by Mmp9 inactivation are 
functional.  Corresponding to the preservation of synapses, motor neuron numbers in the lumbar 
spinal cord initially decreased more slowly in the absence of Mmp9, with significantly more 









controls (p=0.003; Figure 3.6A-C).  However, this protection was transient and by P160 motor 
neuron numbers were comparable between the two genotypes (Figure 3.6C).   
We further observed significant improvements resulting from Mmp9 ablation in other 
functional tests that measure late changes in the mSOD1 mice, such as the rotarod (Figure 3.7A) 
and swim (Figure 3.7B) tests.  Specifically, we consider the swim test in which a mouse is placed 
at one end of a tank and is timed while it swims to a platform on the other end, to be a sensitive 
measure of hindlimb muscle function (Raoul et al., 2005).  The stage at which swim rate was 




 mice, and by 18 days in 
heterozygotes (Figure 3.7B).  The rotarod test is not specific to lumbar level evaluation and 
instead relies on both limb muscles and axial muscles; it also requires intact motor coordination.  
Still, very similar data were obtained using the rotarod test as the swim test, in terms of the 
timing of motor decline (Figure 3.7A).   
Finally, we also consider lifespan in mSOD1 mice to be a functional readout since it is 
determined by the stage at which mice can no longer right themselves in 30 seconds.  Median 
survival of SOD1
G93A
 mice in our C57BL/6 colony was 156 days.  This was increased to 178 
110 
 
days by removal of a single allele of Mmp9 and to 195 days by complete ablation, representing a 
25% increase in lifespan (Figure 3.8).  Though it has been reported that survival time is reduced 
by 5 days in males as compared with females (Heiman-Patterson et al., 2005), we do not see this 
in our colony in which there is no significant differences between males and females for any of 













, p=0.80).  Interestingly, the MMP-9-dependent differences in survival data 
are similar to those reported by Kiaei et al. (2007; see Discussion), even though our studies were 
performed on a different, congenic genetic background, and even though the lifespan of our 
SOD1
G93A






MMP-9 was initially identified as a potential therapeutic target for ALS based on our 
analysis of molecular diversity between motor neurons that are vulnerable or resistant to ALS.  
In Chapter 2 we showed that MMP-9 expression prior to disease onset defines the subset of 
motor neurons that are destined to die which are also most vulnerable in human patients: the fast 
motor neurons.  In this chapter, our data show that MMP-9 is more than just a marker of 
susceptible populations; it plays a major role in motor neuron degeneration in ALS model mice. 
 Importantly, we used a variety of metrics beyond just survival time to assess potential 




with one or both Mmp9 alleles deleted.  Early reports initially 
described the disease as “presymptomatic” in the SOD1G93A transgenic mouse model prior to 
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P90, when significant motor neuron loss from the lumbar spinal cord is detected coincident with 
the onset of tremors and hindlimb weakness.  From this age, progressive paralysis of the 
hindlimbs during the symptomatic phase was reported to culminate in their near complete 
paralysis followed by death when the animal can no longer right itself after being placed on its 
back (Chiu et al., 1995; Gurney, 1994).  However, later studies demonstrated that the die-back of 
axons from the muscle end-plates occurs much earlier and there is a dramatic decline in the 
number of functionally intact motor units during the asymptomatic phase of disease (Azzouz et 
al., 1997; Fischer et al., 2004; Hegedus et al., 2007; Pun et al., 2006).   
We chose to focus primarily on this early axonal dieback because 1) it is the earliest 
reported morphological change in mSOD1 mice; 2) it has been shown to reflect the differential 
vulnerability of FF vs. FR vs. S MN subtypes (Frey et al., 2000); 3) denervation is a 
phenomenon that occurs with near-identical specificity in human patients (Fischer et al., 2004) 
and 4) it has direct clinical relevance since it is the defining event in the onset of muscle 
paralysis.  We find that measuring muscle denervation is extremely robust; indeed, the % 
innervation in the TA is nearly invariable between littermates regardless of sex at a very early 
time point (P50; see Table 3.1, Figure 3.3) and a power analysis showed that only 3-4 animals 
are needed to detect a treatment effect (G*POWER version 3.1, two-tailed test, D = 3.15, 
noncentrality parameter = 4.45, critical T = 2.45, actual power =0.96).  Using this measure, we 





compared to controls.  We further coupled this with CMAP measurements and behavioral 
assessments to show a real preservation of muscle strength.   
Although there are many advantages to using an assessment of the morphology of the 
NMJ as an early outcome, one drawback is that it requires that the animal be killed.  We had 
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hoped to find a less invasive measure, and so explored the use of EIM.  In EIM, a weak, high-
frequency electrical current is passed across a set of electrodes overlying a muscle of interest in 
an anesthetized mouse and the consequent surface voltages are measured.  These voltages 
provide a measure of muscle pathology including muscle atrophy and the presence of fat and 
connective tissue within the muscle (Rutkove, 2009).  Human studies have shown that the EIM 
50 kHz phase value is highly reproducible between individuals and very sensitive to decline in 
ALS and the method is being optimized to transition to preclinical animal studies (Nie et al., 
2006).  Unfortunately, in a small sample, we found that EIM was not very sensitive to 
differences in rates of decline and atrophy in mice.  We speculate that this is because the 
prototype that we used for measurements was designed for use on the GC muscle.  Future studies 
in other muscles, especially the TA, will be of interest to further explore the potential use of the 
method as a part of a preclinical screening protocol.  With these considerations, for the majority 
of the experiments we will describe in the next chapter of this thesis, we used NMJ morphology 
as our primary outcome to evaluate the effect of different treatments. 
Our denervation data in TA and Sol muscles are in line with previous 
electrophysiological studies and fiber type analyses that support the sequence of degeneration 
from FF to FR to S (Hegedus et al., 2007; Kanning et al., 2010).  Further electrophysiological 
studies also suggested that an initial switch in motor unit phenotype from FF to FR may precede 
the loss of FF motor axons (Hegedus et al., 2008).  Our data imply that removing MMP-9 may 
facilitate a motor neuron subtype conversion, as we have shown that there are no differences in 





(Figure 3.4B).  The resistance of FR and S motor units may reflect their high sprouting capacity, 
which may allow them to reinnervate motor endplates (Frey et al., 2000).  Therefore, future 
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studies to assess whether MMP-9 contributes to ALS pathology by preventing regenerative axon 
sprouting or rather by actively triggering denervation will be important.   
The potential role of MMP-9 in preventing axonal sprouting will be discussed in more 
detail in Chapter 4, but we believe it has some role, based on motor neuron numbers and 


















 are still alive and many 
are able to swim and remain on the rotarod.  This suggests that MMP-9 deletion likely promotes 
axonal sprouting and an increase in the average motor unit size.   
Our model of the involvement of MMP-9 in ALS differs significantly from that of Kiaei 
et al (2007), despite the fact that our survival data are very similar.  As mentioned earlier, this 
group explored the contribution of MMP-9 to cytokine-mediated late-stage pathology in mSOD1 
mice on a mixed genetic background.  Though we confirm that their findings are valid on a 
congenic background, in contrast to (Dewil et al., 2005), our data differ from theirs importantly 
in terms of cell-type and timing.  Because they believed that MMP-9 was upregulated late in the 
disease process and was not expressed by healthy motor neurons, they limited their analysis to 
postnatal day 115 (equivalent to P145 on our C57BL/6 background according to Kiaei et al.).  
Further, their expression data for the absence followed by upregulation of MMP-9 is weak:  they 
show a tightly cropped gel zymography image which lacked a protein ladder or protein controls 
and also performed immunostaining using an MMP-9 antibody from Santa Cruz Biotechnology, 
Inc. that is infrequently used for immunohistochemistry and receives bad user reviews on that 
company’s website.  The authors went on to use more unquantified, low-resolution 
immunostaining to conclude that MMP-9 could contribute to the pathogenesis of ALS by 
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facilitating the cleavage of TNF-α and related proinflammatory cytokines and anchorage-
dependent detachment of cells from the extracellular matrix.  Though it is possible that MMP-9 
may indeed play such roles during the final, catastrophic phase of degeneration during which we 
showed that MMP-9 is also expressed by invading microglia (Figure 2.10F), this takes place 
~100 days later  than the early role in TA axonal dieback that we present here.  We will further 
explore the timing and relevant cell types involved in MMP-9’s contribution to disease in the 
next chapter.    
 Though understanding MMP-9’s mode of action is critical, our data showing the strong 
protection conferred by removal of MMP-9 already suggest that MMP-9 is an exciting candidate 
therapeutic target.  This is particularly true given that we saw very significant protective effects 
after deleting just one allele of Mmp9 (thereby reducing MMP-9 levels by ~ 50%).  Completely 
removing MMP-9 from human patients is not feasible, but there are already tools available that 
can reduce MMP-9 activity (Overall and López-Otín, 2002) and controlling MMP-9 expression 
is an area of active research (Yan and Boyd, 2007).  However, at this point it is still not known 
by what mode of action MMP-9 is working to destabilize nerve-muscle contacts.  Rational drug 
design requires a greater understanding of the role of MMP-9 in ALS.  Therefore, the 








Figure 3.1 Extraocular and pelvic sphincter motor units show selective resistance in ALS 
model mice.  
A-D. Overlap of VAChT-positive motor terminals (green) with acetylcholine receptors stained 
using α-bungarotoxin (BTX, red) as an indicator of innervated motor endplates in end-stage 
SOD1
G93A
 mice. (A) The fast TA muscle exhibits marked denervation, whereas the slow Sol 
remains partially innervated (C). (B) The extraocular muscle superior rectus (SR) and (D) the 
external urethral sphincter (EUS) show nearly complete preservation of motor units. Scale bar, 
20 μm.  
E. Percentage of intact neuromuscular junctions in indicated limb (green), extraocular (pink) and 
pelvic (blue) muscles of end-stage SOD1
G93A
 mice (mean ± s.e.m from 3 animals). The 
percentage of intact neuromuscular junctions in age-matched wild-type controls ranged from 97 
to 100% for all muscles (n=3) and is indicated by the grey-shaded region.  Muscles (top row): 
levator palpebrae (LP), medial rectus (MR), inferior rectus (IR), inferior oblique (IO), retractor 
bulbi (RB), superior oblique (SO), lateral rectus (LR), ischiocavernosus (IC), external anal 
sphincter (EAS), bulbocavernosus (BC).  Motor neurons (bottom row): lumbar spinal cord (L), 
oculomotor nucleus (III), trochlear nucleus (IV), abducens nucleus (VI), dorsolateral and 
dorsomedial components of Onuf’s nucleus (DL and DM). 







Figure 3.2 MMP-9 and mutant SOD1 levels in mSOD1 mice crossed to MMP-9 knockouts  
A. Western blotting reveals that MMP-9 levels in the heterozygote are 44% of the wildtype 
control.  Densitometry values were normalized using α-tubulin.  
B. No changes are observed in SOD1
G93A
 copy number in the absence of MMP-9. Quantitative 
real-time PCR (qPCR) data using the Delta Ct method are shown.  
C-K. Immunostaining for ChAT (red), MMP-9 (blue), and mSOD1 (green) at P40 in L5 spinal 
cord of indicated genotypes. Overall motor neuron numbers are similar but MMP-9 intensity per 





 spinal cord, demonstrating the specificity of the MMP-9 antibody. No 




Table 3.1 Percent muscle innervation at indicated time-points of SOD1
G93A
 hindlimb 





















































































Table 3.1 Percent muscle innervation over time  
Percent muscle innervation at indicated time-points of SOD1
G93A
 hindlimb muscles with 0, 1, or 
2 copies of Mmp9.  Numbers are mean ± S.EM, n=3-4 animals with one muscle from each 













A-F. Neuromuscular junctions in TA and Sol muscles in SOD1
G93A
 mice that are either wildtype 
or null-mutant for Mmp9.  At P50 in the fast TA muscle of a normal SOD1
G93A
 mouse, partial 





 littermate at the same age (D).  Even more marked preservation is observed 
at P100 (compare E to B). In the slow Sol at P100 denervation is only partial in mice wildtype 
for Mmp9 (C) and this loss is blocked by ablation of Mmp-9 (F). Scale bars, 20 μm.  
G-H. Morphological and functional evaluation of four different genotypes, color-coded in the 













 (red; -/-), and non-transgenic (gray, WT). (G) Denervation of TA muscle is 
50% complete by 63 days in normal SOD1
G93A
 mice but delayed by ~80 days by removal of 
either one or both alleles of Mmp9. Values represent means ± s.e.m of one muscle from each of 
3-4 animals per genotype (*** p<0.001, **p< 0.01).  (H) Denervation of slow Sol muscle occurs 
90 days after that of the TA, but is further delayed by 50 days in the absence of MMP-9. Values 
represent means ± s.e.m of one muscle from each of 3-4 animals per genotype (***p<0.001, 








Figure3.4 In the absence of MMP-9, fast motor neurons adopt “slower” properties 
 A. In SOD1
G93A
 mice, innervation of the superficial, skin-facing compartment (black points) 
precedes that of the deep, bone-facing fibers (blue points) by >20 days. The difference in the 
mean values of FF vs. FR is greater than would be expected by chance after allowing for effects 
of differences in time (P = 0.039).   




mice become denervated at an 
identical rate (P = 0.560).   
C. There are no significant differences at early time-points in the amount of innervation of the 
“slow” Sol muscle of mSOD1 mice (red points) and the “fast” TA of the SOD1G93A;Mmp9-/- mice 
(blue points).  Therefore, FF and FR motor neurons both adopt a behavior that is comparable to 







Figure 3.5 Measuring electrical activities in SOD1
G93A
 mice shows that removing MMP-9 
rescues muscle function 
A-B. Evoked CMAPs in the TA muscle after stimulation of the sciatic nerve in mice of the 
indicated genotypes. (A) Individual traces show the stimulus artifact (s.a.) followed by the M-
wave (whose maximum peak-to-peak value is used to calculate the CMAP) and H-wave.  (B) 
CMAP measurements from groups of the indicated genotypes aged between P105-130 were 
compared with age-matched non-transgenic controls (WT) by one way ANOVA.  Results are 
shown as mean ± s.e.m. (n= 3-4 animals per genotype); * p<0.05.  
Collaboration with T. Akay. 














 (red triangles). 
 D. Correlation plot of EIM 50 kHz phase with peak CMAP amplitude from the GC muscle from 











Figure 3.6 Motor neuron numbers in the spinal cord initially decrease more slowly in the 
absence of Mmp-9 









 littermates.  
C. Direct counting of motor neurons at L5 from P40 to end-stage shows a significant delay in 







Figure 3.7 Deletion of a single or both Mmp-9 alleles confers significant functional benefit 
in SOD1
G93A
 mice  













 (red; -/-), 
and non-transgenic (gray, WT). 
A. Latency to fall from an accelerating rotarod from P40 until mice were no longer able to 




 mice performed better than controls 
from P70 onward as assessed by one-way ANOVA at each time-point (***, p<0.001, **, P< 
0.01; *, p<0.05).  Mmp9 heterozygotes showed improved performance from P150 (p<0.001). 
B. Mmp9 deletion delays motor impairment in a swimming task that reflects hindlimb function.  




mice (n=7).  From P145 onward, 









(n=10, p= 0.005) mice.  







Figure 3.8 Deletion of a single or both Mmp-9 alleles extends lifespan in SOD1
G93A
 mice 
Kaplan–Meier plot showing the cumulative probability of survival of SOD1G93A;Mmp9−/− 








 (n = 16, black 
line) on a pure C57BL/6 background (log-rank test= 49.2, p<0.001).  Lifespan is prolonged 14% 




Chapter 4:  Role of MMP-9 in motor neuron degeneration 
Introduction 
 In Chapter 2 I reported that MMP-9 is selectively expressed in vulnerable MNs at two 
levels: in susceptible motor pools (trigeminal, facial, L5 MNs, RDL) and also in susceptible MN 
subtypes (fast α-MNs) within spinal motor pools.  Further, we showed that ER stress and UPR, 
measured by p-EIF2α positivity, are selectively induced in MMP-9+ motor neurons, in agreement 
with their FF/FR identity.  In Chapter 3, we found that MMP-9 is a major driver of disease in 
SOD1
G93A
 mice.  Genetic deletion delays TA muscle denervation by approximately 80 days, 
delays functional motor declines in the accelerating rotarod, a swim test, and TA CMAP, and 
increases lifespan by 25%.  These exciting findings raise many interesting questions that we will 
begin to address with experiments presented in this chapter.   For example, in what cell type is 
MMP-9 inducing its pathological effect and when is this happening?  Is MMP-9 sufficient to 
induce axonal degeneration? What is the role of enzymatic activity versus non-catalytic binding? 
Can we identify a candidate mechanism (or parallel mechanisms) downstream of MMP-9 that fit 
into an ER stress-relevant pathway? And finally, what are the potential clinical implications of 
this research? 
First, it may be useful to briefly review pathways that have already been implicated in the 
toxicity of mutant SOD1.  The exact molecular pathway remains unknown, but it is widely 
agreed that the pathological effects of SOD1 mutations are not the result of a loss of dismutase 
activity, but rather from gain-of-function toxic effects.  This theory is supported by several lines 
of evidence.  For example, mice that are completely deficient for SOD1 develop normally and 
show no overt motor deficits out to 6 months in age, though they did exhibit marked 
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vulnerability to motor neuron loss after axonal injury (Reaume et al., 1996).  This suggests that 
SOD1 is not necessary for normal motor neuron development and function but is required under 
physiologically stressful conditions following injury.  Moreover, survival time is the same in 
mice carrying a mutant SOD1 transgene (tgSOD1
G85R
) on a normal mouse background compared 
with the same transgene on a SOD1
−/−
 background,  demonstrating that survival is independent 
of mouse SOD1 loss of function (Bruijn et al., 1998).  Further, motor neuron degeneration occurs 
in transgenic mice overexpressing several different mutant forms of SOD1, irrespective of 
residual dismutase activity (Gurney, 1994).  In motor neurons, mutant SOD1 toxicity may result 
from various effects, including oxidative stress, accumulation of intracellular SOD1-positive 
aggregates, mitochondrial dysfunction and defects in axonal transport (Rothstein, 2009).  A 
unifying theory has been presented in which these multiple stressors converge to generate 
instability of proteostasis through vicious cycles of cell stress and protein misfolding (Saxena 
and Caroni, 2011). 
Because mutant SOD1 is ubiquitously expressed, identifying the cell type(s) in which it acts 
to trigger degeneration has been a very interesting and productive area of research.  Studies 
support the notion that mutant SOD1 in both MNs and non-neuronal cells such as microglia and 
astrocytes contributes to the disease process in vivo (Papadimitriou et al., 2010).  First, when 
expression of mutant SOD1 is restricted to either motor neurons (neurofilament light chain or 
Thy1 promoters) or astrocytes (GFAP promoter), transgenic mice develop normally and do not 
experience spontaneous motor deficits with increasing age (Gong et al., 2000; Lino et al., 2002; 
Pramatarova et al., 2001), except at a very late age with extremely high levels of neuronal mutant 
SOD1 expression (Jaarsma et al., 2008).  Second, Clement et al. (2003) generated chimeric mice 
that are mixtures of normal cells and cells expressing SOD1 mutations and found that as the 
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percentage of wild type cells increases, chimeras show progressively less severe disease.  
Further, wild type motor neurons show pathology in chimeras where they are next to SOD1 
mutant non-neuronal cells. These results argue that motor neuron degeneration in SOD1 mutants 
is not cell-autonomous, but rather is in some way mediated by surrounding, non-neuronal cells 
(Clement et al., 2003).  Finally, removal of mutant SOD1 expression by Cre recombinase-
mediated excision from either astrocytes or microglia slowed the disease progression and 
extended survival (Boillée et al., 2006b; Wang et al., 2011a; Yamanaka et al., 2008).  Therefore, 
the SOD1 mutation acts in both cell-autonomous and non-cell-autonomous manners.   
Although we originally identified MMP-9 because of its expression in susceptible motor 
neurons themselves, it remained possible that MMP-9 from other cell types is the critical actor in 
the degenerative process (Kiaei et al., 2007).  Thus, in order to determine the involvement of 
motor neuron derived-MMP-9, we will use adeno-associated virus (AAV) vectors to selectively 
silence MMP-9 in motor neurons and look for an effect on TA muscle innervation.  AAV vectors 
are small, replicative defective viruses that exhibit a number of properties advantageous for gene 
therapy in the central nervous system.  First, depending on age of administration and AAV 
serotype used, the majority of AAV vector transduction can occur in neurons where it is possible 
to obtain long-term, stable gene expression with very little accompanying toxicity after only one 
injection (McCown et al., 1996).  AAV serotypes are variations of the virus resulting in capsid 
protein motifs that are not recognized by the same neutralizing antibodies. The capsid of AAV 
determines the method of entry into the host cell (Weinberg et al., 2013).  Since the earliest work 
with AAV2, multiple other AAV serotypes that are either naturally occurring or laboratory 
designed have been investigated.  Further, distinct from the tropism inherent to different AAV 
vector serotypes, promoter selection, virus purification method, and route of delivery to the 
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animal all significantly influence the pattern and longevity of neuronal transduction (Blankinship 
et al., 2006).  Finally, another factor that influences transgene expression is the conversion from 
a single-stranded (ss) DNA genome that is transcriptionally inactive into a double-stranded (ds) 
template.  The ssDNA to dsDNA conversion is the rate-limiting step involving either the de 
novo synthesis of the second-strand DNA or the annealing of the plus and minus strands from 
two separate viral particles coinfected into the same cell (Ferrari et al., 1996; Fisher et al., 
1996).  To accelerate transduction, AAV vectors have been developed that package a self-
complementary dsDNA genome (Wang et al., 2003).  
In the last decade, AAV vectors have successfully been used to manipulate CNS function 
through a wide variety of approaches including expression of foreign genes, expression of 
endogenous genes, expression of antisense RNA and expression of RNAi (Weinberg et al., 
2013).  For motor neuron disease in particular, there have been some exciting recent studies that 
have used AAV gene transfer.  Several groups have investigated the use of different AAV 
serotypes to target motor neurons in the spinal cord after intramuscular, intraneural, 
intraparenchymal, or intrathecal injections (Hollis et al., 2008; Snyder et al., 2011; Towne et al., 
2008).  Further, two different groups showed that administration into the facial vein 1 day after 
birth of self-complementary AAV serotype 9 expressing survival motor neuron (SMN) protein  
in spinal muscular atrophy model mice resulted in a substantial extension of life span in these 
animals (Foust et al., 2010; Valori et al., 2010).  Similar results were reported after 
intracerebroventricular (i.c.v.) and intraspinal injection with AAV8 (Passini et al., 2010; 
Samaranch et al., 2012).  Therefore, AAV vectors can serve as powerful tools for preclinical 
studies and are very promising as tools for gene therapy. 
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In this chapter, we will use different strategies to ask when MMP-9 is playing a role in 
ALS, where it is acting, and by what molecular pathway it exerts its effect. We test different 
AAV vectors to find the optimal serotype to overexpress or silence Mmp9 specifically in motor 
neurons.  We will also use pharmacological inhibitors of MMP-9 to explore the role of 




MMP-9 is required for the full activation of ER stress in the ALS disease pathway 
In Chapter 2, I showed there was a selective and early induction of UPR, as measured by 
p-EIF2α, in MMP-9-positive motor neurons at P40.  To determine the relative positions of 
MMP-9 and the UPR in the degenerative pathway, we next examined p-EIF2α staining at P40 
and P50 in SOD1
G93A
 mice that were null or wildtype for Mmp9 at P40 and P50.  We observed a 
strong increase in p-EIF2α staining between P25 and P40 in the SOD1G93A;Mmp9+/+  mice 




  littermates.  In 
fact, at P40, only <25% of the normal number of motor neurons stained for p-EIF2α, and this 
fraction was even lower at P50 (Figures 4.1C and 4.1G).  By P75, when TA muscle denervation 




 mice, the number of motor neurons stained for p-EIF2α 
had risen to 5.8 ± 0.9 (n=2 animals) per section (Figure 4.2B), suggesting that Mmp9 deletion 
delays, but does not indefinitely prevent, the onset of ER stress.  Indeed, at this time point, p-
EIF2α staining in the spinal cords of SOD1G93A;Mmp9+/+ littermates was widespread and 
detectable in almost all motor neurons as well as neighboring ChAT-negative cells (Figure 
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4.2A).  Thus MMP-9 very likely acts as one major factor upstream of activation of the ER stress 
response in a majority of fast motor neurons.  This makes MMP-9 the earliest known 
biochemical intermediate in motor neuron degeneration triggered by mutant SOD1. 
 Acute motor neuron knockdown of Mmp9 also has protective effects 
We next sought to determine the cell type in which MMP-9 exerts its effects on motor 
neuron degeneration.  Since no conditional mutants for Mmp9 have been reported, we decided to 
use the targeting properties of AAV vectors.  We first tested different AAV serotypes and routes 
of administration to find an optimal combination to specifically target motor neurons but not 
other cell types.  The transduction profiles of various vectors are summarized in Table 4.1. 
Along with colleagues in the Henderson lab, various AAV serotypes encoding the 
reporter green fluorescent protein (GFP) were delivered to WT pups at either P1 (for i.c.v. or i.v. 
administration) or P4 (for i.m. administration).  The animals were sacrificed at P25 and the 
transduction efficiency of the AAV administration in their spinal cords was assessed by 
examining the sites of GFP fluorescence.  We found that the AAV6:cmv-EGFP generated by the 
Aebischer group at EPFL resulted in the most specific motor neuron transduction. However, 
AAV6 from UNC did not transduce MNs.  Further, no self-complementary AAV (from 
Guangping Gao at UMMS) exclusively transduced MNs when delivered i.c.v.; that is, we either 
saw no transduction, or transduction of both MNs and other neural cell types.  The 2 best self-
complementary serotypes (following i.c.v. administration) were scAAV6.CB6.eGFP (Figure 
4.3A) and scAAVrh8.CB6.eGFP (Figure 4.3B), though neither were as motor neuron-selective 
as the single-stranded AAV6 from the Aebischer lab (Figure 4.3C-F). 
Also, we observed a high level of toxicity after i.c.v. administration with some serotyopes 
(most toxic: scAAVrh39 and scAAVrh43) and the toxicity by i.c.v administration was highly 
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correlated to the amount of diffusion around the site of injection for that same serotype in the 
intramuscular injection experiment.  For example, for those 2 most toxic serotypes, all 3 of the 
animals treated with each had severe brain dissolution at the time of the perfusion and had 
bilateral whole body fluorescence following a unilateral TA injection.  Consequently, following 
these analyses, AAV6 from EPFL was selected for future motor neuron targeting studies.   
When administered into the cerebral ventricles in neonatal mice, AAV6 engenders stable 
gene expression in 50-60% of motor neurons throughout the rostrocaudal extent of the spinal 
cord, in addition to some dorsal neurons and fiber tracts and sensory ganglia (Figure 4.3C and 
not shown).  However, AAV6 does not efficiently transduce brainstem motor nuclei (Figure 
4.4A-C) and so we limited our analyses to the lumbar level of spinal cord.  Moreover, despite 
efficient MN transduction, no obvious fluorescence was observed in muscles or the livers of the 
animals, suggesting that this route of administration has no or limited transduction of cells in the 
periphery.  Further, in agreement with previous reports (Snyder et al., 2011; Towne et al., 2009; 
Towne et al., 2011), when AAV6-cmv.GFP is injected into a single skeletal muscle (i.m.) at P4, 
only the muscle and the corresponding motor pool are labeled (Table 4.1).  This allowed us to 
compare the effects of reducing MMP-9 in motor neurons + CNS + sensory neurons (i.c.v.) with 
those of knockdown in motor neurons + muscle + proprioceptive sensory neurons (i.m.). 
We first determined shRNA sequences that were optimal for knockdown of MMP-9 (not 
shown). These were incorporated, together with a mismatch control, into AAV6 vectors 
(Figur4.5A).  Virus was injected either at P1 (i.c.v.) or P4 (i.m.) and the effects on MMP-9 
expression in vivo were analyzed at P50.  Injection i.c.v. gave a significant but partial (20%; 
p=0.03) overall reduction in numbers of MMP-9
+
 motor neurons, and a stronger (50%; 
p=0.0003) reduction in MMP-9
hi
 (Figure 4.5F).  The incomplete removal of MMP-9 by this 
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approach can be explained by the fact that not all motor neurons were infected and, of those that 
were, that some did not show complete knockdown (Figures 4.5B and 4.5C).  Overall there was a 
strong correlation between GFP expression and lack of MMP-9 expression, as with i.m. injection 
into TA (Figures 4.5D and 4.5E).   
Despite the fact that MMP-9 reduction was only partial, we observed strong protective 
effects of AAV6 shRNA administered by either route (Figures 4.5G-I).  At P50, when SOD1
G93A
 
mice show <60% innervation of TA motor endplates, the corresponding amount for i.c.v. 
animals was significantly higher: 88 ± 2.2% (Figure 4.5I).  This trend continued out to P100; 
though only 2 SOD1
G93A
 animals were studied at this time-point, their muscle innervation was 
significantly higher than untreated controls (mean ± st. dev: 59.8 ± 14% vs. 29.2 ± 11 %, 
p=0.049).  For i.m. injection into TA, we compared shRNA to MMP-9 with the mismatch 
control injected on the other side of the same animals.  Protection at P50 was strong, and specific 
to shMMP9 (Figures 4.5G to 4.5I).  Likely reflecting the incomplete knockdown of MMP-9, 
both i.c.v. and i.m. routes gave protection indistinguishable from that observed in mSOD1 mice 
that were heterozygotes for MMP-9.  Given that both i.c.v. and i.m. routes led to comparable 
protection, and that i.c.v. administration in neonatal mice selectively infects motor neurons and 
some dorsal spinal and proprioceptive sensory neurons and injection into a single skeletal muscle 
labels only the muscle and the corresponding motor pool and proprioceptive neurons, these 
experiments implicated MMP-9 in motor neurons or possibly proprioceptive sensory neurons.  
However, since proprioceptive neurons do not express MMP-9 even in ALS mice (Figure 2.4), 
our results identify MMP-9 in motor neurons themselves as the trigger of degeneration. 
MMP-9 is sufficient to induce degeneration in fast motor neurons of ALS mice 
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Given that removing MMP-9 from motor neurons rescues muscle innervation, we next 
asked whether MMP-9 was alone sufficient to trigger axonal die-back.  We first tested the effects 
of MMP-9 in ALS-resistant motor units.  An AAV6 vector expressing full-length Mmp9 cDNA 
was injected at P4 into the extraocular muscles of WT and SOD1
G93A
 mice (n=4 each), resulting 
in stable expression of MMP-9 in a significant fraction of oculomotor neurons throughout 
adulthood, at levels comparable to those in FF motor neurons (Figure 4.6A and 4.6C).  However, 
we detected no increase in denervation of extraocular muscles even at P150, with or without 
mutant SOD1 (Figure 4.1B).  Similar results were observed at P100 in left vs. right Sol muscles 
infected in the same way (p=0.20) (Figure 4.6B and 4.6E).  Thus, simple expression of MMP-9, 
or co-expression with mutant SOD1, in a neuron is not sufficient to trigger its degeneration, 
suggesting that other elements of the pathway also need to be present.   Accordingly, when we 
overexpressed MMP-9 in the fast TA motor pool of SOD1
G93A
 mice, denervation of this 
vulnerable muscle was further accelerated (Figure 4.6B and 4.6 D), but there was no effect in 
WT controls.  When we compared the MMP-9
+
 populations from the injected side versus the 
uninjected  side of spinal cord from the SOD1
G93A
 mice that had received unilateral injection of 
AAV6.MMP9 into their TA, we found no difference in the total number of MMP-9
+
 cells per 
ventral horn (9.7 ± 1.0 vs. 9.4 ± 1.1 MNs/side, p=0.18).  However, we found a large increase in 
the number (2.4-fold) of MMP-9
hi
 cells. 
We therefore asked whether MMP-9 is sufficient to restore vulnerability to TA motor 
neurons rendered resistant by Mmp9 deletion.  AAV6-MMP-9 was injected into one TA muscle 




mouse, while either no virus (n=2) or AAV6-GFP (n=2) was 
injected into the contralateral TA as a control (Figure 4.7A).  By P50, the control muscle 
remained fully innervated whereas ~22% of the NMJs became denervated in the injected muscle 
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(Figure 4.7B-G).  There was a strong inverse correlation between the number of transduced 
motor neurons (MMP-9
+
) and the % innervation in the TA (R
2
=0.85, Figure 4.7E).  Overall, 
therefore, within the cellular context of fast motor neurons expressing mutant SOD1, the rate of 
degeneration is proportional to the level of MMP-9.  However, activation of the pathway for 
axonal die-back requires neuronal subtype-specific elements in addition to MMP-9 and SOD1. 
MMP-9 fits into an ER stress-relevant pathway 
 Besides showing that MMP-9 is sufficient to induce muscle denervation in fast motor 





mice provides an in vivo system for further studies on the role of MMP-9 in 
ALS.  Given that we showed that MMP-9 was required for the phosphorylation of EIF2α to 
occur (Figure 4.1), we decided to use this system to situate MMP-9 within a known pathway 
involved in MN vulnerability and induction of ER stress.  Briefly, it was previously shown that 
cultured mSOD1 motor neurons, but not WT motor neurons, are susceptible to cell death induced 
by Fas-ligand and nitric oxide (NO) (Raoul et al., 2002).  Further, elevated calcium levels and 
loss of calreticulin (CRT) are critical determinants of this susceptibility and are upstream of ER 
stress and death (Bernard-Marissal et al., 2012).  It was also shown that this loss of CRT occurs 
selectively in fast motor neurons, as Sol motor neurons showed CRT levels that were 
indistinguishable between WT and SOD1
G93A
 mice, whereas the levels of CRT in TA MNs were 
reduced by 60% (Bernard-Marissal et al., 2012).   Therefore, we decided to ask whether CRT 





mice have normal CRT levels.  We indeed found that the average CRT 




L5 mice was the same as 




 mice (n=3) with MMP-9 virally 
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expressed in the left TA motor pool, there was a significant down-regulation in CRT 
immunofluorescence on the injected side at P50 (Figure 4.8A-C).  When the injected side is 
further divided into MMP9-positive MNs and MMP9-negative MNs versus MMP-9-negative 
MNs from the uninjected side (65-100 MNs in each category), it is clear that the MMP-9-
positive MNs themselves have the lowest CRT levels (Figure 4.8D).  Further, there was no 
difference between MNs transduced with AAV6.GFP and adjacent non-transduced MNs 
(p=0.92), suggesting that AAV6 alone is not sufficient to change CRT levels.  Therefore, these 
results combined with those of Bernard-Marissal et al. (2012) suggest that while Fas activation 
leads to activation of nNOS and NO production in all mSOD1 motor neurons, only those that 
express MMP-9 manifest a decrease in CRT levels and an induction of ER stress.     
 
The enzymatic activity of MMP-9 interferes with axonal sprouting of FF MNs, but is likely 
not involved in their initial dieback 
Neither the results of the experiments with transgenic animals nor AAV-mediated knock-
down indicate by what mode MMP-9 leads to motor neuron degeneration.  MMP-9 has been 
shown to mediate its effects through both its proteolytic activity and through non-enzymatic 
processes that rely on hemopexin domain binding (Van den Steen et al., 2006; Vandooren et al., 
2013b), and it is important to distinguish between these potential modes of action in motor 
neuron degeneration.  Further, it is also unclear whether MMP-9 acts within the spinal cord or at 
the neuromuscular junction.  A previous study using an orally-delivered broad inhibitor of 
MMPs found only a modest 13-day survival benefit in mSOD1 mice (Lorenzl et al., 2006), but 
this may have reflected insufficient CNS exposure.  A commercially available inhibitor (MMP 
inhibitor I, Calbiochem), which is among the most potent and specific for MMP-9, was therefore 
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administered centrally (2 µg i.c.v., daily) to SOD1
G93A
 mice from P55 (the earliest time point at 
which stereotactic administration is feasible) to P75 (Figure 4.9A-B).  The inhibitor caused a 
significant delay in TA muscle denervation as compared to controls (Figure 4.9C) and reduced 
levels of ER stress in the ventral horn of SOD1
G93A
 animals at P75, compared to vehicle-treated 
controls (Figure 4.9D and 4.9E).   This indicates that enzymatic activity is at least partially 
involved in the degenerative process and this likely occurs at the level of the spinal cord, either 
directly on fast motor neurons or on neighboring cells and synapses.  Encouragingly, these 
results show that MMP-9 inhibition initiated even after the start of the degenerative process can 
confer significant protection.   
We next wanted to compare the protection conferred by inhibitors delivered before 
axonal dieback or, as before, after the initial muscle denervation has already occurred.  Because 
we found that before P50 our mice were often too small (<16 g) with skulls that were too thin to 
accommodate a head mount that is required for chronic i.c.v. administration (Figure 4.9B), we 
treated 2 groups of mice with SB-3CT, an irreversible inhibitor of gelatinase activity (selective 
for both MMP-9 and MMP-2) that had been shown to cross the blood-brain barrier at a dose of 
25 mg/kg, i.p. (Gooyit et al., 2012).   Two groups of animals were treated with SB-3CT or 
vehicle (10 % DMSO) from either P35-P50 (Group 1) or from P55 to P75 (Group 2) (Figure 
4.10A).  There were initially 5 SOD1
G93A
 animals in Group 2 that were receiving the inhibitor 
treatment, but we observed serious side effects in 3 of these including one with a massive skin 
lesion (likely from reduced wound healing as a result of the gelatinase inhibition) and 2 from 
apparent gastrointestinal blockages (which were excluded from the study following weight loss).  
Thus, by the P75 time-point, only 2 SOD1
G93A
 animals had received the full treatment schedule, 
which is not a large enough group to detect changes in muscle innervation  and more animals are 
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needed to really understand the effect of the treatment at P75.  However, both of those animals 
had a greater amount of innervation in the TA muscles than any of the controls at P75, though 
with such a small sample size there was not a significant overall difference between the groups 
(avg ± SD, 72.9 ± 11 % vs. 57.1 ± 7.1 %, p=0.13) (Figure 4.10C), and the % innervation was 
very similar to the animals that had been treated during the same timeframe with MMP-9 
Inhibitor I (Figure 4.9C).  Moreover, these values at P75 were much greater than the amount of 
innervation reported in untreated animals at P50 or P60 (Figure 4.10C).  Therefore, these 
preliminary data suggest that inhibiting MMP-9 allowed for a greater amount of reinnervation to 
occur. 
The unexpected side effects were managed better in Group 1, which received drug 
holidays after every 5 days of treatment, and fewer total injections than Group 2 (13 vs. 21 
injections).   In these younger animals, there was no difference between the groups that received 
2 weeks of vehicle treatment versus 2 weeks of the treatment with inhibitor from P35 to P50 
(p=0.91, n=3 animals per group, Figure 4.10).  Because of the low numbers of animals in these 
studies, and because attempts to quantify the amount of inhibition that the treatment caused by 
either gel or in situ zymography have failed thus far (Figure 4.11 and not shown), interpreting 
these data require caution.  However, a tentative model could be that the enzymatic activity of 
MMP-9 inhibits reinnervation, but is not involved in early pathology that results in the initial FF 
axonal die-back, given that SB-3CT had no effect on TA innervation when delivered between 
P30 and P50.  Future studies will be required to support this model, especially with regard to 
understanding the role of MMP-9 in early pathology.  However, the effect of MMP-9 inhibitors 
on muscle innervation at relatively late stages in disease may be very promising as a therapy for 




Overall, these data significantly extend our understanding of the role of MMP-9 in ALS.  
We have shown that MMP-9 in motor neurons themselves contributes to their degeneration.  We 
have also shown that MMP-9 is acting early, and that it is upstream of CRT down-regulation and 
the induction of ER stress.  Since to date CRT down-regulation and ER stress are the earliest 
biochemical events reliably linked to the mSOD1 degeneration pathway, these data suggest that 
MMP-9 is a very early element in the degeneration pathway downstream of SOD1.  Further, we 
show that the effects are mediated by its enzymatic activity after initial muscle denervation, but 
possibly not before.  Therefore, the results of these experiments strengthen the rationale for the 
use of MMP-9 reduction as a therapeutic option for ALS patients. 
 First, we used AAV6 as an important tool for many of the experiments presented in this 
chapter.  We began by comparing different serotypes and routes of administration and found that 
there are important differences in cell transduction between vectors that greatly impact their 
utility.  Of all those tested, we found that AAV6:cmv-EGFP had the most efficient and selective 
motor neuron transduction when administered into the ventricles at P1. Why should this 
particular vector differ so markedly from the other AAV6 vectors that we tested?  We speculate 
that it is one or a combination of the following 3 potential reasons.  First, promoter choice 
certainly plays an important role in transduction of different cells.  The AAV6 vectors from the 
Aebischer lab and UNC used CMV and the scAAV6 from UMMS used the CBA promoter.  
Following our tests with these, it was reported that relative to the CMV promoter, the CBA 
promoter expressed poorly in MNs in the brainstem and spinal cord, resulting in an 
underestimate of the number of MNs targeted by AAV9 (Gray et al., 2011).  This agrees well 
with our data.  However, they also report that while the CMV promoter provides rapid and strong 
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transgene expression, it is prone to diminish significantly over time in certain cell types.  In 
contrast, we found stable, high expression in motor neurons with either AAV6:cmv-EGFP or 
AAV6.cmv.MMMP9 in motor neurons to the latest time point examined (P150, Figure 4.6C).   
Another difference may arise from the purification method used in virus preparation, as it 
has been argued that the method of purification may have a greater impact on cell type tropism 
than packaging (Summerford and Samulski, 1999; Zolotukhin et al., 1999).  Guangping Gao 
(UMMs) and David Dismuke (UNC) both used a classic CsCl2 sedimentation method for 
purification, whereas the Aebischer lab used a newer “HiTrap” heparin column-based method.  
Finally, the titers differed for the 3 different AAV6 vectors sampled.  We compared the different 
serotypes by normalizing to injection volume, but it may have been better to compare a fixed 
vector genome dose.   One of the reasons that we chose volume over titer, is that there is 
currently not a standard way to titer AAV preparations and different groups contest each other’s 
results (David Dismuke, UNC, personal communication).  It is possible that the AAV6 vector 
from UNC would have performed as well as the AAV6 from the Aebischer group if a larger 
volume had been injected.   
 We also saw significant toxicity with several of the vectors from UMMS that we tested, 
but saw no equivalent toxicity with the vectors from EPFL or UNC.  The difference here is likely 
that those vectors from Guangping Gao at UMMS used a self-complementary (sc) vector design 
which has a very different vector biology than the native single strand (ss) vector design which 
the other groups used.  Sc vector has a much faster onset and higher level of transgene gene 
expression as compared to ss vector (5- to 10-fold higher and at least 7-10 days faster, which 
may lead to more and rapid accumulation of toxic EGFP) (Guangping Gao, UMMS, personal 
communication).  Ss vector needs to be converted into double stranded vector genome before it 
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starts expression, whereas sc vector is a double stranded vector and will start expression 
immediately after entering the cells and uncoated.  This ss to double-strand conversion process is 
the rate-limiting step for AAV transduction and many ss AAV genomes get lost in this process  
(Ferrari et al., 1996).  Sc vector bypasses this process and get much better transduction efficiency 
(Wang et al., 2003).  However, for a potentially neural toxic protein such as EGFP (Liu et al., 
1999), this increased efficiency likely was detrimental.     
        Therefore, we chose to use AAV6 from the Aebischer group at EPFL for experiments to 
ascertain the cell type from which the MMP-9 is derived that influences motor neuron 
degeneration.  We found that AAV6 shRNA to MMP-9 administered either i.c.v. or i.m. 
protected muscle innervation to the same extent as that seen in the heterozygote knockout.  The 
only cell types transduced by both routes of administration are motor neurons and proprioceptive 
neurons, and the latter did not express MMP-9.  We therefore conclude that it is the MMP-9 
expressed by vulnerable motor neurons themselves that drives their die-back or, alternatively, 
prevents their regeneration during the cycle of denervation-reinnervation that precedes paralysis 
(Schaefer et al., 2005).  However, since MMP-9 is a secreted extracellular enzyme, this does not 
preclude actions at sites in the immediate vicinity of the motor neurons, such as afferent synapses 
or the neuromuscular junction.  
 In this chapter, we have also presented clear genetic evidence that MMP-9 is required for 
the full activation ER stress, as previously defined in an elegant series of experiments by the 
Caroni lab (Saxena et al., 2009).  Beyond delaying the upregulation of p-EIF2a in MNs, we have 
also shown that down-regulation of CRT is prevented at P50 in SOD1
G93A
 mice with Mmp9 





 mice not only induces muscle denervation in the TA, but also causes a 
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decrease in CRT immunofluorescence on a cell-by-cell basis in their spinal cords.  By what 
mechanism is MMP-9 acting to induce these early changes?  Our experiments suggest that 
MMP-9 could be upstream of the phosphorylation of EIF2α, but do not distinguish between 
enzymatic and non-enzymatic activities of the protein.  Our preliminary study with the 
pharmacological activity inhibitor (SB-3CT) delivered from P35 to P50 suggests that at this 
stage MMP-9 is not inducing pathology through its activity.  Though drawing solid conclusions 
from these data is premature, there is support in the literature for how both MMP-9 proteolysis 
and/or integrin binding could possibly induce these changes.   
MMP-9 has been shown to act in an integrin β1-dependent manner to influence NMDA 
surface trafficking and enhance NMDA receptor function (Michaluk et al., 2009).  This in turn 
activates nNOS (Bredt and Snyder, 1989) and thereby the production of nitric oxide (NO).  
Another potential source of NO is a distinct feedback loop in ALS mice through which activation 
of the Fas death receptor by Fas ligand (FasL) leads in a motor neuron-specific manner to 
transcriptional upregulation of neuronal NOS (Raoul et al., 2002).  Interestingly, MMP-9 itself 
has been shown to regulate the release of FasL (Xu et al., 2011).  Further, NO can activate 
MMP-9 through both direct and indirect mechanisms including S-nitrosylation (Gu et al., 2002), 
creating a potential vicious cycle.  Increased levels of NO can lead through multiple routes to 
enhanced phosphorylation of EIF2α, for example by reductions in levels of calreticulin (Bernard-
Marissal et al., 2012). Therefore, a role for MMP-9 upstream of ER stress is consistent with our 
current knowledge of its mode of action. 
 This model suggests that concurrent with ER stress activation, high levels of NO will also 
convert proMMP9 to the active form which, when deregulated, has been shown to have other 
deleterious effects in the CNS (Yong, 2005).  One of many possible scenarios of how the 
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enzymatic activity of MMP-9 could contribute to disease, is that APP is a known substrate of 
MMP-9 (Backstrom et al., 1996).  N-terminal fragments of APP can activate the death receptor 
DR6, which has been shown to be involved in axonal retraction at the neuromuscular junction 
(Nikolaev et al., 2009).  Moreover, inactivation of the APP gene in SOD1
G93A
 mice delays 
muscle denervation without improving motor neuron survival or lifespan (Bryson et al., 2012).  
Since the effects of MMP-9 deletion appear to be stronger than those of either APP inactivation 
or inhibition of ER stress (Saxena et al., 2009), it is likely that MMP-9 acts upstream of a series 
of parallel pathways, each of which contributes to a specific element of the ALS phenotype.  The 
inhibitor data also support a model involving multiple pathways—in that we found that 
enzymatic activity is not involved in early pathology (by P50), but inhibiting it has protective 
effects later (P75) (Figure 4.10C).  
 These experiments with the pharmacological inhibitors are exciting, but must be 
interpreted with caution as the SB-3CT study has a number of potential drawbacks.   First, SB-
3CT was chosen because it has been documented to cross the blood-brain barrier following 
systemic injection (Gooyit et al., 2012) and has been used successfully in several studies of 
MMP pathology in the central nervous system (Bell et al., 2012; Gu et al., 2005b; Guo et al., 
2010).  However, SB-3CT, unlike MMP-9 Inhibitor I, acts on both MMP-9 and MMP-2 by 
directly binding to the zinc in the gelatinase catalytic site (Brown et al., 2000).  Given that MMP-
2 is not expressed in adult motor neurons (Figure 2.3), we consider potential effects on motor 
function more likely to be the result of the MMP-9 inhibition.  Still, the side effects that we saw 
in 3 of the 5 SOD1
G93A
 animals in Group 2 (Figure 4.10A) are consistent with pan-gelatinase 
inhibition in terms of problems with wound healing (Gill and Parks, 2008) and gastrointestinal 
problems (Medina and Radomski, 2006; Mott and Werb, 2004).  Interestingly, side effects like 
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these have also been reported in human patients treated with MMP2/9 inhibitors, including 
diarrhea and loss of appetite (Hoekstra et al., 2001; Siller and Broadie, 2012).   
Another drawback is that we have not yet been able to determine the actual amount of 
inhibition that had occurred following drug treatment, because our attempts to quantify the 
amount of MMP-9 activity in specific tissues have failed so far.  The standard way to measure 
net MMP-9 activity is using gel zymography or high resolution in situ zymography.  In gel 
zymography, electrophoretic methods are used for measuring proteolytic activity. The method is 
based on a sodium dodecyl sulfate gel impregnated with a protein substrate which is degraded by 
proteases.  Later staining reveals sites of proteolysis as clear or white bands on a dark 
background, and thus visualization is based on protease activity (Leber and Balkwill, 1997).  
Because MMPs are produced and secreted as zymogens that require proteolytic cleavage to be 
activated, separation by size can differentiate between active and pro-MMP-9 (as well as MMP-
2).  In media obtained from cell culture, it is relatively easy to detect MMPs and indeed we were 
able to detect high amounts of MMP-9 activity using conditioned media from human 
macrophage cultures (not shown).  However, the extraction and analysis of MMPs from tissue 
homogenates has proven to be much more difficult, despite the strong expression data that 
indicate presence of the protein in a given cell or region.  There could be a few reasons that we 
have had such difficulty.  First, the amount of MMPs in tissues is about 50 times lower than 
those found in conditioned medium (Woessner, 1995).  Secondly, MMPs are difficult to extract 
from tissues, and it is never certain whether all MMPs are extracted.  Moreover, MMP-9 is often 
tightly bound to the ECM (Snoek-van Beurden and Von den Hoff, 2005; Woessner, 1995).  We 
have tried various ways to circumvent some of these problems, including using Sepharose beads 
to concentrate MMP-9 in homogenates, but so far activity detection has not been robust even in 
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positive controls like spleen or placental samples.  Further, while this technique would be useful 
for measuring endogenous MMP activity (good for testing the hypothesis that MMP-9 becomes 
pathologically active after increases in NO and ER stress), it would not detect activity reduction 
by the pharmacological inhibitors which may become detached from the zinc during the tissue 
homogenization or SDS treatment.  This has been reported to even be true for irreversible 
inhibitors (Hadler-Olsen et al., 2010).   
Another disadvantage of tissue extraction is the preclusion of the localization of MMPs , 
an important aspect for a protein that we have shown to label only a susceptible subpopulation 
(Vandooren et al., 2013a).  Specific MMPs or TIMPs localized in a small part of the tissue may 
not be detected because of their dilution in the entire tissue extract (Yan and Blomme, 2003).  A 
better technique for the localization of enzymatic activity is fluorescent in situ zymography. In 
this approach, a very tightly packed, dye-quenched (DQ-) fluorecein-gelatin becomes fluorescent 
only after its quenching is relieved by the action of the gelatinase.  Pilot attempts to use in situ 
zymography to localize MMP-9 activity in spinal sections in our laboratory have yielded results 
with very poor resolution and unreliable fluorescence even in a negative control or on slides pre-
treated with very high concentrations of inhibitors (Figure 4.11).  Several other groups have 
reported difficulty with this technique (Christopher Overall, UBC, personal communication) and 
many papers that use it including Kiaei et al (2007), show cropped images and do not include 
important controls.  Finally, we have also tried antibodies that were designed to recognize either 
pro or active forms of the enzyme but we discontinued their use after we found they both gave 
signals in Mmp9
-/-
 tissue.  Therefore, experiments to quantify activity levels have all proven 
unsuccessful.  Alternative strategies for future work on the role of the enzymatic activity of 
MMP-9 will be discussed further in Chapter 6.   
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 Therefore, though questions remain about the exact molecular mechanism by which 
MMP-9 exerts its pathologic effects, we have gained some valuable insights in this chapter.  Our 
data have shown that the cell-autonomous role in motor neurons is at least partially mediated 
through its enzymatic activity in the spinal cord and that MMP-9 plays an early role, upstream 
even of the phosphorylation of EIF2α.  Further, we believe that the strategies to explore the 
relationship of MMP-9 and ALS that we have described in this and previous chapters (including 
AAV knockdown and overexpression and systematic analyses of muscle denervation) will be of 
great use in studying other candidate therapeutic targets.  In fact, in Chapter 5 we will present 






Figure 4.1 MMP-9 is required for the full activation of ER stress during the degenerative 
process in SOD1
G93A
 motor neurons 
 
  A–F. The normal abrupt appearance of P-EIF2α at P40 in SOD1G93A motor neurons (Saxena et 
al., 2009) is severely damped in the absence of MMP-9.  Scale bar, 20 μm.  
 




 mice (red) but occurs in 
>4-fold fewer motor neurons than in normal mSOD1 mice (black). ***p<0.01 compared to p-







Figure 4.2 Mmp9 deletion delays, but does not indefinitely prevent, the phosphorylation of 
EIF2α 
A-B. Immunostaining for MMP-9 (green) and ER stress marker phospho-EIF2α (p-EIF2α, red) 
in P75 spinal cord of SOD1
G93A




mice (B).  Though p-EIF2α 
immunopositivity is widespread by P75 in the SOD1
G93A
 spinal cord, it is restricted to motor 
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IM= intramuscular injection into the TA (2 µL virus injected into the TA @ P3); 
ICV=intracerebroventricular administration (unilateral injection of 4 µL virus + 1 µL dye @ P1), 
IV= intravascular administration into the facial vein (100μL injected @P1) 
scAAV= self-complementary adeno-associated virus 




Table 4.1 Comparison of AAV Vectors for motor neuron gene delivery 
 
Summary of the transduction profile in the spinal cord after administration with several AAV 
serotypes generated in different labs and administered by different routes.  AAV6:cmv-EGFP 
generated by the Aebischer lab at EPFL resulted in the most specific motor neuron transduction 
and  was selected for future motor neuron targeting studies.   







Figure 4.3 Different AAV serotypes have very different transduction profiles following a 
single intracerebroventricular injection at P1. 
 
A-B. The self-complementary viruses generated by Guangping Gao (UMass) transduce some 
motor neurons, as well as other cell types. Representative images of lumbar level ventral horns 
from animals treated with scAAV6.CB6.eGFP (A) and scAAVrh8.CB6.eGFP (B) with motor 
neurons labeled with ChaT (red) and tranduced cells stained with anti-GFP (green). 
 
C-F.  AAV6 from the Aebischer group (EPFL) selectively infects motor neurons and not other 
cell types as shown here by representative immunostained cryosections of adult lumbar cord.   
GFP staining overlaps with VAChT-labeled motor neurons (D), but not GFAP-labeled astrocytes 






Figure 4.4 AAV6 delivered i.c.v does not efficiently transduce brainstem motor nuclei  
 
A-C. Representative immunostained cryosections of adult oculomotor (A), trigeminal (B), and 
facial (C) nuclei show that very few motor neurons (ChAT, red) were transduced following an 






Figure 4.5 Gene silencing of MMP-9 in motor neurons delays muscle denervation.  
 
A. Schematic of viral construct and procedures. (Top) AAV6 expressing the MMP-9 silencer 
sequence TRC31231 under the H1 promoter together with GFP under the CMV promoter 
(AAV6:shMmp9). (Middle) i.c.v injections (n=3 for each genotype) were performed at P1. 
(Bottom) Injections into TA muscle (mismatch control on contralateral side) were performed at 
P4 (n=2/3 animals per genotype).  
 
B- E. Reduction of MMP-9 at the single-cell level in P50 WT mice following AAV6:shMmp9 
administration by each route. Transduced α-MNs, visualized by colocalization of GFP 
fluorescence (green) and NeuN immunostaining (blue), stained for MMP-9 (red). Asterisks: 
GFP
+ α-MNs negative for MMP-9; arrowheads: less frequent GFP+ α-MNs that retain MMP-9 
immunoreactivity. Scale bars, 20 μm. 
 
F. AAV6:shMMP9 (i.c.v) leads to a 19% reduction in the total number of MMP9
+
 motor neurons 
(*p=0.03), and a 47% reduction in the numbers of MMP-9
hi
 (p=0.0003).   
 
G-H. MMP-9 silencing delays muscle denervation in TA. Images from  contralateral TA muscles 
of the same SOD1
G93A
 animal show normal levels muscle denervation on the side injected with 
AAV6:mismatch (H), but significant preservation following injection with AAV6:shMMP9 (G) .   
 
I. Comparable effects of AAV6 vectors administered by either central or peripheral routes 
implicate motor neuron MMP-9 as the trigger of muscle denervation in mSOD1 mice. Degree of 
TA innervation at P50 in SOD1
G93A 
mice following genetic reduction in MMP-9 levels (gray 
bars, data from Figure 5G) or viral silencing performed i.c.v. (purple) or i.m. (red).  Knockdown 
by either route confers protection similar to that afforded by heterozygote deletion of Mmp9 
(dotted line).  The contralateral mismatch control is shown in black. Values are means ± s.e.m 








Figure 4.6 MMP-9 induces degeneration in fast, but not slow, motor neurons of ALS mice 
 
A. Schematic of viral construct and procedures. (Top) AAV6 expressing full-length mouse 
MMP-9 under CMV promoter. (Bottom) Injections into TA or Sol muscles or intraorbital 
injections (control AAV6-GFP  injection contralateral side) were performed at P4 (n=3-4 
animals per genotype). 
 
B. Comparison of AAV6-MMP9-injected muscles (red bars) with contralateral control muscles 
(black bars) reveals that introduction of MMP-9 is not sufficient to accelerate denervation in 
resistant motor pools - Sol or SR - of SOD1
G93A
 mice.  In contrast, further increasing levels of 
MMP-9 in a susceptible pool (TA) does accelerate denervation. 
 
C-E. Immunostaining for MMP-9 of the oculomotor nuclei of a P150 SOD1
G93A
 mouse whose 
extraocular muscles had been infected at P4 with AAV6-MMP9 confirms successful 
transduction and stable, high levels of MMP-9 (red) in infected motor neurons (ChAT
+
, green) 
(C). High levels of MMP-9 (white) in motor neurons are observed in P100 (E) and P50 (D) 
SOD1
G93A
 spinal cord sections following injection of AAV6-MMP9 into the Sol or TA muscles 
at P4.  
 






Figure 4.7 MMP-9 is sufficient to restore vulnerability to TA motor neurons rendered 
resistant by Mmp9 deletion 
 





 mouse that was injected at P4 with AAV6-MMP9 into its left TA muscle. 
 






in which MMP-9 was 
virally expressed in the left TA motor pool, but the  contralateral side remained without MMP-9.  
The right TA (C) is still almost completely preserved, whereas significant denervation has 
occurred on the left side (B).  
D.  Mmp9 significantly restores vulnerability to the TA muscle (red bar), compared to the control 
contralateral side (black bar). **p<0.01 
 
E. The number of motor neurons that were transduced by a single intramuscular injection of 








Figure 4.8 Virally introducing MMP-9 precipitates a decrease in calreticulin levels in TA 
motor neurons rendered resistant by Mmp9 deletion 
 





 mouse that had been injected into one TA at P4 with AAV6.MMP9 stained 
with CRT (green) and MMP-9 (red). 
B-C. There is a significant decrease in CRT immunopositivity in all neurons of the injected side 
versus the control side (B).  Further, when the injected side is divided into MMP-9 positive and 
MMP-9 negative categories, it is clear that the lowest CRT levels are in the MMP-9 positive 
cells themselves (mean ± sem, n=3 animals)   **p<0.01 







Figure 4.9 Central MMP-9 inhibition confers significant protection 
 
A. Experimental timeline.  Animals were treated with MMP-9 Inhibitor I (2 µg, i.c.v) daily from 
P55 to P75. 
 
B.  Picture of a mouse receiving i.c.v drug administration into a chronically implanted cannula. 
 
C.  MMP-9 Inhibitor I protected the TA muscle from denervation in SOD1
G93A
 mice at P75 
(purple bar), compared with a vehicle-treated group (red bar, n=5-6 per treatment).  The inhibitor 
did not have an effect on muscle innervation in WT controls (grey bar), nor was there a 
difference between SOD1
G93A
 mice treated with vehicle and the animals that received the SHAM 
surgery but no drug (black bar). 
 
D-E.  The normal high levels of p-EIF2α (white) at P75 in SOD1G93A motor neurons are 







Figure 4.10 The enzymatic activity of MMP-9 inhibits reinnervation, but is not involved in 
early pathology that results in the initial FF axonal die-back 
 
A. Experimental timeline.  All mice were SOD1
G93A.  Animals in “Group 1” were treated with 
SB-3CT (25 mg/kg, i.p.) from P35 to P50, daily except for a 1 day holiday after every 5 days of 
injections.  Animals in “Group 2” were treated with SB-3CT (25 mg/kg, i.p.) from P55 to P75 
every day. 
 
B. Results of inhibitor treatment on Group 1.  There is no difference in muscle innervation 
between the groups that received 2 weeks of vehicle treatment (black bar) versus 2 weeks of 
treatment with SB-3CT (red bar). 
 
C. Results of inhibitor treatment on Group 2. When given daily from P55-P75, surviving animals 
showed greater amounts of innervation at P75 (blue point) than vehicle-treated controls (yellow 
point) or than other control SOD1
G93A 
mice at P60.  This suggests that there was a greater 







Figure 4.11 In situ zymography (ISZ) is an unreliable indicator of MMP-9 activity 
 
A. Table showing the rankings for reliability of signal obtained using various tissue preparation 
methods.  To evaluate these protocols, 2 positive control tissues were tested from mouse 
(placenta and spleen) and 1 negative control (midbrain from an Mmp9
-/-
 mouse).  No tissue 
preparation was ranked 4 (best), because all samples had at least some fluorescence in the 
negative control.  The method that was chosen for further investigation is marked with an *. 
 
B-C. Representative sections of P60 spinal cord from a WT (B) or G93A (C) mouse prepared for 
ISZ.    ISZ is designed to confirm net functional activity of MMP-9 and is predicted to be in only 
a subset of cells that are positive for MMP-9 by IHC, which cannot discriminate between active 
and inactive forms of an enzyme (Vandooren et al., 2013a).  However, both of these sections had 
signal from ISZ beyond what is detected by IHC. 
 
D-I. Sections of TA from either a WT or G93A mouse prepared for ISZ.  All sections appeared 
to give a signal along the length of the muscle fibers, though there was a large amount of section 
to section variability within a given sample.  Pre-treating the muscle sections on the slide with 
MMP-9 Inhibitor I (E, H), or SB-3CT (F,I), did not quench fluorescence.   The baseline level of 
fluorescence in all samples and lack of inhibition suggested that future use of this assay may be 
limited. 







Chapter 5: Preliminary experiments with other candidate targets 
 
Introduction 
Despite decades of research, there is still currently no cure for the devastating effects of 
ALS.  The standard treatment approach for patients is mostly restricted to supportive care, 
including respiratory and nutritional management.  In fact, the only disease-modifying drug 
approved for ALS by the US Food and Drug Administration (FDA) is riluzole, a drug with 
multiple potential modes of action, including inhibition of Na
+
 current and glutamatergic 
transmission (Bellingham, 2011), which provides only modest benefit to ALS patients (Andrews, 
2009; Bensimon et al., 1994).  Further, though several small molecule chemicals aimed at 
reducing excitotoxicity, oxidative stress, or inhibiting various apoptotic effectors had were 
considered promising in preclinical studies (Turner and Talbot, 2008), most have been too toxic 
or have failed to show significant benefit to patients in clinical trials (Andrews, 2009).  
Therefore, more candidate therapeutic targets are desperately needed.  Our results with MMP-9 
presented in Chapters 2-4 suggest that it is an extremely promising therapeutic target.  However, 
mutant SOD1 mice lacking MMP-9 do eventually exhibit motor neuron degeneration and 
succumb to the disease, indicating that other mechanisms also contribute to degeneration.  
Therefore, an ideal treatment strategy may be to intervene in multiple pathways to modify the 
disease.   
In order to identify additional targets, the candidate ALS resistance and susceptibility 
genes from the microarray were again examined.  Of the 18 genes that were co-regulated 
between the resistant and vulnerable populations, we selected one putative ALS resistance gene, 
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semaphorin 3e (Sema3e), and one additional ALS susceptibility gene, prolyl hydroxylase 3 
(Phd3) for further study. 
First, Sema3e encodes a class 3 semaphorin, which are secreted signaling molecules 
implicated in axonal guidance.  Previous reports have shown that, depending on its interactions 
with receptors, Sema3e can function as either a chemoattractant or chemorepellent during 
formation of specific neuronal circuits.  Specifically, Sema3e induces repellent responses 
through direct interactions with the PlexinD1 receptor (Plxnd1) (Chauvet et al., 2007; Gu et al., 
2005a; Oh and Gu, 2013) or attractant responses through interactions with a PlexinD1-
Neuropilin-1(Nrp1) complex (Chauvet et al., 2007), leading the authors to propose that 
neuropilins have a gating function in semaphorin-plexin signaling.  Further, though both Sema3e 
and its receptors are abundantly expressed in various brain regions (Watakabe et al., 2006), 
embryonic Sema3e is restricted to several cervical and lumbar motor pools (Cohen et al., 2005; 
Livet et al., 2002).  Moreover, in mice mutant for Pea3, Sema3e expression is lost and the 
pattern of monosynaptic sensory-motor connections is altered, further suggesting that it may be 
involved in the formation of pool-specific circuitry (Livet et al., 2002; Vrieseling and Arber, 
2006).  This has indeed been shown in the case of the Sema3e+ cutaneus maximus (CM) motor 
pool, which is characterized by the lack of monosynaptic connections with Ia proprioceptive 
afferents.  Using homozygous null Sema3e
nlz/nlz
 mice and conditional PlexinD1
flox
 mice in 
which PlexinD1 function in DRG neurons was eliminated by intercrossing with Wnt1
Cre
 mice, 
Pecho-Vrieseling et al. (2009)  found that specific expression of Sema3e in the CM motor pool is 
required to prevent the formation of monosynaptic contacts between these motor neurons and 
Plexnid1+ Ia proprioceptive afferents.  Therefore, this study confirmed a functional role of pool-
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specific Sema3e expression.  However, it still remains to be determined whether Sema3e has 
similar functions in other motor pools, especially in the oculomotor and Onuf’s pools. 
Previous work in the Henderson Lab showed that at P7 by ISH, Sema3e expression was 
undetectable in motor neurons of disease-susceptible trigeminal and L5 motor neurons.  In 
contrast, high levels of Sema3e were present in the majority of motor neurons of the oculomotor 
nucleus.  Likewise, DL nucleus motor neurons expressed high levels of this transcript.  This 
confirmed the microarray results, which found that Sema3e was expressed at ~58–fold higher 
levels in III and ~69-fold in DL, as compared to L5.  These expression patterns suggest that 
Sema3e expression could contribute to neuroprotection.  Therefore, we hypothesized that 
removing this candidate resistance gene from SOD1
G93A
 mice should exacerbate the disease and 
might shorten lifespan or induce muscle denervation in normally resistant pools. 
  Compared to Sema3e, Phd3 had the inverse expression pattern in the microarray and was 
highly expressed in subsets of lumbar MNs, but strikingly absent from oculomotor and Onuf’s 
MNs.  Phd3 is also called Egln3 and SM-20 (in rat), and belongs to a family of three vertebrate 
genes that are homologous to the C. elegans gene, egl-9, which is a gene required for normal egg 
laying behavior and resistance to bacterial pathogens (Darby et al., 1999).  This gene encodes a 
protein that is a prolyl hydroxylase that under normal oxygen tension marks hypoxia-inducible 
factor (HIF) for proteasomal degradation (Fong and Takeda, 2008).  Under hypoxia, PHD3 
cannot function and therefore allows HIF to accumulate and activate the transcription of many 
genes required for adaptation to a low-oxygen environment.  
Low PHD3 levels and high HIF levels have been reported in cancers and may be 
permissive for cell growth within the hypoxic environment of tumors (Yan et al., 2009).  In 
contrast, PHD3 is up-regulated by vascular tissue injury, ageing of cells (cardiac cells), and when 
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neuronal cells are deprived of neurotrophic support (Fong and Takeda, 2008).  Forced PHD3 
expression has also been shown to induce the formation of protein aggregates in an oxygen- and 
hydroxylase activity-dependent manner and these PHD3-induced aggregates have apoptosis-
inducing potential in HeLa cells (Rantanen et al., 2008).  PHD3 also causes caspase-dependent 
cell death when microinjected into sympathetic neurons (Lipscomb et al., 2001).  
Correspondingly, Phd3  knock-out mice  have modestly increased numbers of neurons in the 
superior cervical ganglion (Bishop et al., 2008) .  However, the mechanisms by which this 
occurs, and the degree to which the phenotype is cell-autonomous, were not determined. 
Moreover, the role of PHD3 in motor neuron death has never been studied. 
Though PHD3 has not been directly implicated in ALS, deregulation of oxygen sensing 
has been (Moreau et al., 2011; Quaegebeur and Carmeliet, 2010).  All three prolyl hydroxlases 
destabilize HIF-1α under normoxic conditions, and thus prevent the cellular responses to hypoxia 
including activation of transcription of multiple genes such as vascular endothelial growth factor 
(VEGF) and angiogenin (ANG) (Jaakkola and Rantanen, 2013; Pugh and Ratcliffe, 2003).  
VEGF has been shown to be neuroprotective in ALS: it delayed disease onset and progression in 
mSOD1 mice following either genetic overexpression of VEGF (Wang et al., 2007), 
intracerebroventricular administration of VEGF (Storkebaum et al., 2005), or intramuscular 
delivery of VEGF-expressing lentiviral vectors (Azzouz et al., 2004).  Given that expression of 
VEGF is blocked by PHD3 (via destabilization of HIF), PHD3 has been implicated in cell death 
in other cell types, and it is highly expressed in vulnerable motor neurons, but absent from 
resistant ones, we hypothesized that PHD3 may play a role in motor neuron degeneration in 








Therefore, I performed the following preliminary experiments to test the potential interest 
of these two additional candidate therapeutic targets for ALS. 
Results 
Deleting Sema3e does not affect the disease phenotype of SOD1
G93A
 mice 
Given that Sema3e was enriched in oculomotor and Onuf’s nuclei but absent from 
susceptible L5 motor neurons of WT P7 mice, it was considered a potential resistance gene.  As 
such, we hypothesized that deleting it in SOD1
G93A
 mice would exacerbate the ALS phenotype.  
To test this hypothesis, Artem Kaplan crossed homozygous null Sema3e
nlz/nlz 
mice on a mixed 
background to SOD1
G93A





 mice had an average lifespan of 140.5±11.6 days, (mean ± S.D., n=8), 




 mice (148.5 
± 27 days, n=3).  These values are lower than the average lifespans we found in the SOD1
G93A
 
mice on a pure C57BL/6 background, and this different genetic background might serve to 
conceal or diminish a potential phenotype.  However, Artem did note that the clinical course of 
these mice was not different from that observed in our C57BL/6 SOD1
G93A
 colony, with mice 
developing progressive loss of strength and paralysis with similar kinetics.  As an additional 
check for differences, I then examined the oculomotor nucleus and extrocular muscle innervation 





 mice and the average number of Chat
+
 MNs was the same as in the 




 controls (average MNs per section: 33.0 ± 1.9 vs. 
30.2 ± 3.8; p=0.74).  Moreover, the extraocular muscles innervated by this motor pool, superior 
rectus (SR), inferior rectus (IR), medial rectus (MR), and levator palpebrae (LP), were assessed 
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by immunostaining as in Figure 3.1 and were found to be almost completely resistant to 
denervation, even without Sema3e (Figure 5.1D).  Therefore, these preliminary data suggest that 
Sema3e is not the sole determinant of disease resistance in the oculomotor motor neurons. 
 
Selective PHD3 expression in motor neurons decreases with age 
Next, the putative susceptibility gene Phd3 was analyzed.  The microarray analysis revealed 
that Phd3 had the inverse expression pattern of Sema3e, with a high level of expression in 
susceptible L5 motor neurons, whereas it was absent from oculomotor and Onuf’s nuclei (fold 
changes: DL vs. L5: -13.2, and III vs. L5:-11.9).  This selective expression was confirmed by 
ISH at P9 in WT midbrain and P7 in spinal MN populations (Figure 5.2).  Specifically, Chat was 
used to locate the EOM-innervating oculomotor (Figure 5.2A) and trochlear (Figure 5.2C) 
nuclei.  Directly adjacent sections lacked Phd3signal (Figure 5.2B, D).  In contrast, vulnerable 
spinal motor neurons at L5 and L6 had robust Phd3 expression (Figure 5.2F, H).  Comparing 
Chat and Phd3 expression on adjacent L5 sections suggests that Phd3 is present in nearly all 
motor neurons and possibly other cells types as well (Figure 5.2E, F).  In L6 cryosections, the 
number of Phd3 cells and intensity of the signal within them were lower than Chat in both RDL 
and DL, but very high in DM (Figure 5.2G, I).  
Because PHD3 is one of three prolyl hydroxylases, the expression levels of the two other 
genes on the original microarray were compared (Table 5.1).  PHD1 (Egln2) and PHD2 (Egln1) 
are expressed at comparable levels to PHD3 (Egln3) at L5 where all three are present at high 
levels.  However, PHD1 and PHD2 do not show the same selective expression and are also 
expressed at very high levels in oculomotor and DL nuclei, where PHD3 is considered absent.  
These values remain to be confirmed by ISH. 
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We next looked at Phd3 expression in lumbar cryosections of adult WT mice and found that 
Phd3 was only weakly expressed at P30 and P40, compared to P7 (Figure 5.3A-C).  By P57, 
Phd3 was absent from the lumbar spinal cord and similar observations were made at P162 
(Figure 5.2 D-E).   Therefore, Phd3 expression down-regulates in adulthood in WT mice.  This 
finding is consistent with data generated by Timothy Spencer in the Henderson lab.  He analyzed 
the molecular characteristics of motor neurons retrogradely-labeled from the TA from WT mice 
at P4, P12, and P60 that were isolated by laser capture microdissection.  Using microarray 
analysis he found that Phd3 expression also decreases over time in an identified fast motor pool 
(Figure 5.3F).   
 
Genetically ablating Phd3 does not affect motor neuron death during development or 
disease 
 Despite the down-regulation of Phd3 in susceptible motor pools in the adult mouse, we 
wanted to investigate if genetically deleting Phd3 protected SOD1
G93A
 mice, as with MMP-9.  
First, because it was reported that Phd3 knock-out mice have modestly increased numbers of 
neurons in the superior cervical ganglion (Bishop et al., 2008), we established whether there was 
a role for PHD3 in developmental motor neuron death by counting MNs in L5 and L6 of WT and 
PHD3 KO mice.  MN survival was not significantly increased in the Phd3
-/-
 mice compared to 
WT controls at P30 in any of the 3 motor pools studied: L5 (21 ± 1.2 vs. 18.8 ± 0.8, p=0.18), 
RDL (10.7 ± 0.9 vs. 9.3 ± 0.8, p=0.32), and DL (7.87 ± 0.4 vs. 6.8 ± 0.3, p=0.14), though 
increasing the sample size here would strengthen this claim (Figure 5.4).   
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 Next we crossed SOD1
G93A
 mice in our C57BL/6 colony to the Phd3
-/-
 mice on a CD-1 
background and compared the average lifespan of the SOD1
G93A
 littermates with or without 
PHD3.  The SOD1
G93A
 mice now on a mixed background had a statistically shorter lifespan than 
the C57BL/6 SOD1
G93A
 mice in our colony, with a 7 day reduction in median survival time (log-
rank test= 4.2, p=0.04, black lines in Figure 3.8 and 5.5).  Next, we compared littermates on the 
mixed background with one or both alleles of Phd3 deleted.  There was no significant difference 
in the median lifespan of these mice (log-rank test= 5.3, p=0.07, Figure 5.5).  Because the 
breeding of these animals was slower than expected and the number of Phd3
−/−
 live births among 
the offspring of heterozygous matings was less than expected, in agreement with an earlier study 
(Bishop et al., 2008), only 19 animals total were included in this study.  It is possible that a larger 
sample size may have resulted, contrary to expectations, in a significant exacerbation of the 
disease phenotype, since there was a trend that SOD1
G93A
 mice with reduced or absent PHD3 








: 150, 138, and 135 
days, respectively).  Overall, we no longer consider PHD3 a promising therapeutic target for 
ALS, as Phd3 is not expressed in adult motor neurons and genetically deleting it does not protect 
mSOD1 mice.              
 
Discussion 
In this chapter, we present the results of experiments to explore a potential role for two 
additional candidate genes in the selective resistance or vulnerability of different motor pools in 
ALS.  In a first set of experiments, we genetically removed a candidate resistance gene, Sema3e, 
from mutant SOD1 mice, and in the second set we removed another candidate susceptibility 
gene, Phd3.  Neither genetic manipulation had a significant effect on the disease progression, as 
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measured by lifespan or changes in muscle innervation.  These results show the importance of 
careful functional validation of the candidate genes from the initial screen. 
Differential enrichment of Sema3e in the oculomotor and DL motor neurons raised the 
possibility that this gene could be involved in the resistance of these motor neurons to 





 mice showed that loss of Sema3e function did not appear to affect the resistance of the 
oculomotor nucleus, as it did not affect average motor neuron numbers or the amount of 
innervation of the extraocular muscle.  Further, Artem Kaplan’s earlier work did not show a 











group would further strengthen this 
analysis.  Therefore, these results argue against a prominent role of Sema3e in disease resistance. 
When the analysis was limited to genes whose expression levels showed >10-fold 
differences, 14 genes were more strongly expressed in vulnerable motor neurons than in the two 
resistant populations.  To determine which of these 14 genes to further investigate, we 
considered a number of selection criteria, as discussed in Chapter 1.  For example, when we 
chose Mmp9 as a target, we did so because its expression was motor neuron-specific, it was 
expressed selectively in motor neurons throughout adulthood, and its ranking was low in both 
individual pairwise comparisons (III vs. L5) and (DL vs. L5), but high using the three-way 
triangulation, suggesting that it had a greater chance of being linked to ALS rather than to 
specific properties of either pool.  Further there were numerous reagents available to study 
MMP-9 and there was a preexisting literature indicating a potential role in ALS.  Phd3 did not 
meet all of these criteria.  Though we did confirm by ISH that Phd3 was absent from EOM-
innervating pools and expressed at low levels in DL, it appeared that Phd3 was also expressed in 
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other cell types besides motor neurons at lumbar spinal cord levels at P7.  Further, Phd3 was not 
stably expressed into adulthood, as we found variable expression at P30 and P40, and none at 
P57 or P162.  It remains a possibility that this expression profile changes in a disease context 
given that PHD3 has a role in oxygen sensing and oxidative stress likely plays an important role 
in ALS pathogenesis (Barber and Shaw, 2010).  Therefore, it may still be useful to map the 
expression of Phd3 in SOD1
G93A 
motor pools at disease-relevant time-points.  Further, the value 
added by triangulation rank for Phd3 was only moderate (Table 1.1), with a “value added” score 
of 47 (compared to 91 for Mmp9).   
However, PHD3 had been implicated previously in cell death and knock-out mice were 
available to us, so we performed the cross with SOD1
G93A 
mice as a preliminary study to assess a 
potential neuroprotective role for prolyl hydroxylase inhibition.  Unfortunately, genetically 
removing one or both alleles of Phd3 did not prolong lifespan, and may have even diminished 
overall survival, though the number of mice included in this study was too low to detect a 
significant change.  It may be worthwhile to examine the effect of Phd3 removal at an earlier 
disease stage, as it is possible that early protective effects exist, but are masked at late disease 
stages because the Phd3
-/-
 have non-motor phenotypes that contribute to premature death.  We 
did not characterize age-matched Phd3
-/-
 without mutant SOD1, so this remains an open 
question.  It has been reported that Phd3 null mice display decreased apoptosis in SCG neurons, 
reduced adrenal medullary secretory capacity, abnormal adrenal medulla morphology, reduced 
circulating adrenaline and noradrenaline levels, and reduced systolic blood pressure (Bishop et 
al., 2008; Chen et al., 2012).  No reports suggest that these mice have reduced survival, but the 
phenotyping studies were performed on animals between 2 months and 6 months of age, so 
differences still may emerge at later time points.   
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Finally, follow-up studies are needed to examine the possibility that other PHD isoforms 
compensate for the Phd3 deletion.  PHD2 and PHD3 are suggested to have partially redundant 
roles in vivo with combined loss resulting in increased HIF1α levels as well as increased HIF 
target gene expression (Minamishima et al., 2009).  Further, loss of Phd2 results in a small 
upregulation in Phd3 levels (Takeda et al., 2006).  To my knowledge, whether the reverse is true 
has not yet been investigated.  However, the results of the microarray suggest that the other PHD 
isoforms are expressed at similar levels at L5, but 7-12 times higher in the resistant motor pools 
(Table 5.1).  Therefore, there is a strong possibility that if PHD3 is related to motor neuron 
degeneration at all, its role could be redundant.  This is a significant disadvantage for any 
candidate therapeutic target. 
Overall, therefore, determining the precise contribution of to Phd3 and Sema3e to disease 
vulnerability or resistance, if any, awaits multiple future experiments.  For example, virally 
introducing Sema3e to vulnerable pools, such as TA-innervating MNs, and looking for protective 
effects may be more clinically meaningful than genetically deleting Sema3e and investigating 
changes in EOM-innervation.  However, at this point neither target is considered a high priority 
for further work to develop viable therapeutic strategies for ALS.  However, there is evidence 
that extraocular muscle and pelvic sphincter-innervating motor pools are also preserved in spinal 
muscular atrophy (SMA) patients and mouse models (Lee et al., in preparation).   It is possible 
that these specific genes may play a more prominent role in that disease.  Ongoing experiments 
in collaboration with Justin Lee to perform crosses of Phd3 knockout mice with SMA-Δ7 mice 
will answer this question.   
New candidate genes are still needed for the treatment of ALS and these targets may still 
be revealed by further analysis of the original microarray followed by functional validation 
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studies in vivo.  In the future it may also be beneficial to add more motor pools with different 
degrees of resistance to the gene list already identified from the extreme ends of the resistance 
and vulnerability spectrum (that is, the most resistant EOM and sphincter-innervating MNs and 
the most vulnerable lumbar motor neurons).  This even finer grained analysis could potentially 
reduce the number of potential targets, allowing us to more easily identify genes that co-









Figure 5.1 Ablation of Sema3e in SOD1
G93A
 mice does not confer vulnerability onto the 
EOM motor pool 
 
A – B. Representative cryosections of the oculomotor nucleus stained with ChAT (green) at end-
stage from a SOD1
G93A





C. There is no difference between the average number of motor neurons in the oculomotor nuclei 








 mice (red bar) at end-stage, 
showing that ablation of Sema3e did not lead to increased cell death in this motor pool (n=3, 
mean ± SEM). 
D. There are also no differences between the degree of innervation of extraocular muscles 








 mice (red bars) at end-stage (n=3, mean ± SEM).  
None of the muscles showed significant loss of NMJ innervation in either group, relative to WT 







Figure 5.2 Prolyl hydroxylase 3 (Phd3) is expressed in subsets of spinal motor neurons but is 
absent from oculomotor and DL nuclei 
 
 
A-D. ISH on adjacent cryosections from P7 and P9 WT mice reveal that Phd3 is absent from the 
oculomotor (B) and trochlear (D) nuclei, detected by their Chat expression (A,C). 
E-H. Both Chat and Phd3 are expressed in wild type spinal cord at P7.  Phd3 appears to be 
present in both motor neurons and other cells in L5 (compare E and F).  In L6, the levels of Phd3 
























Table 5.1 Gene expression of other PHD genes 
 
Averaged gene expression values obtained from the microarray expressed and fold change over 
the averaged values for Egln3 (red text) in the 3 motor pools sampled. The other PHD isoforms, 
PHD1 (Egln2) and PHD2 (Egln1), are expressed at comparable levels to PHD3 (Egln3) at L5 
where all three are present at high levels.  However, PHD1 (Egln2) and PHD2 (Egln1) are 
expressed at high levels in oculomotor and DL nuclei, where PHD3 is considered absent. 
 
 
Fold Change  
[average absolute value], gene expression/Egln3 
Gene symbol     L5 III DL 
Egln1 [1186] 1.06 [1068] 10.26 [854] 7.06 
Egln2 [1553] 1.39 [1323] 12.72 [1558] 9.56 







Figure 5.3 Motor neuron expression of Phd3 decreases with age in WT mouse lumbar 
spinal cord 
 
A – E. Phd3 is expressed at high levels in the ventral horn of a cryosection of lumbar spinal cord 
from a P7 wild-type mouse (A), is expressed at much lower levels at P30 (B) and P40 (C), and is 
absent from lumbar spinal cord sections at P57 (D) and P162 (E). 
F. Raw expression levels of Phd3 in laser-captured TA MNs from WT mice at P4 (blue bar), P12 
(red bar), and P60 (green bar) assessed by microarray shows a decrease in Phd3 expression 







Figure 5.4 Genetic ablation of Phd3 does not result in reduced susceptibility of motor 
neurons to developmental cell death 
A-B. Immunostaining for ChAT (green) in P30 spinal cord of Phd3
-/-
 mice at lumbar level L5 
(A) and L6 (B). 
C. Deleting Phd3 has no effect on MN numbers at P30 in L5 or L6 as there are no significant 
differences between numbers of ChAT
+
 cells in Phd3
-/-
 (grey bars) and WT (black bars) mice 







Figure 5.5 Lifespan is not significantly altered following deletion of one or both alleles of 
Phd3 in SOD1
G93A
 mice.  









 mice (black) (n=5-7 animals per genotype; 






Chapter 6: General Discussion 
 
All neurodegenerative diseases are characterized by dysfunction and death of select 
neuronal populations.  The term “selective regional vulnerability” was coined almost 80 years 
ago by Alfred Meyer, who declared that “the most fascinating fundamental question is the 
problem of selective vulnerability in the brain” (1936).  He described selective lesions in 
epidemic encephalitis, Pick’s disease, and Wilson’s disease.  Since this seminal paper, it has 
been widely recognized that nearby populations of neurons with generally similar characteristics 
and functions can have greatly divergent responses to disease-induced cell damage in 
neurodegenerative diseases.  For example, in AD there is differential damage to pyramidal 
neurons in entorhinal and hippocampal subregions, as well as different cerebral cortical layers  
(Hyman et al., 1984).  Specifically, in the hippocampus, CA1 pyramidal neurons are readily 
injured or die under conditions that for the most part do not affect the adjoining CA3 pyramidal 
neurons or dentate granule cells (Michaelis, 2012).  In Parkinson’s disease, dopaminergic 
mesostriatal neurons are susceptible to degeneration while mesolimbic and mesocortical 
dopaminergic neurons are more resistant.  And in ALS certain motor neuron subsets show 
different degrees of resistance to degeneration, as has been observed in patients and confirmed in 
the most widely used mouse model (mutant SOD1 mice) by us and others.  Importantly, all three 
of these neurodegenerative diseases are strongly associated with ageing. 
In this thesis we have used a precise analysis of the molecular diversity within motor 
neuron subpopulations to answer broader questions about the timing and regional selectivity of 
neurodegenerative diseases.  Focusing on ALS, we show that the MMP-9 expression is localized 
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to the vulnerable population of motor neurons and that its expression begins at the age when the 
first signs of pathology are reported in ALS model mice.  Further, we demonstrate that MMP-9 is 
functionally contributing to the disease.  In this discussion, I will first briefly review these 
findings and put them into context.  I will then discuss advantages and also some drawbacks to 
the approach that we took, as well as highlight some unanswered questions and future directions.  
Finally, the clinical implications of this thesis will be examined. 
 
Localization of MMP-9 in disease vulnerable populations 
We found that MMP-9 expression is restricted to the most vulnerable class of neurons 
(motor neurons), the most vulnerable populations within this class (lumbar motor neurons, but 
not the resistant oculomotor or Onuf’s nuclei), and the most vulnerable neuronal subtype within 
a vulnerable region (fast α- motor neurons).  This pattern suggests that the tightly restricted 
expression of MMP-9 in fast motor neurons effectively gates the onset of disease that is caused 
by the widespread expression of mutant SOD1 in the SOD1
G93A
 mouse.  Thus, the specific 
localization of MMP-9 may explain the highly selective degeneration of FF motor neurons on a 
clear cellular basis.  Our identification of MMP-9 as a marker of susceptible populations will 
make it possible to someday systematically assess potential molecular differences that 
distinguish all vulnerable motor neurons by assessing gene expression profiles in MMP-9 
expressing and MMP-9-negative motor neurons, isolated by laser capture microdissection. 
Moreover, though other potential markers of fast and slow motor neurons have been 
reported previously (Chakkalakal et al., 2010; Enjin et al., 2010; Kanning et al., 2010), no known 
markers had been identified to distinguish FF and FR motor neurons in rodents.  Based on motor 
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neuron size and backfill data from muscles of known fiber type composition that I presented in 
Chapter 2, we hypothesize that the population that shows intermediate size and lower levels of 
MMP-9 could correspond to FR motor neurons, though this awaits further confirmation.   
It was serendipitous that our approach looking at genes that were absent from oculomotor 
and Onuf’s nuclei uncovered a marker for fast motor neurons and this unexpected result may 
help to inform the mechanism of disease vulnerability.  For example, aside from lacking MMP-9, 
type S motor units have other features in common with extraocular and pelvic motor units such 
as high activity levels.  Specifically, different muscles exhibit significant variations in the 
cumulative time they are active throughout an 8 hour period, with  postural muscles such as Sol 
active 14 % of the time compared to 2% for the TA (Monster et al., 1978).  When continuous 
recordings were made for extended periods from single motor units in the fast extensor digitorum 
longus and the Sol muscles of freely moving adult rats, it was revealed that Type S motor units 
indeed fired more frequently, with an active duty that is approximately 300 times greater than 
Type FF motor units (Hennig and Lømo, 1985; Hennig and Lømo, 1987).  Strikingly, extraocular 
motor units are active almost continuously during the day and during REM sleep (Robinson, 
1978) and pelvic sphincter motor units are active throughout the day and at night ceasing only 
during brief periods of urination and defecation (Enck and Vodusek, 2006).  This suggests that 
levels of daily activity of motor pools are correlated to their disease resistance. A possible 
explanation may be that highly active motor neurons may have evolved to deal with the high 
metabolic burden required to maintain sustained nerve conduction and synaptic transmission, as 
recently suggested in a report by the Caroni group in which the authors showed that increasing 
activity levels made motor units more ALS resistant (Saxena et al., 2013).  Whether MMP-9 
could modulate firing properties of fast motor neurons to make them more vulnerable will be an 
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important question to address in future studies.  Thus, MMP-9 is potentially very useful for 
studies aimed at understanding basic motor neuron biology, in addition to its relationship to 
disease.    
Pathological changes in mSOD1 mice do not begin until MMP-9 is expressed 
Further, in ALS mice, although mutant SOD1 is expressed embryonically, the first 
pathological changes in vivo are only detected in the first postnatal week (Kanning et al., 2010).  
Specifically, the earliest change reported is an increase in the electrical excitability of 
hypoglossal motor neurons between P4 and P10 (van Zundert et al., 2008).  The authors also 
noted behavioral changes (errors in forelimb placement and delays in righting) that can occur as 
early as P10.  Similarly, misfolded SOD1 is detected in a subpopulation of alpha-MNs in the 
lumbar spinal cord in mutant mice from P7 on, but is not yet there at P1 (Saxena et al., 2013).  
Strikingly, MMP-9 is not expressed by embryonic motor neurons and is first detected in the 
spinal cord only around P5.  Therefore, the timing and localization of the expression of MMP-9 
suggest that it may be gating the disease phenotype.   
 
Functional involvement of MMP-9 to disease vulnerability 
Using multiple approaches to control MMP-9 expression and activity, we found that 
MMP-9 plays a major role in motor neuron degeneration in ALS model mice.  This action is cell-
autonomous in motor neurons and is at least partially mediated through the enzymatic activity of 
MMP-9 in the spinal cord.  Moreover, MMP-9 influences the degenerative process early, as it is 
needed for full CRT down-regulation and the induction of ER stress to occur.  However, MMP-9 
is not alone sufficient to trigger neurodegeneration since it is expressed in many wildtype motor 
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neurons and does not induce axonal dieback when virally introduced into extraocular muscle- or 
Sol-innervating motor neurons.   These findings are significant in that we have shown that we 
can manipulate the molecular make-up of FF motor neurons postnatally so that they more closely 
resemble resistant motor neurons.  The strong protection thereby conferred provides hope that 
not only MMP-9 but also other genes with subtype-specific expression may provide a basis for 
rational therapies in ALS and other neurodegenerative diseases. 
 
Advantages of our approach 
The work presented in this thesis has several strengths.  First, though over the last few 
years several groups have taken a similar laser-capture dissection and microarray approach of 
resistant and vulnerable populations to study potential mechanisms of degeneration in both PD 
and ALS (Brockington et al., 2013; Chung et al., 2005; Duke et al., 2007; Greene et al., 2005; 
Hedlund et al., 2010; Lu et al., 2006), we have extended the analysis in a number of ways.  First, 
prior studies did not map out the expression of differentially expressed genes in the same detail 
as I have in this thesis.  For example, a study comparing global gene expression profiles in motor 
neurons of the oculomotor nucleus to the hypoglossal nucleus found hundreds of differentially 
expressed genes (Hedlund et al., 2010).   Of these, the authors selected insulin-like growth factor 
II (Igf2) and guanine deaminase (Gda) for further study and confirmed that they are present in 
oculomotor neurons, but absent from hypoglossal and cervical spinal motor neurons only by 
unquantified immunostaining of sections of rat tissue, from animals whose age and genotype 
were not specified in the text.  However, Hedlund et al. (2010) did present some functional data 
for these genes, showing that pretreatment with recombinant IGF-2 and GDA were protective in 
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vitro against glutamate-induced neurotoxicity.  Unfortunately, these experiments were not 
followed with any experiments to remove these genes and assess susceptibility or in vivo 
analysis.  In contrast, in this thesis I take several complementary approaches to demonstrate in 
vivo therapeutic relevance of a differentially expressed gene, Mmp9.       
Moreover, compared to earlier profiling studies, our work also produced a smaller list of 
targets because of the triangulation method generated by including an additional resistant pool 
(Onuf’s nucleus).  Examining genes that were co-regulated between oculomotor and Onuf’s 
nuclei ensured that we were not looking at genes that just controlled rostro-caudal identity or 
something else peculiar to individual motor demands, but rather co-segregated with resistance.  
In fact, the triangulation provided by studying these two resistant populations led us to a target 
that is unlikely to be deduced from simple comparison of oculomotor and vulnerable motor 
neurons.  Specifically, MMP-9 did not rank above #24 on any pairwise comparison, and so we 
would not have identified MMP-9 if we had looked only at genes that were top in an individual 
comparison.  For instance, MMP-9 was not specifically identified in a very recent study by 
Brockington et al. (2013), in which they used microarray analysis to compare the gene 
expression profiles of isolated motor neurons from the oculomotor nucleus and lumbar spinal 
cord from human post-mortem tissue from four neurologically normal control subjects.  They 
noted that extracellular matrix components, including seven different collagen subunits, were 
expressed at higher levels in lumbar motor neurons than oculomotor neurons, but they did not 
specifically pull out MMP-9 as being a gene of interest.  However, when we looked at MMP-9 
values from these samples as reported in their repository in the online GEO omnibus database, 
we found that MMP-9 was considered present in lumbar MNs and absent in oculomotor MNs, 
with levels that are ~2.5-fold lower in oculomotor nucleus than in lumbar motor neurons.  Still, 
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even with this triangulation approach, we found genes that did not modify the disease course in 
vivo (Sema3e and Phd3), demonstrating that, though the list of identified genes is an enriched 
source of candidates, the genes revealed by this approach may also not be involved in resistance 
or vulnerability to degeneration in ALS.   
Another advantage to our approach is that rather than just looking at a late stage event, 
we track the expression and effects of MMP-9 throughout life (by the use of Mmp9 null mice), 
from postnatal onward (by the use of AAV knock-down and expression), and from after start of 
denervation (using a pharmacological inhibitor).  These experiments have allowed us to identify 
MMP-9 as an early disease trigger.  Further, we have shown that motor neurons are the cellular 
site of action of MMP-9 at these early disease stages, rather than invading microglia.  Moreover, 
all of this work was done in vivo, which I think is a real strength given that MMP-9 is a secreted 
enzyme and so is likely affecting other nearby cell-types and pathologically altering a 
complicated extracellular environment.  It would be hard to recapitulate this in a cell culture 
system.  Though undoubtedly it would be more convenient to study MMP-9 in an in vitro system 
such as from mouse embryo derived- or stem-cell derived- MNs (discussed below), the in vivo 
TA MN targeting approach that I describe in Chapter 4 can serve the same purpose.  In fact, 
studying the function of human MMP-9 in a mouse otherwise devoid of the enzyme bypasses 
some of the limitations of in vitro systems, including the loss of functional connectivity and 
alterations in 3D cytoarchitecture.  Moreover, it is not yet possible to culture FF motor neurons 
specifically and therefore potentially relevant cofactors to MMP-9 could be absent from 
currently available model systems. 
Finally, this study shows the potential for using AAV as an experimental tool to assess 
gene function in intact animals.  This gene targeting approach can produce tissue-specific gene 
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ablation results similar to those obtained with conditional knock-out mice, in which Cre 
recombinase, expressed under the control of a brain region-selective promoter, excises DNA 
sequences located between loxP sites in a spatially controlled manner (Sauer, 1998; Tsien et al., 
1996).  However, the generation and breeding of conditional knock-out mice is a resource- and 
time-intensive task.  Further, the breeding strategies can increase the variation in the genetic 
background of the resultant offspring, potentially confounding behavioral and other analyses 
(Kaspar et al., 2002).  Also, depending on the promoter, excision may occur during development, 
causing disadvantageous side effects.  Therefore, our AAV approach in collaboration with the 
Aebischer lab offers several advantages for spatially controlled gene ablation.  First, AAV 
viruses can be generated, administered, and results can be analyzed over the course of several 
months versus years for the conditional knock-out approach.  Moreover, fewer animals are 
needed because no intermediate breeding generations are required.  Also, AAV-mediated gene 
knock-down occurs exclusively postnatally.  Finally, in some instances such as with 
intramuscular injections of AAV6, pools within a single animal can be compared, decreasing the 
variability and further strengthening the conclusions.  Therefore, we believe that increased 
preclinical use of AAV vectors will be valuable for the future evaluation of candidate therapeutic 
targets for ALS and in other disease model mice. 
 
Drawbacks to our approach 
Though there are many advantages to the experimental strategies that we have taken, 
there are a few drawbacks to our experiments that are also worth noting.  First, a limitation of the 
microarray approach is that we look at intrinsic differences between motor neurons, but do not 
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examine disease-responsive changes in gene expression that may at least partially underlie 
disease resistance.  Further, we are unable to detect post-transcriptional (e.g. splicing) or post-
translational (e.g. phosphorylation) differences by our profiling and comparisons.  Finally, by our 
triangulation approach, there could be real oculomotor-specific or Onuf’s-specific resistance 
genes excluded. 
Another disadvantage to the experimental strategy that we have taken in this thesis is that 
even though AAV knock-down or overexpression is less time intensive than comparable genetic 
approaches, there still involves waiting at least 6 weeks between viral administration and 
analysis.  Thus, biochemical experiments to better understand potential molecular pathways in 
which MMP-9 acts would be aided by having an in vitro model system.  Beyond their 
convenience, the primary advantage of in vitro studies is that they offer a controlled environment 
to test specific cellular and molecular hypotheses relatively quickly.  Unfortunately, MMP-9 is 
not expressed in ES-MNs, which is perhaps expected given that we show in Chapter 2 that 
MMP-9 is not expressed in motor neurons in vivo until about P5.  Further, though motor neurons 
generated from mouse embryonic fibroblasts (iMNs) do tend to express higher levels of MMP-9 
than stem cell-derived MNs, the expression level is still rather minimal (personal 
communication, Eggan Lab).  However, the same fibroblasts grown for 15 days in serum-free 
media have high levels of MMP-9 and the members of the Eggan lab have noticed that several 
pathways expressed in fibroblasts are maintained in iMNs made from them.  It is therefore 
possible that iMNs made from fibroblasts grown for 15 days in serum-free media would have 
high levels of MMP-9.  It is also possible, but as of yet untested, that iMNs from adult fibroblasts 




Unanswered questions and future directions 
Although I argue above that these studies have advanced the field significantly, they open 
up as many questions as they answer and there are many future research directions that warrant 
more study.  For example, what if anything about MMP-9 itself makes motor pools “fast”?  What 
other subtype specific elements in addition to mutant SOD1 and MMP-9 lead to degeneration?  
How can we better understand the relative roles of the enzymatic vs. non-enzymatic activities of 
MMP-9 in driving neurodegeneration?  What are the pathways downstream of MMP-9, and how 
do these interact with mutant SOD1 and, potentially, other disease triggers?  And, how can we 
apply what we learn about the mode of action of MMP-9 to designing therapeutic strategies for 
ALS patients?  These are only some of many questions that arise from this work, and, though I 
will discuss each in more detail below, this is not a complete list. 
 
Does MMP-9 make motor units fast? 
Skeletal muscle is highly plastic and is able to switch fiber type (and thus alter its total 
composition of fiber types), in order to meet particular physiological demands or in response to 
injury by damaging agents or disease (LeBrasseur et al., 2011).  Several factors can induce fiber 
type switching, with the best-studied factor being changes in nerve activity or loading 
(Schiaffino and Reggiani, 2011).  The role of the nerve in affecting the fast/slow properties was 
first demonstrated in the cat, where slow muscles became faster when reinnervated by a fast 
nerve, and fast muscles become slower when reinnervated by a slow nerve (Buller et al., 1960).  
Subsequent studies using different impulse patterns to reproduce the firing pattern of fast and 
slow motor neurons in innervated or denervated muscles showed that the effect of the nerve is 
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mediated by these specific impulse patterns (Pette and Vrbová, 1999; Schiaffino and Reggiani, 
2011; Vrbová and Ward, 1981). 
Our examination of the superficial versus deep layers of the TA as well as our 
comparison of the TA and the control slow Sol muscles suggest that fast SOD1
G93A
 motor 
neurons without MMP-9 adopt the axonal die-back properties of slow motor neurons.  Strikingly, 
this is not the first time MMP-9 has been reported to play a role in regulating fast/slow motor 
properties.  In fact, Mehan et al. (2011) showed that muscle fiber cross-sectional area (CSA) and 
fiber type distribution were significantly altered in female MMP-9 null mice compared to female 
WT mice.   Specifically, the absence of MMP-9 significantly decreased the CSA of different 
types of skeletal muscle fibers expressed in the TA, GC and Sol muscles, including slow fibers.  
Consistent with what we would predict, this effect was most dramatic in the fastest fibers 
(MyHC type IIb-expressing fibers) in TA and GC.   However, in contrast to our expectations, 
they also report that the percentage of MyHC IIb-expressing fibers was greater in both the TA 
and GC of MMP-9 null mice, though this was only measured by staining for different MyHC 
isoforms and not by examining functional changes.  The authors also note that these changes 
appear to occur in the absence of significant changes in type IV collagen staining and are not 
accompanied by compensatory changes in MMP-2 expression in the muscle.  They further show 
that neither MMP-9 inactivation nor the compensatory fiber type or size changes accompanying 
it resulted in a change in hindlimb twitch force output in an in vivo functional test (HEFT).  This 
result is consistent with ours, in that we detected no motor phenotype in the Mmp9
-/-
 group in 
either the accelerating rotarod task or in a swim test.  Thus, though this particular study is 
consistent with our data and predictions for Mmp9
-/-
 muscle with regard to their reports of 
unchanged contractile force in hindlimb muscles and reductions in fast fiber CSA, the direction 
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of fiber-type composition alteration from slow to fast does not align simply with our axonal die-
back data.  
 However, a subsequent study reported  that mice engineered to overexpress active MMP-
9 predominantly in skeletal muscle using the MCK promoter had an increased proportion of fast-
type glycolytic fibers (Dahiya et al., 2011).   When the authors focused on the Sol muscle, they 
found that type IIB and type IIx fibers, which were not detectable in the WT Sol muscle, 
emerged in the MMP-9-overexpressing Sol muscle.  Interestingly, there was no significant 
difference in fiber-type composition in the TA, likely because the TA muscle is already 
predominantly fast.  If we compare these results to the data we generated, they are in general 
conceptual agreement.  However, we did not see an increase in muscle denervation when MMP-
9 was virally introduced into the Sol motor pool (Figure 4.6).  The difference here could result 
from the fact that the MMP-9 we added was full-length and needed to be activated, in contrast to 
the enzymatically active form that Dahiya et al. expressed (2011).  Another possible explanation 
may be that the cellular source of MMP-9 that results in fiber type switching is not neuronal.  In 
fact,  a wide range of cell types found within skeletal muscle can express MMP-9 during post-
damage repair including endothelial cells (Kherif et al., 1998), satellite cells (Chen and Li, 2009; 
Fukushima et al., 2007; Guérin and Holland, 1995), and inflammatory cells (Choi and Dalakas, 
2000; Kherif et al., 1999).   Our knockout studies do not distinguish between the possible cellular 
sources of the MMP-9 that leads to the fast to slow switching.  In the future it will be interesting 
to examine the denervation of the skin facing versus bone facing TA compartments in 1) mutant 
SOD1 mice with MMP-9 silenced only in motor neurons at later time-points (for instance, with 




 mice with MMP-9 
overexpressed only in motor neurons.  We could also perform the converse experiments by 
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delivering cDNA or shRNA packaged in a different serotype (AAV7) into the TA, because that 
serotype will very efficiently transduce muscle, but is not retrogradely transported to MNs  (Gao 
et al., 2002).   
Therefore, these results and ours suggest that MMP-9 critically affects the functional 
properties of motor neurons and the muscle fibers they innervate.  How could MMP-9 alter the 
properties it affects and regulate this plasticity and adaptation?   From the neuronal end, given 
that muscle plasticity reflects motor neuron plasticity, MMP-9 may exert its effect by altering 
neuronal activity as it has been widely reported to do in the hippocampus (Gorkiewicz et al., 
2010; Michaluk et al., 2011; Vandooren et al., 2013b; Wilczynski et al., 2008).  It will be 
interesting to measure the excitability of TA motor neurons with or without MMP-9.  Based on 
recent results that showed that increased excitation of motor neurons can prevent  their 
degeneration (Saxena et al., 2013), we would predict that expressing MMP-9 somehow decreases 
motor neuron excitability.  However, this prediction runs counter to results in the hippocampus, 
wherein it was demonstrated that MMPs increase neuronal excitability and burst dynamics, as 
measured by increased overall spike counts, burst number, and burst duration (Niedringhaus et 
al., 2012). 
On the muscle side, MMP-9 from fast motor neurons may be released and activated as 
needed at the NMJ.  Once activated, MMP-9 mediated remodeling of the extracellular matrix 
(ECM) could allow muscle fibers to adapt their size or thickness, their internal structure and their 
extracellular surroundings (for example, capillary density) to better cope with their metabolic 
activities (Schiaffino and Reggiani, 2011).  For example, one (possibly simplistic) scenario is 
that MMP-9 in fast fibers degrades ECM proteins, thus causing a laxation of the restriction by 
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ECM on muscle fiber, allowing for increased fiber growth.  In this scenario, when MMP-9 is 
removed, unchecked ECM proteins could create a physical barrier that restricts fiber size. 
  Furthermore, degradation products of ECM components can be more than just debris; 
several fragments of structural proteins have biological activity after proteolytic processing, and 
MMP activity can therefore release growth factors stored in the ECM to induce these changes 
(Rullman et al., 2009).  Follow-up experiments to measure gelatinolytic activity in muscle and/or 
levels of various ECM components in fast fibers with or without MMP-9 in the motor neurons 
that innervate them are potentially interesting and feasible experiments.  Further, it would be 





muscles assess whether there are still distinct waves of denervation (albeit, 




 littermates), or if all of the denervation is compressed 
into a single wave, which would be consistent with a switch from FF to FR in the absence of 
MMP-9.  Therefore, studying the role of MMP-9 in shaping motor units’ fast properties is an 
exciting avenue for future research.    
 
Unidentified elements that are specific to fast motor neurons in the mSOD1/MMP-9 
pathway lead to degeneration 
 Another exciting open question arises from the observation that the activation of the 
pathway for axonal die-back requires neuronal subtype-specific elements in addition to MMP-9 
and SOD1.  Specifically, we showed in Chapter 4 that MMP-9 induces degeneration in fast, but 
not slow, motor neurons of ALS mice.  What are the additional molecular player(s) that are 
present in fast but not slow pools that help to mediate the effect of MMP-9?  The microarray  
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reported by Saxena et al. (2009) comparing fast (GC-L1 -innervating) and slow (Sol innervating) 
motor neurons may be a valuable resource to find other elements that are expressed in these 
vulnerable lumbar MNs that could be contributing to the pathology in these cells.   
Based on our data with the pharmacological inhibitors of MMP-9, we know that 
enzymatic activity is at least partially involved.  As such, we expect that we will find a factor (or 
factors) to be either upstream of MMP-9 and thus activate it from its proform, or substrates of 
MMP-9, whose cleavage has negative consequences.  An example of a potential substrate that 
could lead to toxicity is stromal cell−derived factor 1α (SDF-1), a chemokine overexpressed 
during HIV infection that has been reported to become highly neurotoxic after proteolytic 
processing by gelatinases in the basal ganglia of mice, leading to neurodegeneration (Zhang et 
al., 2003).  However, we also speculate that non-catalytic hemopexin domain-mediated processes 
could be involved, so we could also look for the selective expression of integrins that can be 
engaged to stimulate glutamatergic transmission.  Once a potential cofactor is identified, we 
hypothesize that adding it to the slow Sol or EOM-innervating motor pools in addition to MMP-
9 in a mutant SOD1 mouse should be sufficient to induce axonal dieback in these muscles.  
 
The role of the enzymatic activity of MMP-9 in motor neuron degeneration  
In Chapter 4 we presented a preliminary attempt to distinguish between the enzymatic 
and non-enzymatic activity of MMP-9.  We showed that mice treated with either a centrally-
delivered, specific inhibitor of MMP-9 (MMP-9 Inhibitor I) or a systemically-delivered inhibitor 
of both MMP-9 and MMP-2 (SB-3CT) exhibited a greater degree of TA muscle innervation as 
compared to controls at P75.  These experiments already suggest that the pathologic mechanism 
217 
 
of MMP-9 involves its enzymatic activity, at least in part.  This confirms the conclusions of 
Lorenzl et al. (2006), who used another inhibitor and reported a modest 13-day survival 
(discussed more below).  However, the protection that we observe is not complete, and this could 
result either from 1) a role for non-enzymatic mechanisms, or 2) from incomplete enzyme 
inhibition.  As discussed in Chapter 4, all experiments to quantify activity levels have proven 
unsuccessful thus far.  As such, we suggest an additional strategy to test the role of activity. 
  In Chapter 4, we also presented a robust in vivo gain-of-function assay, which can be 
used to explore the effects of MMP-9 in vulnerable ALS motor neurons (Figure 4.7).  Briefly, 
when we re-expressed MMP-9 by intramuscular injection of AAV6-Mmp9 cDNA into the 




 mice, the innervation was reduced to 78 ± 2%.  Thus, we 
propose using this system to determine 1) whether the induced degeneration is MMP-9 specific 
or whether other MMPs would have similar effects, and 2) whether enzymatic activity and/or the 
hemopexin domain of MMP-9 is required for axonal dieback or induction of ER stress and 
protein misfolding at early and late time-points in the disease.  In order to do this, we will need 
additional AAV6 vectors that express either other MMPs, such as MMP-2 or MMP-7, or 





 mice.  The following MMP-9 variants would be useful in 
determining the mode of action of MMP-9 : 1) full-length, catalytically active; 2) full-length, but 
with the catalytic Glu replaced by Ala, so lacking enzymatic activity; 3) truncated, with a normal 
active site but deleted hemopexin domain; and 4) active MMP-9, with a mutation of glycine 
residue 100 to leucine in the prodomain of MMP-9 that would weaken the interaction 
between the prodomain and the catalytic subunit, inducing the autolytic cleavage and 
removal of the prodomain.  The first 3 of these constructs were initially generated in the lab of 
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G. Opdenakker, Leuven (Van den Steen et al., 2006) and he generously provided plasmids to our 
collaborators in Patrick Aebsicher’s group in order to generate the viruses.   
  Unfortunately, there have been some unexpected setbacks with the virus production.  
Specifically, the subcloning of the Mmp9 sequences into the pAAV backbone was not 
successful.  In order to troubleshoot what went wrong, Bernard Schneider (Aebischer Lab) 
sequenced the original plasmids and found that the sequences had been fused in frame with a 
mellitin secretion signal, causing the restriction sites indicated to be useless for subcloning.  The 
next step taken was to attempt a PCR strategy to generate fragments compatible with their AAV 
backbone.  Again, this failed, invariably producing a 200bp sequence instead of the expected 
2.2kb amplicon and attempts to troubleshoot this have also not worked thus far.  Our next 
anticipated step is to get a commercial source to generate the fragments from sequences that can 
be sent to the Aebischer lab for viral production.  At that point, the Aebischer lab can generate 
the vectors (their turn-around time has been between 4-6 months) and then send them back to 
Columbia for in vivo testing in our colony.  
Though this approach is likely to be more definitive that others, another interesting 
direction is to further investigate a role of activated MMP-9 and a potential link with NO by 
determining if and when MMP-9 is S-nitrosylated.  There is growing evidence that 
overproduction of NO can be neurotoxic via aberrant S-nitrosylation of a variety of proteins, 
which contributes to the accumulation of misfolded proteins, mitochondrial dysfunction, synaptic 
damage, and neuronal cell death (Nakamura et al., 2013).  As discussed previously, MMP-9 is 
activated by S-nitrosylation when NO reacts with the cysteine residue to expose the catalytic 
Zn
2+
 in the active site to substrate (Gu et al., 2002).   This activation may occur concurrently 
with other S-nitrosylation events that have also been shown to be harmful to cells.  An example 
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of such an event is that cellular defense proteins such as protein disulfide isomerase (PDI) can be 
inhibited by S-nitrosylation.  Specifically, the formation of SNO-PDI inactivates the chaperone, 
halting its ability to correct protein misfolding  (Jeon et al., 2013; Nakamura et al., 2013; Uehara 
et al., 2006), which aggravates ER stress.  This is likely damaging, as pharmacological inhibition 
of PDI enzymatic activity has been shown to increase the presence of mSOD1 inclusions in 
mutant SOD1 mice (Chen et al., 2013a) and substantial levels of SNO-PDI are present in human 
postmortem brains from patients with sporadic ALS (Walker and Atkin, 2011).   
Thus, an increase in NO can set off parallel pathways that are potentially harmful: 
activating MMP-9 and inactivating proteins involved in the maintenance of cellular homeostasis.  
Importantly, there have been a number of  recent advancements in methodologies to quantify S-
nitrosylation events in normal or in diseased tissues (Chen et al., 2013b).  Therefore, it would be 
very interesting to characterize the timing of this post-translational modification of MMP-9 in 
mutant SOD1mice, compared to WT controls.   
These experiments will be very important for future analysis on the mechanism of MMP-
9 in vivo which remains perhaps the most pressing unanswered question from this work.  There 
are in fact numerous potential mechanisms that we can deduce from existing literature.  For 
example, MMP-9 has long been known to degrade laminin (Giannelli et al., 1997).   This 
interaction has been shown to directly lead to cell death in different cell types.  For instance, it 
was recently shown that injecting an MMP-9 inhibitor into the neonatal hippocampus increased 
laminin levels and promoted neuronal survival (Murase and McKay, 2012).  MMP-9 also has 
been shown to trigger the death of retinal ganglion cells, likely by degrading laminin in the inner 
membrane (Chintala et al., 2002; Guo et al., 2005).  Moreover, synaptic laminin is required to 
maintain adult neuromuscular junctions (Samuel et al., 2012).  Intriguingly, laminin-alpha4 
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remains at synaptic basal laminae of extraocular muscles from ALS patients and mSOD1 mice, 
but disappears from their limb muscle NMJs (Kjellgren et al., 2004; Liu et al., 2011).  Therefore, 
MMP-9 could be acting by directly degrading laminin at the neuromuscular junctions of fast 
fibers. 
Another substrate of MMP-9 that potentially could link it to ALS is profilin-1.  Profilin-1 
is a small protein that is essential for the polymerization of monomeric G-actin to filamentous-
actin (Witke, 2004), and thus axonal integrity.  Although profilin-1 is intracellularly localized, it 
has been shown to be an MMP substrate (Cauwe et al., 2009; Cauwe and Opdenakker, 2010).  
Mutations in the profilin-1gene have been shown to cause familial ALS and primary MNs that 
express mutant profilin have smaller growth cones (Wu et al., 2012).  Therefore, MMP-9 may 
contribute to ALS pathogenesis by degrading profiln-1 and destroying axonal integrity. 
Moreover, MMP-9 has also been reported to cleave amyloid precursor protein (APP) 
(Backstrom et al., 1996; Yin et al., 2006; Yong et al., 2001).  APP is a single pass type-I 
transmembrane protein that undergoes a series of proteolytic processing steps that create multiple 
bioactive species.  Minute differences in species length can translate into dramatic changes in 
systemic effect (De Strooper and Annaert, 2010; Lange and Overall, 2013).  For example, N-
terminal fragments of APP can activate the death receptor DR6, which has been shown to be 
involved in axonal retraction at the NMJ (Nikolaev et al., 2009).   Further, DR6 expression is 
upregulated in motor neurons of ALS post-mortem samples and SOD1
G93A
 mice and blocking 
via antibody promotes motor neuron survival in vitro and in vivo (Huang et al., 2013).  Finally, 
inactivation of the APP gene in SOD1
G93A
 mice delays muscle denervation (Bryson et al., 2012).  
Follow-up studies with an N-terminal specific antibody in SOD1
G93A
 mice with and without 
MMP-9 will be very interesting. 
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 A final substrate of MMP-9 that could be involved in ALS pathology is NG2.   NG2 is a 
proteoglycan that is strongly expressed by oligodendroglial precursors in the ALS spinal cord 
(Kang et al., 2010).   The degradation of NG2 by MMP-9 reduces proliferation of these 
progenitors and blocking MMP-9 post spinal cord injury allowed for NG2 precursors to mature 
into oligodendrocytes and enhanced recovery (Liu and Shubayev, 2011).  However, it has also 
been reported that MMP-9 facilitates remyelination by processing NG2 (Larsen et al., 2003), 
which was demonstrated to have an inhibitory effect on axonal elongation (Dou and Levine, 
1994).  Further, a very preliminary study we did in collaboration with the lab of Dwight Bergles 
(JHU) found that Mmp9
-/-
 mice have greater NG2 immunoreactivity in their spinal cords than 
WT age-mates.   However, Mmp9
-/-
 mice also have lower NG2 cell proliferation than WT age-
mates.  Finally, we found that NG2 cell proliferation increases with age in SOD1
G93A
 animals, 




 mice.  Therefore, the processing of NG2 by MMP-9 
may have an effect on ALS, but more work is needed to understand the relationship. 
Thus, there are many potential downstream targets of MMP-9 that could contribute to 
ALS pathology.  Once the role of activity of MMP-9 and the timing of these effects are 
elucidated, a more informed investigation of potentially ALS-relevant substrates can begin.  
Further, understanding the role of activity could have important implications for the design of 
therapeutic agents.    
 
Clinical implications of this work 
The most exciting aspect of this work is that it demonstrates that MMP-9 is a promising 
therapeutic target for the treatment of this devastating disease.  We have several reasons to make 
this claim.  First, genetically ablating MMP-9 has a large protective effect in mutant SOD1 mice.  
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The MMP-9 null mice lived 25% longer and had an approximately 80-day delay in the 
denervation of the susceptible TA muscle.  Importantly, even partial reduction in gene 
expression is enough to confer significant benefit and this is also the case when the reduction 
was driven postnatally using RNAi.  Moreover, so far MMP-9 is the earliest known intermediate 
in the disease pathway triggered by mutant SOD1.  Finally, we show that commercially available 
inhibitors of MMP-9 have protective effects in these mice at an intermediate disease stage.  This 
is particularly encouraging because the inhibitor treatment began after symptom onset. 
  However, all of this work was done in a mouse model of ALS with a mutation found in 
only about 2 % of all ALS cases.  An important future direction will be to determine whether 
MMP-9 is relevant to non-SOD1 forms of ALS, especially the sporadic cases of ALS which 
make up ~90% of all patients.  Other groups are working hard to develop additional rodent 
models of ALS using other identified mutations, including TDP-43 (Tsao et al., 2012), FUS 
(Huang et al., 2011), and C9orf72, and it will be exciting to target MMP-9 in these and look for 
protective effects similar to those we observed in the mutant SOD1 mice.  There are a few 
reasons we suspect that MMP-9 will be relevant to these non-SOD1 FALS cases as well as to 
SALS.  First, we initially identified MMP-9 in WT motor pools that are selectively resistant to 
ALS in both the mSOD1 mouse model (Figure 3.1) and sporadic ALS patients.  Further, a very 
recent paper which studied a Chinese population showed that the C(21562)T polymorphism in 
the MMP-9 gene, which leads to higher Mmp9 promoter activity, is significantly associated with 
an increased risk of sporadic ALS (He et al., 2013).  This link with human sporadic patients is 
very encouraging, especially because our staining of human samples did not show strong MMP-9 
expression in lumbar motor neurons (Figure 2.12).  We therefore consider the positive results in 
mSOD1 mice as highly promising for future studies in ALS patients. 
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There are a few different strategies that can be taken to assess the therapeutic effects of 
altering MMP-9 activity or levels in ALS patients, though determining which is optimal awaits 
future mechanistic insights.  First, in order to reduce MMP-9 activity, pharmacological inhibition 
is a classic strategy.  Our data with specific gelatinase inhibitors suggest this is a promising 
approach.  Further, a previous study by Lorenzl et al. in which Ro 26–2853, a large spectrum 
MMPs inhibitor from Roche that inhibits MMP-1, -2, -3, -7 and ‐9, was orally administered to 
mutant SOD1 mice before or after disease onset (starting at P30 or P90), showed that it could 
extend the survival of transgenic mice, but only when administered early (Lorenzl et al., 2006).  
However, minocycline, an antibiotic that also inhibits MMP-9, among many other actions 
including direct effects on apoptosis and inflammation (Kim and Suh, 2009), had very 
disappointing results in a large Phase III randomized clinical trial (Gordon et al., 2007).  In fact, 
the results suggested that minocycline harms ALS patients; of the 412 patients with ALS studied, 
those treated with minocycline declined more rapidly than those on placebo.  Further, 
gastrointestinal side effects were reported.  The authors speculate that the potential 
neuroprotective effects of the drug may depend on when in the course of the illness it is given 
and acknowledged that the majority of patients included in this study were diagnosed and treated 
a year or more after their symptoms began.  It is also possible that MMP-9 activity was not 
effectively reduced at the dosage given or that a beneficial effect was masked by harmful non-
MMP-9 related effects.  More specific inhibitors of MMP-9 including newer pharmacological 
inhibitors or blocking antibodies should be evaluated. 
Another interesting, activity-related clinical direction is using MMP-9 activity to control 
drug release.  All drug delivery systems have to meet several requirements to be successful 
including: high stability, high accumulation at disease target site, efficient drug release at the 
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right target site that matches drug pharmacodynamics, and tolerability.  The encapsulation 
method for a given compound greatly influences all of these aspects  (Andresen et al., 2010).  
Enzyme sensitive encapsulation systems where over-expressed disease-associated enzymes are 
utilized to trigger drug release have been an interesting and promising area of research.   Mallik, 
Srivastava and co-workers at the University of North Dakota have pioneered the use of 
liposomes containing MMP-9-degradable lipopeptides to unmask therapeutic compounds for 
controlled drug release (Banerjee et al., 2009; Dutta et al., 2011; Elegbede et al., 2008; Nahire et 
al., 2012; Sarkar et al., 2008; Sarkar et al., 2005).  These papers demonstrate the promise for the 
specific delivery of cytotoxic drugs to cancer cells, which produce high levels of MMP-9.  Given 
the selective expression of MMP-9 that we report in Chapter 2, we propose using a comparable 
system to selectively target a drug to vulnerable, fast motor neurons, but not others (Figure 6.1).  
In the illustrated example, tauroursodeoxycholic acid (TUDCA), which has been shown to be 
neuroprotective in animal and cell culture models of ALS (Thams et al., in preparation), is 
concentrated into the core of a nanoparticle which can be activated by proteolysis either outside 
of fast motor neurons or taken up into these cells by endocytosis and released by MMP-9 
intracellular proteolysis.  This drug delivery system could reduce off-target side effects.    
Further, if future studies point to non-enzymatic roles for MMP-9 in ALS pathogenesis, 
strategies to reduce MMP-9 transcription or translation may be clinically useful.  Examples of 
these include repressors of gene activation (Labrie and St-Pierre, 2013) and antisense 
oligonucleotide-based technologies.  Antisense oligonucleotides (ASOs) are single-stranded 
DNA oligonucleotides, usually 8-50 nucleotides in length, which target cellular mRNA 
transcripts via complementary base pairing (Dias and Stein, 2002).  The resultant DNA/RNA 
duplex gets degraded by RNAse H, and the single stranded ASO gets recycled to mediate 
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multiple rounds of selective RNA degradation.   Therefore, a single administration of ASOs can 
effectively block protein translation.  Further, a previous study showed that an ASO that blocks 
an SMN2 intronic splicing silencer element still promoted approximately 90% SMN2 exon 7 
inclusion 6 months after treatment (Hua et al., 2010).  Therefore, an ASO against MMP-9 may 
be as or more effective than AAV knock-down, but could be delivered to adults.    
Thus, understanding the mechanism of MMP-9 and using this knowledge to benefit patients 




Taken together, this thesis presents data which shed light upon novel aspects of motor 
neuron biology, define a potential therapeutic target for ALS and suggest potentially exciting 
new research directions.  My results provide proof of concept for the general usefulness of 
investigating the selectivity of neurodegeneration to learn more about underlying disease 










Figure 6.1. Understanding MMP-9’s mechanism of action could aid in the drug delivery 
design of other candidate therapeutics 
 
Schematic of a system to deliver drugs only to cells with active MMP-9.  When a hydrophilic 
polymer (such as PEG, blue) is attached to a hydrophobic drug like TUDCA (red), a micelle 
forms in aqueous conditions in order to minimize free energy of the system. The hydrophobic 
regions coalesce and the hydrophilic regions are exposed externally to the aqueous environment. 
Nanoparticles such as micelles are readily taken up by cells, and free MMP9 in the cells would 
cause degradation of the outer core and release of the free drug. This technique has been used to 




Chapter 7: Experimental Procedures 
 
Transgenic Mice 
For expression studies, ChAT-Cre [B6;129S6-Chattm1(cre)Lowl/J] and ROSA-TdTomato 
reporter [B6;129S6-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J] mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and crossed to generate offspring whose motor neurons 
selectively express TdTomato.  Chodl-LacZ mice were obtained from Lexicon Pharmaceuticals.  
For functional studies, male mice heterozygous for the mutant human SOD1
G93A
 transgene 
(B6.Cg-Tg(SOD1*G93A)1Gur/J Jackson Laboratory) were crossed with the following mice:   
females with an MMP9 gene disruption (B6.FVB(Cg)-Mmp9
tm1Tvu
/J, Jackson Laboratory) on a 
C57BL/6J background, homozygous null Sema3e
nlz/nlz 
mice (Pecho-Vrieseling et al., 2009) on a 
mixed background obtained from Dr. Yutaka Yoshida (Cincinnati Children's Hospital Medical 
Center), and Phd3
-/-
 mice on a CD-1 background obtained from Thong Ma (Burke Medical 
Research Institute), which had been generated originally in the lab of Guo-Hua Fong (University 














littermates. The clinical course for the mutant SOD1 mice was monitored 
weekly.  The disease invariably progressed from hindlimb tremor, and reduced splay to gait 
abnormalities, followed by complete paralysis. End-stage of disease was defined as the age at 
which mutant SOD1 mice could no longer right themselves for 30 seconds after being put on 





Mice were deeply anesthetized using 3.5 % avertin and transcardially perfused with 10 mL of ice 
cold phosphate-buffered saline (PBS) followed by 50 ml of 4% paraformaldehyde in PBS. 
Muscles were washed in PBS overnight, and spinal cords and brains were post-fixed in the 4% 
paraformaldehyde overnight and then all were processed in a sucrose gradient for cryoprotective 
embedding.  For visualization of the NMJ in various whole muscles, α-bungarotoxin conjugated 
to tetramethylrhodamine (TMR), Alexa fluor 488, or Alexa fluor 647 (Invitrogen, Carlsbad, CA, 
Carlsbad, CA) 1:500 was added with rabbit anti-VAChT 1:2000 (Sigma-Aldrich, St. Louis, MI) 
or rabbit anti-VAChT 1:32,000 (Henderson Lab via Covance, Denver, PA).  For analysis of 
motor groups in the brainstem and spinal cord, the following primary antibodies were used: goat 
anti-ChAT 1:100 (Millipore, Billerica, MA), rabbit anti-MMP-9 1:4000 (Abcam, Cambridge, 
MA), goat anti MMP-9 1:2000 (Sigma-Aldrich, St. Louis, MI), rabbit anti-GFP 1:1000 
(Invitrogen, Carlsbad, CA), mouse anti-NeuN 1:600 (Chemicon, Billerica, MA), rabbit anti-
phosphorylated EIF2α (Ser51) 1:150 (Cell Signaling Technology, Inc. Beverly, MA), rabbit anti-
calreticulin 1:1000 (Thermo Fisher Scientific Inc, Rockford, IL), and chicken anti- β-
galactosidase 1:1000 (Abcam, Cambridge, MA).  Secondary antibodies conjugated to Alexa 
fluor 488, 555, and 594, and 647 were generated in Donkey (Invitrogen, Carlsbad, CA). Images 
were acquired on a Nikon Eclipse TE-2000-E fluorescent microscope.  The protocol was 
modified slightly for p- EIF2α staining; slides were blocked in 3% BSA, 0.3% triton X and the 
primary antibody remained on the slides for at least 48 hours. Staining was always performed 
alongside a negative control so that when imaged the exposure could be adjusted to the control 





In situ hybridization  
Tissue preparation was performed as described above and in-situ hybridization protocol was 





 mice , all on pure C57BL/6J background.   Probes were generated from cDNA 
vectors purchased from Open Biosystems Inc. (Huntsville, AL). These included the following 
OpenBiosystem (clone ID numbers are in parentheses): Mmp9 (6309245), Egln3 (6528802), 
Mmp2 (6813184), Timp2 (6821553), Timp3 (4239015), and Chodl (40126392).  Chat and Sv2a 
were previously generated in the Henderson laboratory by Kevin Kanning.  Vectors contained 
either full-length cDNA sequences or the sequences corresponding to the 5’ UTR regions of 
genes of interest flanked by SP6, T3, or T7 promoters. For each of these, clones were first 
linearized at the 5’ end of the cDNA sequences with restriction enzymes and used as a templates 
for synthesis of antisense RNA probes using either T7, SP6, or T3 polymerases, depending on 
which of the promoters was located to the 3’ of the cDNA sequence, and digoxigenin (DIG)-
labeled UTPs (Roche Applied Science, Indianapolis, IN). Successful synthesis was verified by 
running the labeled RNA probes on 1.2 % agarose gels to check for appropriate sizes.  
 
Retrograde labeling 
Cholera Toxin Subunit B conjugated to Alexa fluor 488 or 555 was injected was injected into the 
Sol, TA, or GC muscles of WT or Mmp9
-/- 
mice at P5 or P40.  Animals were perfused and spinal 
cords were collected 48-96 hrs later.  At that time, the injected muscle and surrounding muscles 






Mice were assessed for motor function using the accelerated rotarod task twice weekly from P40 
onward.  Briefly, we weighed each mouse before the trial and then placed animals on an 
accelerating rod (4-40 rpm over a 5 minute period) and recorded the time it took for each mouse 
to fall from the rod. We performed 2 trials at each time point for each animal and recorded the 
longest time taken to fall and used it in analyses. A decrease in time on the rotarod was observed 
with increasing motor impairment. 
 
We also used a weekly swim tank test to assess progression of motor deficit from P40 onward.  
The test was constructed as per the specifications of Raoul et al. with some slight modifications 
(2005). Test subjects were lowered individually into one end of a 75 cm long x 6 cm wide x 40 
cm high Plexiglas container filled partially with 20°C water and induced to swim to a ramp at the 
other end that protruded into the water.  Footage of each trial was recorded using a video camera. 
Each subject underwent a minimum of five trials, with the shortest time excluded from analysis 
and the next three shortest times averaged to obtain a value for that individual at that timepoint. 
Length of swim was determined from when the hindlimbs first contacted the surface of the water 
to their first contact with the ramp.  A progressive slowing of an animal’s swim rate was 
considered a signal of motor dysfunction. 
 
Electrophysiological measurements 
Mice were anaesthetized with inhalational isoflurane.  Two stimulating electrodes were placed at 
a paraspinal site on both sides of the sciatic nerve.   A controlled stimulation was applied to the 
nerve in 10 to 50 µA increments from 50 µA to evoke and record unitary and maximal isometric 
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twitch and tetanic isometric contractions from each muscle.  The M-wave was measured at each 
escalating amplitude, until the maximal response was elicited and did not increase further.   
 
Electrical impedance myography 
All EIM measurements were performed as previously reported (Li et al., 2013).  The animals 
were anesthetized with isoflurane delivered by nosecone with a heating pad underneath the limb 
to maintain a consistent temperature.  After the fur overlaying the left GC muscle was clipped, a 
depilatory agent was applied to the skin to remove all remaining fur and the skin was then 
cleaned with saline.  The impedance measuring system consisted of a multi-frequency lock-in 
amplifier (Model 7280, Signal Recovery, Oak Ridge, TN) coupled with a very low capacitance 
active probe (Model 1103 of Tektronix, Beaverton, OR) providing data from 0.5-1000 kHz. The 
two parameters obtained from this system are resistance (R) and reactance (X) from which the 
third parameter, phase (θ) is calculated via the relationship θ = arctan(X/R).  
 
Experiments with viral vectors 
Generation of AAV6 vectors from Aebischer lab:   The following sequences were subcloned into 
the AAV6:shSOD1 vector (Towne et al., 2008) replacing the shRNA sequence targeting mutant 
SOD1 with TRC31231 under the H1 promoter: 
 AAV6:shMmp9 : the TRC31231 clone expressing a shRNA sequence 
5’GAGGCATACTTGTACCGCTAT3’ targeting nt 145 – 165 in the coding region of Mmp9  
AAV6:mismatch : an off-target shRNA control vector containing an shRNA insert that does not 
target human and mouse genes (SHC002) 
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Both were purchased from Sigma Aldrich (St. Louis, MI).  AAV6 virus was produced and 
concentrated as previously described (Towne & Aebischer, 2009).  Viral titers for AAV6:U6-sil 
MMP9 (trc31) were 2.1 x 10
14




Other vectors: All self-complementary vectors were designed and made by Guangping Gao 
(University of Massachusetts Medical School) and mailed overnight on dry ice to avoid freezing 
and thawing.  rAAV6/TR-eGFP was generated by David Dismuke (University of North 




Vector administration: For intracerebroventricular (i.c.v) injections, P1 pups were anesthetized 
by hypothermia by placing them on wet tissue overlaying the ice for 2 minutes. Pups were placed 
ventral side down onto the metal stage that was previously cooled on ice and stabilized with 
scotch tape. To identify the injection site on the skull a diagonal from lambda to the eye was 
traced. A point 1 mm away from the midpoint toward lambda was marked. Using 31 Gauge 1/2 
cc Insulin syringe (BD Ultra-Fine* II Short Needle Insulin Syringe, VWR) 2 µl of virus was 
injected at the marked point into the third ventricle. 3mm was the maximum depth the syringe 
was allowed to penetrate the skull. Virus solution was colored by addition of a small amount of 
Fast Green dye (Sigma-Aldrich, St. Louis, MI). Success of the i.c.v injections was monitored by 
transilluminating the head of the injected pup to assess whether the dye spread to both ventricles. 
If the dye did not spread to both ventricles, the injections were deemed unsuccessful and the 
pups were sacrificed. For intramuscular (i.m.) injections, P4 pups were anesthetized by 
hypothermia. The skin overlaying the TA muscles was opened and 1 µl of the AAV6.shMMP9 
virus was injected using an insulin syringe.  Following that injection, the pup was flipped and the 
contralateral TA muscle was injected with 1 µl of the AAV6:mismatch virus.  Successfully 
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injected pups were allowed to recover for 5 -10 min on the warming blanket before being 
returned to the mother. 
 
Tissue Homogenization 
Mice were perfused with ice cold PBS and lumbar ventral spinal cord fragments, muscles, 
spleen, and placenta were rapidly dissected and snap-frozen in liquid nitrogen and stored at -
80°C. The fragments were then extracted for 1 h on ice using 50 mM Tris-HCl, pH 7.4, 
containing 1% Triton X-100, 0.2 M NaCl, 10 mM CaCl2, the proteinase inhibitor cocktail set III 
(Calbiochem) and 1 mM phenylmethylsulphonyl fluoride.  The protein concentration of the 
extracts was measured using a Coomassie Protein Assay (Thermo Scientific, Waltham MA) and 
then adjusted to equal 2 mg/ml each. The extracts were then allowed to bind gelatin Sepharose-
beads overnight at 4°C. After extensive washing, the bound material was eluted using 2×SDS gel 




Gel Zymography was performed using Novex Zymogram Gels containing 0.1 % gelatin 
(Invitrogen, Carlsbad, CA) following manufacturer’s protocol. Briefly, recombinant MMP-9 and 
MMP-2, tissue homogenates, or conditioned media from macrophage cultures were loaded in 
Novex Tris-Glycine 2x SDS sample buffer (Invitrogen, Carlsbad, CA) onto 10% zymogram 
(gelatin) gels (Invitrogen, Carlsbad, CA).  Proteins were resolved by elecrophoresis. Gels were 
washed in zymogram renaturing buffer to remove SDS (Invitrogen, Carlsbad, CA), followed by 
incubation in the zymogram developing buffer (Invitrogen, Carlsbad, CA) overnight at 37º C.  
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Gels were rinsed with water and stained for 1 hour with Coommassie blue (SimplyBlue 
SafeStain, Invitrogen, Carlsbad, CA), followed by destaining with water. Areas of gelatinolytic 
activity appeared as clear bands. After distaining the gels were scanned.  Digital images were 
processed using Image J software (National Institutes of Health, Bethesda, MD) for 
densitometric analysis. 
 
In Situ Zymography 
For in situ zymography, mice were perfused with ice cold PBS and lumbar ventral spinal cord 
fragments, muscles, spleen, brain, and placenta were rapidly dissected and placed in a mold filled 
with OCT compound (Tissue-Tek) and frozen on crushed dry ice.  Cryostat sections were cut at 
variable thicknesses between 8 µm and 40 µm and allowed to dry on coated slides.  Slides were 
then treated with one of the following fixatives (or, in the “no fix” condition, just washed with 
PBS): acetone for 10 minutes at -20° C, 100% methanol for 10 minutes at -20° C, 70% ethanol 
for 10 minutes at 4° C, or 4 % PFA for 10 minutes at 4 degrees.  Slides were washed 2 X 5 
minutes with PBS + 0.1% Triton X and  were then either blocked first at room temperature for 1 
hour with 1% BSA or were immediately incubated at 37° C with 10 µg/mL or 100 µg/mL DQ 
gelatin fluorescin conjugate (EnzChek Gelatinase Assay kit; Invitrogen) for 2 hours.   
 
Pharmacological Inhibition 
MMP-9 Inhibitor 1: WT or SOD1
G93A
 mice (18-22 g) were anesthetized with isoflurane at P50 
and placed in a stereotaxic instrument and a guide cannula (Plastics One, Inc., C311GS-4/SP 
with tubing length below pedestal of 3 mm) with a dummy inserted in it to prevent clogging 
when not in use (Plastics One, Inc., C311DCS-4/SP to fit 3mm without projection) was placed 
1 mm lateral and 1 mm caudal to bregma, at a depth of 2.5 mm. The guide cannula was secured 
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to the skull using mounting screws (Plastic One) and dental cement (Dental Products of India, 
Mumbai). The animals were allowed to recover for 5 days and then given daily injections into 
their cannulae of MMP-9 Inhibitor I (2 µg per day dissolved in 10% DMSO, Calbiochem) or a 
vehicle. The volume of all i.c.v. injections was 10 μl, using a 25 μl syringe (Hamilton Co., Reno, 
NV, USA) connected to internal cannula (26 gauge, Plastics One, Inc, C311IS-4/SP to fit 3 mm 
with a 0.1 mm projection) by polyethylene tubing. Animals were perfused after 20 days of 
injections, at P75.   
 
SB-3CT:  Two groups of animals were treated with SB-3CT (EMD Biosciences, San Diego, CA) 
(25 mg/kg, i.p.) or vehicle (10 % DMSO) from either P35-P50 or from P55 to P75.  Mice were 
weighed daily before drug administration for dosing and also to measure potential weight loss 
and/or other negative health outcomes.  The younger group of animals were given drug holidays 
after every 5 days of treatment, and therefore had fewer total injections than the older group of 
animals (13 vs. 21 injections).  Animals were sacrificed at either P50 or P75 and TAs were 
harvested for innervation analysis.     
Human tissue immunostaining  
Postmortem human spinal cord tissues were obtained from the New York Brain Bank (Columbia 
University, New York) and were paraffin embedded and sectioned at 8 µm.  Routine H&E and 
antibody staining using rabbit anti-human MMP-9 (Prestige collection, Sigma) were performed 
by the immunohistochemistry laboratory in Columbia University’s Department of Pathology.   
 
Anatomical and Statistical analyses 
For the quantification of VAChT and BTX staining of muscle cryosections, consecutive 
longitudinal 30-40 µm cryosections of muscles were stained with VAChT and BTX.  For large 
237 
 
muscles (TA, Sol, IC, BC, EAS, EUS) this analysis was performed on every second or third 
section.  For the extraocular muscles, every section was used.  Overlap was most often counted 
manually, but occasionally also by using the NIS-Elements 3.0 software (Nikon Instruments Inc, 
Melville, NY) to process the images.  For this type of processing, a region of interest was drawn 
manually around the synaptic band.  For each image, pixel intensity in the region of muscle 
outside the synaptic band in each channel was sampled and designated as background.  Binary 
thresholding was performed to identify discrete areas of pixel intensity above background levels.  
These areas were counted in both VAChT and BTX channels. Areas of overlap between the two 
channels were identified and counted.  %NMJ innervation was determined by dividing the total 
number of areas of overlap between VAChT and BTX signals (total number innervated 
endplates) by the number of areas containing BTX signal (total number of endplates). 
 
For the quantification of motor neuron numbers, motor neurons were counted in consecutive 
transverse 20 μm cryosections of the L5 and L6 levels of the spinal cord from age- and sex-
matched wild-type littermate controls stained for ChAT.  A 2-mm extent of the L5-S1 spinal 
cord (67 sections) was sampled.  In each animal, the cryosection corresponding to the L6/S1 
border region was identified by visual inspection of the disappearance of the DL nucleus and the 
prominent V nucleus.  The L6 level on each side was defined as the 1-mm region rostral to the 
L6/S1 border section.  Motor neurons in this region were counted in every consecutive 20 μm 
section.  DL motor neurons were identified by their characteristic location at the lateral border of 
the ventral horn and the characteristic positions.  Motor neurons located dorsally to this 
population were considered to be RDL motor neurons.  For each animal numbers of motor 




For the quantification of MMP-9 fluorescence intensity, staining for MMP-9 and ChAT was 
performed on 20-μm cryosections of the spinal cord and 30-μm free-floating cryosections of the 




 motor neurons were performed in every fifth section 
in left and right ventral horns (10 sections total per animal).  Oculomotor, trochlear, and 
abducens nuclei were located in coronal sections of brainstems based on the published 
rostrocaudal positions in adult brainstem as previously described (Ferrucci et al., 2010).  Counts 
were performed in six sample sections from the entire rostrocaudal extent of the oculomotor 
nucleus spaced at 150 μm and in two and three sample sections spaced at 60 μm for trochlear and 
abducens nuclei, respectively 
 




 were clearly 
distinguished. Only cells with ChAT
+
 cytoplasm surrounding a clearly visible nucleus were 




 motor neurons, 
ImageJ software (National Institutes of Health, Bethesda, MD) was used to process images 
acquired for L5 motor neurons in one wild-type animal (273 motor neurons counted). A 5-μm2 
area within the cytoplasm of each ChAT
+
 motor neuron was manually picked. The summed 
fluorescence intensity in the MMP-9 channel for each area was then calculated. To eliminate 
variation between images, a background, non-ChAT
+
 point was also selected and the summed 
intensity from this region was then subtracted from all other intensity values from that image. 
The data were then sorted by intensity and plotted using Excel. A best-fit trendline, determined 
by maximizing the R
2
 value, was then added and the second derivative was taken to find the 
inflection points of the function. The ordinate values of the two inflection points were considered 
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to be the bin threshold. Specifically, all cells with an intensity lower than the first inflection point 
were considered MMP-9
neg
, all cells between the two inflection points were considered MMP-9
lo
 
and all cells above the second inflection point were considered MMP-9
hi
. The number of cells in 
each category was then compared to manual counts. 
 
For motor neuron cell size measurements, the largest cross-sectional areas were determined 
using NIS-Elements 3.0 software (Nikon Instruments Inc, Melville, NY) for cells with a ChAT
+
 
cytoplasm with a visible nucleus.  All ChAT
+
 MNs with a visible nucleus were imaged at 10x 
and outlined.  Distribution histograms were constructed for each level of MMP-9 staining 
intensity, by grouping cell body cross-sectional areas in 100-μm2 bins.  
 
For CRT intensity measurements, CRT immunofluorescence was measured in the spinal cord 




 mice (n=3 animals) that had been injected into one TA at 
P4 with AAV6.MMP9.  For all alpha-MNs (identified by NeuN positivity), the pixel intensity 
was measured using Image J software (National Institutes of Health, Bethesda, MD).  After 
intensity measurements were taken from the channel with CRT fluorescence, the channel was 
switched to the channel with MMP-9 in order to characterize the MN into one of the following 
categories: MMP9-positive MNs, MMP9-negative MNs from the injected ventral horn, MMP-9 
negative MNs from the uninjected side (65-100 MNs each).  The resultant categories had 
unequal variance, so a non-parametric statistical analyses, so were compared using either a 
Kruskal-Wallis One Way Analysis of Variance on Rank or a Mann-Whitney Rank Sum test, 
depending on if the “injected side” categories were combined or not.   WT mice that had been 
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given TA injections of AAV6.GFP were used as a control for potential changes in CRT 
fluorescence resulting from viral transduction.   
 
Tests of significance between two genotypes were conducted using an unpaired Student’s t-test. 
A Student’s t-test was also used to for the p-EIF2α and MMP-9 co-localization analysis.  
Specifically, the probability of cells being co-positive by chance was calculated (#MMP9 -
positive MNs/ total MNs * #p-EIF2α-positive MNs/ total # MNS), and that number was 
compared to the observed population of co-positive cells (co-positive cells/ total # MNs) for each 
animal.  Tests between three or more groups were conducted using a one-way ANOVA with a 
Student Newman-Keuls post hoc analysis.  For analyses of skin facing versus bone-facing side 
denervation in TA muscles, data were analyzed by two way ANOVA, with the 2 factors 
designated as time and fiber type.  Post-hoc pairwise comparisons were made by the Holm-Sidak 
method.  Survival analyses were generated by Kaplan-Meier estimates with a log rank analysis. 
All calculations were performed using SigmaPlot software. All α-thresholds were set at 0.05 
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